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ABSTRACT 
Sex differences in mammalian gene expression result from differences in genotypic sex 
as well as in hormonal regulators between males and females.  In rat, mouse and human 
liver, ~1000 genes are expressed in a sex-dependent manner, and contribute to sex 
differences in metabolism of drugs, steroids and lipids, and in liver and cardiovascular 
disease risk.  In rats and mice, sex-biased liver gene expression is primarily dictated by 
the sexually dimorphic pattern of pituitary growth hormone (GH) release and its STAT5-
dependent transcriptional activities.  Studies presented in this thesis include the 
following.   (1) A computational approach based on DNA sequence and phylogenetic 
conservation was developed and used to identify novel functional STAT5 binding sites − 
both consensus and non-consensus STAT5 sequences − near prototypic GH-responsive 
genes.  (2) Global gene expression analysis of livers from pituitary-ablated male and 
female mice identified four major classes of sex-biased genes differing in their profiles of 
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GH dependence.  (3) Sex-differences in DNase-hypersensitive sites (DHS, corresponding 
to open chromatin regions) were identified genome-wide in mouse liver.  These sex-
differential DHSs were enriched for association with sex-biased genes, but a majority 
was distant from sex-biased genes.  Furthermore, many were responsive to GH treatment, 
demonstrating that GH-mediated regulation involves chromatin remodeling.  Analysis of 
sequence motifs enriched at sex-biased DHSs implicated STAT5 and novel transcription 
factors such as PBX1 and TAL1 in sex-biased gene regulation.   (4) Genome-wide 
mapping of histone modifications revealed distinct mechanisms of sex-biased gene 
regulation in male and female liver: sex-dependent K27me3-mediated repression is an 
important mechanism of repression of female-biased, but not of male-biased, genes, and a 
sex-dependent K4me1 distribution, suggesting nucleosome repositioning by pioneer 
factors, is observed at male-biased, but not female-biased, regulatory sites.  STAT5-
mediated activation was most strongly associated with sex-biased chromatin 
modifications, while BCL6-mediated repression primarily occurs in association with sex-
independent chromatin modifications, both at binding sites and at target genes.  The 
relationships between sex-dependent chromatin accessibility, chromatin modifications 
and transcription-factor binding uncovered by these studies help elucidate the molecular 
mechanisms governing sex-differential gene expression, and underscore the utility of 
functional genomic and epigenetic studies as tools for elucidating transcriptional 
regulation in complex mammalian systems.   
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Chapter 1  
Introduction 
1.A Summary 
Sex-differences characterize >1000 genes in liver and are a consequence of release of GH 
from the pituitary gland in a sexually dimorphic manner, which in turn activates the 
transcription factor STAT5 in a sexually dimorphic manner, and GH signaling has been 
shown to have chromatin remodeling activity at select genes. The actions of GH, STAT5, 
other liver-enriched TFs, and their interplay with chromatin structure in order to achieve 
sex-biased gene expression have been examined via targeted analyses of specific genes as 
well as microarray and high-throughput sequencing technology. Genome-wide 
approaches have been widely utilized in recent years to elucidate mechanisms of cell 
type-specific and hormone-responsive gene regulation, including the role played by 
chromatin structure. Mapping of open chromatin regions genome-wide generates maps of 
active regulatory elements that encompass the vast majority of functional transcription 
factor (TF) binding sites, and that distinguish cell type-specific regulatory sites; by 
integrating this information with gene expression, genomic loci that regulate cell type-
specific genes can be identified, and sequence analysis of such loci can identify TFs that 
play a role in regulation. Distinct combinations of chromatin modifications mark different 
types of genomic loci, such as transcription start sites or distal enhancers, and influence 
TF binding and gene expression. Chromatin modifications and TFs interact with each 
other in complex ways; some TFs bind at closed chromatin to facilitate remodeling and 
enable other TFs to bind, other TFs stabilize the chromatin structure at a locus, and yet 
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other TFs bind active enhancers dynamically in response to stimulus. Thus, genome-wide 
mapping of specific chromatin modifications across cell types or in response to hormonal 
stimuli can provide novel insights into mechanisms governing cell type-specific and 
hormone-responsive gene expression. Steroid hormone-activated regulatory pathways 
involve interactions between chromatin environment, hormone-activated nuclear 
receptors (NRs), and other TFs, with some NRs having chromatin remodeling activity 
while others bind sites that have been remodeled by pioneer factors. Such pioneer factors 
include FOXA1, which is required for liver differentiation and involved in sex-
differences in susceptibility to hepatocellular carcinoma.  
1.B Overview of dissertation 
The goal of this dissertation is to elucidate sex-biased liver gene regulation, which is a 
consequence of the sexually dimorphic growth hormone (GH) profile. Many of the 
transcriptional actions of GH are mediated by STAT5, a GH-activated TF; therefore, 
Chapter 2 of this dissertation describes an attempt to computationally predict STAT5 
binding sites for a set of well-characterized GH-responsive genes. Chapter 3 takes a more 
global approach – comparing sex-differences and GH-responses in global gene 
expression in mouse liver, following a similar study in rat. Chapters 4 and 5 chapters 
delve into epigenomics in mouse liver. First, I examine sex-differences and GH-
responsiveness of DNase hypersensitivity, which illustrates that sex-differences in DNase 
hypersensitivity genome-wide can explain sex-differences in gene expression and contain 
information about transcription factors (TFs) of interest including STAT5. Finally, I 
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analyze genome-wide mapping data for six chromatin marks in male and female liver, to 
characterize sex-biased DHS and genes in terms of chromatin modifications, and 
integrate this information with global TF binding data for TFs including the 
transcriptional activator STAT5, repressive TFs CUX2 and BCL6, and pioneer factors 
FOXA1 and FOXA2, which reveal distinct mechanisms of sex-biased gene regulation in 
male liver and female liver. 
This introduction will be a literature review of research in relevant fields, along with an 
overview of the studies that are to be described in the dissertation. I first provide an 
overview of the biological system of GH-regulated sex-dependent gene regulation in 
liver. Next, I review genome-wide studies of chromatin modifications that have provided 
insights into cell type- and tissue-specific TF binding and gene regulation. Finally, I 
describe studies and conclusions made by integration of genome-wide chromatin 
modification, TF binding, and gene expression data, with a focus on hormone-regulated 
systems, including GH action in liver.     
 
1.C Sex differences in liver gene expression in rodents and humans 
1.C.1 Physiological and pharmacological impact 
Sexual dimorphism in gene expression in the liver affects >1000 genes and is a result of 
sexually dimorphic GH secretion patterns from the pituitary gland (Wiwi and Waxman 
2004; Mode and Gustafsson 2006). Genes that are differentially expressed between male 
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and female liver include genes involved in xenobiotic metabolism and drug metabolizing 
genes such as the cytochrome P450 genes (reviewed in (Waxman and O'Connor 2006) 
and (Waxman and Holloway 2009)). Cyp genes that show sex-differences in liver 
expression include the mouse genes Cyp2b9 and Cyp2b13, rat genes CYP2C11 and 
CYP2C12, and human CYP3A4. The resulting sex differences in drug metabolism can 
have significant impact on drug effectiveness, as well as susceptibility to side effects, in 
men and women (Schmidt et al. 2001; Schwartz 2007). Genes that are differentially 
expressed between livers of men and women are associated with lipid metabolism and 
cardiovascular disease risk, including genes at loci that have been implicated in polygenic 
dyslipidemia and coronary artery disease by genome-wide association studies (Zhang et 
al. 2011). Sex differences are also seen in susceptibility to disease, including hepatic 
fibrosis, cirrhosis, and hepatocellular carcinoma (HCC) (Yokoyama et al. 2005; Nguyen 
et al. 2009; Ruggieri et al. 2010). Estrogen receptor (ER) confers resistance to HCC in 
females (Yamamoto et al. 1991; Shimizu et al. 1998; Naugler et al. 2007), while 
androgen receptor (AR) confers susceptibility to HCC in males (Ma et al. 2008; Wu et al. 
2010). Moreover, steroid hormone-dependent resistance and susceptibility is dependent 
on the pioneer factors (Zaret and Carroll 2011) FOXA1 and FOXA2 (Li et al. 2012).  
1.C.2 Role of growth hormone and STAT5 
Sexually dimorphic gene expression in rats and mice is controlled by the sexually 
dimorphic pattern of release of GH from the pituitary gland. In rats, the male GH profile 
is regular and pulsatile, with sharp peaks of GH released at ~3.5-hour intervals with 
intervening periods of little or no circulating GH. In contrast, pituitary GH release in 
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female rats is much more frequent, leading to a near continuous presence of GH in 
circulation and the absence of GH-free intervals (Tannenbaum and Martin 1976; Eden 
1979; Jansson et al. 1985). Several studies in mice and rats have surveyed the impact of 
removal of the pituitary gland (hypophysectomy, or ‘Hypox’), which results in loss of 
GH along with other pituitary hormones (Flores-Morales et al. 2001; Gardmo et al. 2002; 
Wauthier and Waxman 2008; Wauthier et al. 2010 and Chapter 3 of this dissertation). 
Sex-differences in gene expression are largely abolished by hypophysectomy. When 
analyzed using global gene expression microarrays, 90% and 94% of liver sex-biased 
gene expression in rats (Wauthier and Waxman 2008) and mice (Wauthier et al. 2010 and 
Chapter 3), respectively, is lost when the pituitary gland is removed.  This could be a 
result of loss of GH, but could also indicate sex-differences that are dependent on other 
pituitary hormones. However, responses to either pulsatile GH replacement (Choi and 
Waxman 2000; Thompson et al. 2000; Wauthier and Waxman 2008; Wauthier et al. 2010 
and Chapter 3), or continuous GH infusion (Ahluwalia et al. 2004; Stahlberg et al. 2005) 
have shown that a large majority of sex-differences in mouse and rat liver gene 
expression are regulated by the plasma GH profile, although some intrinsic sex-
differences in GH-responsiveness of hypophysectomized mice were apparent (Wauthier 
et al. 2010 and Chapter 3). 
The male plasma GH profile in mice is similar to that in rats, with regular pulses spaced 
by ~2.5-hour interpulse intervals. Female mice however, instead of a continuous low 
level of GH as in rats, are characterized by pulses of GH that are released more 
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frequently than in males, at ~1.4-hour intervals (MacLeod et al. 1991). Other studies in 
mice suggest that plasma GH patterns in female mice, but not male mice, vary between 
night and day, with significantly higher plasma GH levels in female mice during the day 
(Xu et al. 2011). Thus, it appears that the lack of sustained GH-free intervals is what 
distinguishes the female GH profile from the male GH profile. Indeed, treating male mice 
with continuous GH delivered via an osmotic pump feminizes liver gene expression – 
male-biased genes are down-regulated and female-biased genes are up-regulated  
(Holloway et al. 2006). In humans, the sex-difference in plasma GH profiles more subtle, 
with regular pulses in men and more irregular pulses in women (Veldhuis 1998). Despite 
this difference between humans and rodents, treatment with continuous and pulsatile GH 
result in distinct responses for specific genes examined in humans, just as in rodents. 
Thus, pulsatile GH treatment of GH-deficient men and women stimulates osteocalcin and 
down regulates CYP1A2, while continuous GH more effectively up regulated CYP3A4, 
which is expressed more highly in women than in men (Jaffe et al. 2002). However, other 
studies showed opposite effects on CYP3A4 expression by treatment with GH pulse 
(Watkins et al. 1993; Jurgens et al. 2002). Moreover, a global profiling of human liver 
gene expression (Zhang et al. 2011) showed that half of the genes we found to be sex-
biased in expression in human liver show sex-biased expression and GH-regulation in 
mouse liver, indicating that there is some level of conservation between sex-dependent 
liver gene regulation in humans and rodents. 
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STAT5 is the main effector of transcriptional responses to GH in liver. STAT5 is 
activated by tyrosine phosphorylation induced by GH binding to the GH receptor and 
activation of Jak2 (Janus kinase 2), a tyrosine kinase that phosphorylates STAT5 at Tyr 
699 (STAT5b) or Tyr 694 (STAT5a).  Phosphorylated STAT5 dimerizes and translocates 
to the nucleus, where it binds regulatory elements with the consensus sequence 
TTCNNNGAA in order to regulate target genes. Liver STAT5 activity levels mirror 
plasma levels of GH in individual male rats (Choi and Waxman 1999; Choi and Waxman 
2000), which raises the possibility that STAT5’s transcriptional regulatory activity is 
dynamic in response to plasma GH levels. Dynamic binding by STAT5 in response to the 
sex-dependent plasma GH profile may facilitate sexually dimorphic gene regulation, 
insofar as STAT5 mRNA levels are sex-independent in expression (Wauthier and 
Waxman 2008), and active STAT5 is present in both male and female livers (Choi and 
Waxman 1999). This was confirmed experimentally in in vivo experiments in rat: STAT5 
binding cycles on and off with GH pulses, and low-affinity STAT5 binding sites are more 
likely to be male-biased in STAT5 binding (Laz et al. 2009). This suggests that the 
pulsatility of GH secretion and associated pulsatility in liver STAT5 activity contributes 
to the sexual dimorphism of STAT5-dependent gene regulation by binding at loci that 
have different levels of affinity for STAT5 binding  (Laz et al. 2009).  
A small-scale attempt to predict STAT5 binding sites in genomic regions encompassing 
100kb upstream, the entire coding region, and 25kb downstream of well-characterized 
GH-responsive genes in rat liver, using a phylogenetic conservation approach, yielded a 
8 
 
 
 
positive prediction rate of just 27% (Laz et al. 2009), and is described in Chapter 2 of this 
dissertation. Although this approach identified 3 functional binding sites that do not 
match the STAT5 consensus sequence, as did earlier in vitro and in vivo studies (Soldaini 
et al. 2000; Basham et al. 2008), the presence of a consensus site turned out to be one of 
the best predictors of STAT5 binding, and a better predictor than phylogenetic 
conservation of the genomic locus. This is consistent with a later finding from genome-
wide studies of binding sites for liver-enriched TFs (HNF4α and CEBPA) that binding 
site conservation between placental mammals is very low (Schmidt et al. 2010).  
However, using improved predictors, just 31% of predictions in a second set of GH-
responsive genes tested positive for binding in vivo (Laz et al. 2009 and Chapter 2).  This 
indicates that other influences not considered in this study, such as chromatin 
environment, may be important in determining STAT5 binding at a STAT5 motif. 
STAT5 can bind at loci that are very distant (at least 75 kb) from its target genes in both 
rat and mouse (Eleswarapu et al. 2008 and Chapter 2; Laz et al. 2009), showing that 
promoter-based approaches are insufficient for identification of functional binding sites 
for this TF, and the broad genomic region that needs to be considered illustrates the 
necessity of using a more genome-wide approach. Correspondingly, gene set enrichment 
analysis using precomputed motif genesets (Subramanian et al. 2005) -- sets of genes that 
contain a conserved sequence motif within 2 kb of the TSS -- did not identify STAT5 as a 
regulator of sex-biased, GH-regulated genes in mouse liver (Wauthier et al. 2010 and 
Chapter 3); this result could be a consequence of distal binding by STAT5. Instead, the 
transcription factor Mef2 emerged as a potential regulator of male-biased, GH-responsive 
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genes (Wauthier et al. 2010 and Chapter 3). Mef2 is involved in muscle development 
(Potthoff and Olson 2007) but is also found in hepatic stellate cells, which are strongly 
activated in HCC, where Mef2 protein is also strongly expressed (Sato et al. 2003; Wang 
et al. 2004; Bai et al. 2008). 
1.C.3 Insights from TF knockout and developmental time course microarray studies 
In addition to directly investigating the impact of GH on sex-biased gene expression, 
microarray technology has also been employed to investigate the global effects of loss of 
specific TFs implicated in responses to GH. Gene knockout studies have identified genes 
that are regulated in a sex-dependent manner by the transcription factors STAT5a 
(Clodfelter et al. 2007) and STAT5b (Clodfelter et al. 2006), and HNF4α (Holloway et al. 
2008).  HNF4α plays a central role in regulation of liver function through its effects on 
glucose, fatty acid and cholesterol homeostasis, bile acid and urea biosynthesis, and liver 
development (Hayhurst et al. 2001; Hanniman et al. 2006; Miura et al. 2006). The 
STAT5b knockout microarray study (Clodfelter et al. 2006) showed that STAT5b is 
necessary for sex-biased gene expression of 90% of male-biased genes, and 61% of 
female-biased genes were affected by STAT5b knockout in males, supporting the 
hypothesis that dynamic activity patterns of STAT5 lead to sexually dimorphic gene 
expression. In contrast, 90% of all sex-dependent genes were unaffected by STAT5b 
knockout in females, whereas STAT5a knockout had limited impact on female liver, with 
15% of female-biased genes down regulated by STAT5a knockout in female liver 
(Clodfelter et al. 2007), pointing to a secondary role for STAT5a in regulation of female-
biased genes. Three female-biased TFs, Tox, Trim, and CUX2, whose expression is 
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dependent on GH, STAT5 and HNF4α, have been identified in mouse liver (Laz et al. 
2007). A recent time course microarray (Conforto and Waxman 2012) showed that while 
most sex-differences begin at 8 weeks, some transcriptional regulators, including Cux2, 
Tox, and Trim, show sex-biased expression beginning at 4 weeks (~ the onset of puberty) 
and are therefore potential mediators of later developmental changes associated with the 
emergence of global sex-biased gene expression. CUX2 has transcriptional repressive 
activity (Gingras et al. 2005) and was proposed to repress male-biased genes in female 
liver (Laz et al. 2007). 
 
1.D Genomics and epigenomics of gene regulation in mammalian systems 
The studies described above identify large numbers of genes that respond to a given 
treatment, such as hypophysectomy or GH treatment, or that require a particular TF for 
expression, as measured by TF knockout arrays, but do not distinguish direct vs. indirect 
actions by TFs involved in a gene regulatory network, and do not elucidate any interplay 
between TFs and chromatin modifications at genomic loci in order to regulate target 
genes. Furthermore, the above studies do not address the impact of GH on the chromatin 
level, or address interplay between STAT5 and other transcription factors and chromatin 
modifications to regulate gene expression.   
Some of these issues can be addressed using functional genomics. High throughput 
sequencing technology can be used to identify the genome-wide localization of TFs and 
other genomic features of interest. Below, and in the following section 1.E, I describe 
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efforts by this and other laboratories to characterize TF binding sites and chromatin 
features across the genome with the goal of understanding gene regulation, with an 
emphasis on the actions of GH and other hormone-regulated systems. 
1.D.1 Open chromatin – a map of active regulatory elements 
DNase I hypersensitivity is a measure of open chromatin in the genome. The enzyme 
DNase I digests DNA by introducing single-strand cuts (Song and Crawford 2010) where 
the DNA is accessible – i.e., regions of low nucleosome occupancy. This method has 
been used to identify active regulatory elements since the 1980s (McGhee et al. 1981; 
Wu and Gilbert 1981; Reinke and Horz 2004). Sex-dependent DNase hypersensitive sites 
have been identified near the sex-biased genes CYP2C11 and CYP2C12 in rat liver 
(Strom et al. 1994; Endo et al. 2005) and Slp in mice (Hemenway and Robins 1987). 
With the advent of high-throughput sequencing technology, DNase hypersensitivity has 
been mapped on a genome-wide scale using tiling microarray (DNase-chip, Crawford et 
al. 2006) and massively parallel sequencing (DNase-seq, Song and Crawford 2010). 
These techniques can be used to map open chromatin regions across the genome; these 
regions include promoters, enhancers, silencers, insulators, and locus control regions.  
Open chromatin regions mapped in this way can distinguish cell type-specific enhancers.  
DHS sites in CD4+ T cells, for example, are enriched for motifs of TFs that regulate 
immune system function, and genes lacking a DHS site in the TSS are enriched for GO 
categories unrelated to CD4+ T cells (Boyle et al. 2008). An alternative method to map 
open chromatin regions is FAIRE-seq (Formaldehyde Assisted Isolation of Regulatory 
Elements), which targets a different but overlapping set of open chromatin regions from 
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those targeted by DNase I (Song et al. 2011). Micrococcoal nuclease (MNase), which 
cannot digest DNA that is wrapped around a histone octamer, can also be coupled to 
high-throughput sequencing (MNase-seq) to map nucleosome occupancy more precisely 
(Schones et al. 2008). Periodicity corresponding to nucleosome positioning has also been 
observed in DNase-seq data (Boyle et al. 2008).  
As will be described in Chapter 4 of this dissertation, DNase-seq has been used to 
identify sex-differences in chromatin accessibility in mouse liver (Ling et al. 2010). 
Chromatin samples prepared from untreated male and female mouse livers, as well as 
livers of male mice given GH by continuous infusion (female-like plasma GH pattern) 
were analyzed by DNase-seq to identify DNase hypersensitive sites (DHS). These DHS 
encompassed 67-93% of known mouse liver genome-wide TFBSs from the existing 
literature at the time, confirming that this dataset contains a large fraction of the active 
regulatory elements in mouse liver. There was a strong association between sex-biased 
DHS and sex-biased genes, and sex-biased DHS were feminized by continuous GH 
infusion in males, supporting the proposal that the absence of a GH-free interval is the 
key distinguishing feature between male and female plasma GH profiles. A large fraction 
of sex-biased DHS and genes were distant from each other, which may be explained by 
distal regulation as well as other modes of gene regulation that are not manifested at the 
chromatin level (Ling et al. 2010). Only 2 out of 6 sex-biased DHS conferred sex-biased 
regulation when transfected into mouse liver in vivo. This suggests that sexually 
dimorphic DNase hypersensitivity alone is insufficient to determine sexually dimorphic 
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gene regulation; the reporter gene assay may have failed to recapitulate sex-differences in 
local chromatin environment, or DHS that work in concert to achieve a regulatory 
outcome. Enriched sequence motifs at sex-biased DHS include binding sites for TFs 
known to be involved in sex-biased gene regulation, including STAT5, CUX2, and 
HNF4. While the family of HNF4-like motifs was enriched at sites that are close to sex-
biased gene TSSs, the STAT5 motif was enriched at sites that were distant from sex-
biased gene TSSs, providing further indication that STAT5 tends to act as a distal 
regulator. Furthermore, a CUX2-like motif was enriched at male-biased DHS, suggesting 
that CUX2 acts as a female-specific repressor by closing DHS in female liver, or 
preventing DHS opening. In addition to these TFs, several novel TFs were also 
implicated in sex-biased gene regulation. These results show that DNase-seq data 
provides information that can generate hypotheses before obtaining ChIP-seq data for 
specific transcription factors. 
The utility of DNase-seq in identifying active binding sites for multiple TFs has been 
demonstrated more recently by the ENCODE project (Dunham et al. 2012). Mapping of 
human DHSs in 125 cell and tissue types found that cell type-dependent differences in 
DNase hypersensitivity at a genomic locus can predict cell-type specific expression 
(Thurman et al. 2012). Of the almost 3 million DHS reported, 34% are active in only one 
cell type and 66% in two or more cell types, with only 0.1% of DHS (3,962 sites) active 
in all cell types. 97% of experimentally validated cis-regulatory elements outside 
promoter regions are found within DHSs, and the sum of ChIP-seq signals for multiple 
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TFs is highly correlated with DNase hypersensitivity, providing evidence for chromatin 
accessibility being regulated by interactions between multiple DNA-bound TFs. When 
logistic regression was used to quantify the contribution of DNA sequence features to 
predict cell type-specific regulation of target genes across 19 human cell types, the 
inclusion of DHSs in the model had better predictive value than using promoters alone 
(Natarajan et al. 2012). Candidate regulatory TFs were identified by determining the 
motifs that were most informative, which implicated TFs known to be involved in the 
system as well as novel ones. The predicted TF binding sites had significant overlap with 
experimental ChIP data that was available, for two TFs; predictions for several TFs were 
also validated by presence of digital footprints (discussed below). For a subset of cell-
type-specific TFs, the cell-type-specificity of TF expression correctly predicted cell-type-
specific target gene expression (Natarajan et al. 2012). Thus, cell-type-specific 
expression is mediated not only by cell-type-specific DHSs, but can also be regulated by 
the binding of cell-type-specific TFs at ubiquitous DHSs. TF expression was compared 
across cell types in order to characterize predicted TFs as activators or repressors in a cell 
line (Natarajan et al. 2012). Thus, the combination of DHS mapping with gene expression 
data can provide valuable insight into cell type-specific gene regulation. 
DNase footprinting improves the  precision of TF binding prediction 
Experimental DNase I footprinting has been used to precisely define transcription factor 
binding sites (TFBS) that are protected from cleavage (Galas and Schmitz 1978).  More 
recently, high-resolution DNase-seq technology has been applied to perform digital 
DNase footprinting analysis on a genome-wide scale (Hesselberth et al. 2009; Boyle et al. 
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2011). Genome-wide digital DNase footprinting was first carried out in yeast, a simple 
eukaryotic system (Hesselberth et al. 2009). This method requires high-depth sequencing 
of DNase-digested fragments, which allows the identification of short regions within 
DHS that are protected from DNase cleavage by a bound protein. Digital footprinting was 
later implemented in lymphoblastoma cell lines and five other human cell types (Boyle et 
al. 2011). DNase cuts were shown to be locally depleted at genomic sites corresponding 
to known TF binding motifs, and were enriched at TF-occupied binding sites identified 
by ChIP-seq. Motif instances that lacked a digital footprint showed very little ChIP-seq 
binding. Thus, digital DNase footprints correspond to occupied protein binding sites and 
can be detected in mammalian cell types, and so a hidden Markov model (HMM) was 
developed to identify footprints de novo. The emission parameters of the HMM 
correspond to relative levels DNase I cuts at each base. A DNase footprint consists of a 
traversal from an HMM state of baseline DNase hypersensivity, to a state of increasing 
cuts, a state of decreasing cuts, a footprint state depleted of cuts, and back – i.e., a region 
depleted of cuts surrounded by high DNase digestion. Putative sites of TF binding were 
identified at each footprint by matching the sequence to known motifs from the 
TRANSFAC and JASPAR databases. Cell type-specific differences in footprint pattern 
were also observed; these correlate with cell type-specific gene expression for TFs that 
bind in a cell type-specific manner. Digital footprinting analysis greatly expands the 
utility of DNase-seq datasets, and could ultimately decrease the need for high quality 
antibody and ChIP-seq experiments for multiple transcription factors. Digital DNase 
footprinting does not rely on assumptions of sequence-specificity made by PWM 
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(position weight matrix)-based approaches, and provides base-pair level resolution of TF-
binding site interactions. The footprinting approach used by Boyle et al (2011) had 
greater PPV (positive predictive value) than using PWMs alone, or PWMs at DHSs 
alone. DNase footprinting was integrated with histone modification data using a Bayesian 
algorithm, CENTIPEDE (Pique-Regi et al. 2011), and it turned out that although 
combinations of histone modifications are informative in distinguishing different 
genomic loci, such as active or inactive promoters or enhancers (described below), 
histone modification data did not provide additional predictive information for TF 
binding beyond that  provided by DNase footprinting. Although the DNase-seq study in 
mouse liver (Ling et al. 2010) was not performed at sufficient sequencing depth to 
identify footprints genome-wide, examples of footprints were observed at very dense 
DHS peaks. This is an area that needs to be explored further for mouse liver. 
Distal regulation and chromosome looping 
The potential for long-range interactions leading to distal regulation, indicated by 
analysis of sex-biased DHS in mouse liver (Ling et al. 2010 and Chapter 4), is also 
supported by analysis of genomic patterns associated with cell type-specific regulation. 
Gene promoters are largely invariant between cell types in terms of chromatin 
accessibility, chromatin status, and transcription factor binding, while distal DHSs often 
show cell-type dependent differences (Heintzman et al. 2009; Heinz et al. 2010; 
Natarajan et al. 2012; Thurman et al. 2012). These findings suggest that cell-type specific 
regulation in mammalian systems is commonly achieved via distal regulatory sites. While 
17% of intergenic DHSs from 19 human cell types (Natarajan et al. 2012) are cell-type-
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specific (i.e. DHS present in only one cell type or overlapping with a DHS from another 
cell type by <50%), less than 1% of DHSs at TSSs are cell-type-specific, despite 
variations in expression of the associated genes. Consistent with the paradigm of cell-
type-specific expression mediated by distal regulatory sites, genes that are up-regulated in 
a subset of cell lines are associated with intergenic and gene body DHSs (Natarajan et al. 
2012). The possibility of direct physical interaction between distal DHSs and promoter 
DHSs was investigated by correlating DNase hypersensitivity across cell types at distal 
DHSs with DNase hypersensitivity at promoters in order to map distal DHSs to target 
genes (Thurman et al. 2012), and predicted interactions were validated with 5C 
technology (Dostie et al. 2006).  Looping interaction distances peak at 120 kb upstream 
of the TSS, evidencing the very long distances over which enhancer-promoter 
interactions take place; the upstream bias may indicate that active enhancers tend to be 
located in intergenic rather than intragenic regions, or it may indicate a directional 
preference by protein complexes at TSSs (Sanyal et al. 2012). Using 5C, most promoters 
were mapped to multiple DHSs; moreover, ~50% of distal DHSs mapped to more than 
one promoter, indicating many genes are subject to complex and coordinated regulation 
by multiple regulatory sites (Thurman et al. 2012).  
Three models have been proposed for the mechanism of regulation by distal regulatory 
sites: chromosomal looping, whereby enhancer- and promoter-bound TFs share a 
coactivator complex; tracking, which involves transfer of RNA polymerase II (Pol II) 
from a distal enhancer to the promoter; and linking, which proposes that looped 
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enhancers and promoters communicate via propagation of nucleoprotein structures 
(Bulger and Groudine 2011). One example of a distal enhancer is the androgen response 
element (ARE) located ~4 kb upstream of the PSA gene. Androgen receptor (AR) binds 
to the enhancer, where Pol II is first recruited, after which it tracks along looped 
chromatin to the promoter (Wang et al. 2005). Thus, in this case, both looping and 
tracking models apply. Analysis of the PSA gene and this distal ARE showed that AR and 
TBP (TATA binding protein) are bound to the enhancer and to the promoter but not to 
sequences in between, and looping was confirmed by ChIP-3C. In contrast, Pol II is first 
recruited to the PSA enhancer, then to the intervening region between enhancer and 
promoter, and then to the promoter (Wang et al. 2005). Motif analysis of sets of 
regulatory sites paired by 5C (Thurman et al. 2012) show co-associations between motifs 
at the distal DHS and at the promoter in a DHS-promoter pair: for example, the PU.1 
motif is significantly more likely to be present at distal DHSs that are paired with 
promoters that contain a motif for the ETS domain family. This result could indicate 
enhancer-promoter looping mediated by complexes of TFs.  
1.D.2 Epigenomics of cell type- and tissue-specific gene expression  
The epigenome is comprised of modifications to DNA or to histone proteins, which can 
be heritable – transmitted to daughter cells and even trans-generationally (Greer and Shi 
2012) – or they may be dynamic and responsive to changing cell stimuli (Biddie 2011). 
These epigenetic modifications influence chromatin structure, which can be in an open, 
permissive state, or a closed and inaccessible state, and this, in turn, impacts binding of 
DNA-binding proteins including transcription factors and polymerases, with effects on 
19 
 
 
 
gene expression. Non-covalent epigenetic modifications include chromatin remodeling 
such as nucleosome repositioning or incorporation of histone variants (Goldberg et al. 
2007). One well-studied covalent epigenetic modification is DNA methylation at CpG 
islands, which marks inactive regions including repetitive and centromeric sequences, 
and plays a role in X chromosome inactivation and imprinting. There is evidence that 
DNA methylation and histone methylation reinforce each other to keep chromatin in a 
repressive state (Fuks 2005). Covalent epigenetic modifications also include 
posttranslational modifications – e.g. acetylation, methylation, and ubiquitinylation – of 
histone proteins (Goldberg et al. 2007), which are laid down by a large number of histone 
modifying enzymes (Ram et al. 2011). Chromatin regulators bind the genome in 
characteristic modular combinations that are associated with distinct genomic features; 
further, the modules tend to include enzymes with opposing activity, which helps 
maintain dynamic chromatin regulation (Ram et al. 2011).   
The impact of different chromatin modifications on DNA compaction and on the 
expression or activity level of genes and regulatory sites has been investigated by 
genome-wide mapping of chromatin modifications in many mammalian cell lines and 
tissues. In general, histone acetylation marks active genomic regions, while histone 
deacetylation marks inactive regions. Acetylation of histone lysine residues neutralizes 
the lysine’s positive charge, which can weaken the interaction between histones and 
DNA (Bannister and Kouzarides 2011). Acetylations of different histone tails exhibit 
different patterns of genomic localization within active genes (Wang et al. 2008).  
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The impact of histone methylation varies with the histone protein and specific amino acid 
that is methylated. Trimethylation of H3K4 is highly enriched at the TSSs of actively 
transcribed genes (Barski et al. 2007; Mikkelsen et al. 2007), and at genes that are poised 
for expression and bivalently marked with H3K4me3  in combination with H3K27me3,  a 
repressive modification (described below). Gene promoters are also marked by H3K4 
mono- and di-methylation, which are also found at distal enhancers (Barski et al. 2007; 
Mikkelsen et al. 2007; Ernst et al. 2011). H3K4me1 marks ‘poised’ enhancers as well as 
active enhancers (Creyghton et al. 2010; Rada-Iglesias et al. 2011). Further, poised 
enhancers, which are marked by H3K4me1 alone, can be distinguished from active 
enhancers, which are marked by H3K27ac with or without H3K4me1 (Creyghton et al. 
2010). Several chromatin marks are associated with actively transcribed gene bodies, 
notably H3K36me3, H4K20me1, H2BK5me1, and H3K79 methylation. The density of 
H3K36me3 marks is lowest at the promoter, increases along the length of the gene body, 
and is highest at the 3’ end, while H4K20me1, H2BK5me1, and H3K79me3 peak at or 
near the TSS (Barski et al. 2007; Hon et al. 2009; Schulze et al. 2009; Ernst et al. 2011). 
As mentioned above, trimethylation of H3 lysine 27 is a repressive modification, 
catalyzed by Polycomb Repressive complex 2 (PRC2). H3K27me3 is observed in broad 
domains across the gene body of repressed genes (Squazzo et al. 2006; Pauler et al. 
2009), where it inhibits transcriptional elongation (Chen et al. 2012). H3K27me3 is also 
observed in combination with H3K4me3 at ‘bivalent’ promoters, which are frequently 
found in embryonic stem (ES) cells, and resolve during differentiation into active or 
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inactive genes, marked by H3K4me3 or H3K27me3, respectively (Bernstein et al. 2006); 
Bivalently marked promoters are also found in differentiated cells (Roh et al. 2006).  
Histone 3 can be marked by K4me3 and K27me3 on the same nucleosome (Voigt et al. 
2012), hence the bivalency observed in genome-wide studies does not merely describe a 
situation where one cell population is marked by K4me3 and another by K27me3. 
H3K9me3 is another repressive mark; it occurs at promoters and throughout gene bodies 
of inactive genes, but is more strongly associated with heterochromatic non-genic regions 
such as repetitive elements, centromeric, and telomeric regions (Rosenfeld et al. 2009). 
Finally, specific combinations of chromatin modifications have been observed at exons 
and introns, with fine-tuned patterning that distinguishes exons closest to the promoter 
from those near the 3’ end of genes, and these patterns may link splicing, elongation and 
transcription (reviewed in Black et al. 2012). 
Characterizing the genome by chromatin environment 
Studies mapping multiple chromatin modifications genome-wide have provided insight 
into the roles played by combinations of chromatin marks in maintaining chromatin 
structure at different genomic loci and in different cell types, and how the chromatin 
environment at regulatory sites and genes relates to gene expression. Wang et al (2008) 
mapped 39 histone modifications, including methylations, acetylations, and the histone 
variant H2A.Z across the genome in CD4+ T cells. Binary ‘present’ or ‘absent’ calls were 
assigned to each modification at each promoter (TSS ± 1 kb) or enhancer (DHS ± 200 
bp), and based on these binary designations, patterns of chromatin modifications that 
occur at promoters and enhancers were defined. Three classes of chromatin patterns were 
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most prevalent at promoters, based on gene expression. First, an inactive promoter class 
was characterized by no modifications, or K27me3 with other modifications, or K4me3 
alone. Second, one active class was associated with expressed genes that contained 
K36me3 or a “backbone” of 17 chromatin modifications that tend to coexist with each 
other and not with K27me3. These backbone modifications provide evidence of 
cooperation and cross-talk between histone modifications in order to achieve a desired 
expression level by “reinforcing” a particular chromatin state. Third, a second active class 
was associated with highly expressed genes and enriched for housekeeping GO (gene 
ontology) terms. Distal enhancers were assigned to their nearest genes, but by this 
approach, correlations were not seen between enhancer-associated modifications and 
target gene expression, which illustrates the difficulty of simply mapping putative 
enhancers to the nearest gene, due to the complexity of gene regulation by distal 
enhancers. Indeed, 5C analyses have shown that distal elements have looping interactions 
that frequently ‘skip’ nearby genes, with only 20% of distal elements interacting with the 
nearest TSS, and 47% with the nearest expressed TSS (Sanyal et al. 2012).  
Analysis of chromatin states is facilitated by use of segmentation methods such as a 
hidden Markov Model ChromHMM, applied to subdivide the human genome into 
chromatin states based on chromatin modifications and CTCF binding sites (Ernst et al. 
2011). Binary parameters are assigned for the presence or absence of each chromatin 
modification at predefined 200-bp segments of the genome, and the binary emission 
parameters are input into the HMM to uncover the hidden state structure. Using eight 
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chromatin modifications and CTCF, a 15-state model was found to be biologically 
meaningful and consistently recovered in the nine human cell types examined. The 
learned model very well predicted the locations of TSSs and transcribed regions, and it 
also distinguished active, repressed, and poised promoters, strong and weak enhancers, 
and strongly and weakly transcribed regions. In concordance with results from DNase-
seq studies, promoter states were more stable across cell types than enhancer states. More 
specifically, k-means clustering of promoters and enhancers by their probability of being 
in ‘strong’ or ‘active’ chromatin states across each of the nine cell types, followed by 
functional enrichment analysis of clusters, revealed that developmental genes are 
regulated by promoters and enhancers, housekeeping genes are primarily regulated by 
promoters, and cell-type-specific genes are largely regulated by enhancers. Enhancers can 
be linked to putative target genes more accurately than using a nearest-gene approach, by 
training logistic regression classifiers to use correlations across cell types between 
‘activity profiles’ of enhancers and genes – gene expression and signal intensities for 
enhancer-associated modifications – in combination with genomic distance (Ernst et al. 
2011). Motif enrichment can then be carried out to predict TFs that bind at enhancers in 
an enhancer cluster. To determine whether a predicted TF serves as an activator or a 
repressor, motif enrichment scores can be correlated with TF expression scores, defined 
as the correlation between TF expression and enhancer activity profile across cell types. 
A positive correlation between motif enrichment and TF expression score indicates 
activation, while a negative correlation indicates repression. Following this approach, 
predicted enhancer-gene linkages are validated using eQTL (expression quantitative trait 
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loci) data for SNPs (single nucleotide polymorphisms) that affect expression of distal 
genes, and TF binding predictions are validated by looking for nucleosome depletion at 
putative TF binding sites and using luciferase reporter assays (Ernst et al. 2011). Thus, by 
identifying chromatin states genome-wide across multiple cell types, two tiers of 
regulation can be elucidated: TFs that bind trans and either stabilize enhancers in an 
active conformation or act as repressors, and cis-regulation activity by enhancers that 
control downstream gene expression. This analysis can be used to identify both known 
and novel regulators in individual cell types, as well as identify potential regulatory 
functions of disease-associated SNPs.  Another genome-segmentation approach, Segway, 
uses a Dynamic Bayesian Network (DBN) approach, which is not limited to the 
assignment of binary signal values in 200-bp windows, giving finer resolution (Hoffman 
et al. 2012). Segway can be used to integrate chromatin modification data with TF 
binding data and data on open chromatin (DNase-seq and FAIRE-seq).  
 
1.E Integration of epigenomics with TF binding and gene expression 
The interplay between TF binding and chromatin modifications has been explored 
considerably to elucidate how chromatin organization influences cell type-specific TF 
binding and gene regulation, and to discern the impact that individual TFs have on 
chromatin environment.  
1.E.1 Chromatin structure and cell type- and tissue-specific gene regulation 
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The temporal relationship between cell type-specific TF binding, and cell type-specific 
gene expression was examined in studies of the mammalian hematopoeitic system by 
mapping binding sites for transcription factors, enhancer associated modification 
H3K4me1/H3K4me3, and gene expression (Heinz et al. 2010). In order to establish 
dependency between TFs, binding site maps for various transcription factors were 
generated in macrophages and B cells and compared between cells that either expressed 
or did not express other TFs. To deduce the relationship between TF binding and 
chromatin remodeling, H3K4me1/H3K4me3 and nucleosome occupancy were mapped 
over time following activation of the pioneer transcription factor PU.1. PU.1 is required 
for the generation of common lymphoid progenitor and granulocyte-macrophage 
progenitor cells from a lymphoid-primed multipotential progenitor.  
Macrophage-specific and B cell-specific PU.1 binding sites were found to be enriched for 
sequence motifs of macrophage-specific and B cell-specific transcription factors, 
respectively, and this was confirmed by ChIP-seq (chromatin immunoprecipitation 
coupled to high throughput sequencing) mapping of C/EBPα and C/EBPβ in 
macrophages and Oct-2 in B cells. ChIP-seq was carried out in cells deficient in PU.1 or 
in cell-type-specific TFs in order to determine whether PU.1 promotes binding of its 
associated factors, or vice versa. PU.1 binding was dependent on the activity of lineage-
determining TFs, and the opposite was also true – lack of PU.1 also resulted in loss of 
C/EBPβ binding. Thus, there is interplay between factors that interact with each other to 
achieve cell type-specific binding. In contrast, for a signal-responsive TF, LXRβ, binding 
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was found to be dependent on PU.1, but not vice versa, and consequently, signal-
responsive expression of target genes was also dependent on PU.1 binding (Heinz et al. 
2010). The authors describe these as a two-tier system of transcription factors – first tier 
TFs collaborate to generate active enhancers, and second tier TFs include signal-
dependent TFs, which in at least one case (Ghisletti et al. 2010), recruit the coactivator 
p300 at pre-existing H3K4me1 sites.  
Cell-type-specific binding sites for PU.1, Oct-2 and C/EBP are also associated with cell-
type-specific H3K4 methylation, with a bimodal H3K4me1 peak centered at PU.1 
binding sites (Heinz et al. 2010). H3K4me1 was mapped in a time course study at 0, 1-
hour, and 24-hour time points following activation of PU.1, to ascertain the temporal 
relationship between TF binding and H3K4 monomethylation. The largest group of sites 
(43% of highly induced PU.1 binding sites) gained H3K4me1, in a bimodal distribution, 
within 1 kb of an induced PU.1 site over the 24-hour period, and 90% of gained 
H3K4me1 occurred at induced PU.1 sites, together suggesting that PU.1 directs H3K4 
monomethylation. A smaller set of sites (32%) had preexisting H3K4me1 marks but 
exhibited C/EBPβ binding. No increase in H3K4me1 deposition was seen at a third set of 
sites (25%), but these sites, unlike the others, were not enriched for up-regulated target 
genes. Thus, PU.1 and associated factors induce an increase in H3K4me1. Further, 
MNase-seq analysis showed that PU.1 binding induces nucleosome remodeling within 1 
hour by expansion of the linker region between nucleosomes, centered on the PU.1 
binding site, and compression of nucleosomes in either direction. Since H3K4me1 marks 
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were not detected at the H3K4me1-induced until the 24-hour time point after stimulation 
of PU.1 binding, H3K4 monomethylation is apparently a late response that follows PU.1-
induced nucleosome remodeling. Promoter-distal enhancers marked by H3K4me1 were 
found to be enriched for cell-specific TF motifs in other cell types in mouse, including 
liver (Heinz et al. 2010). 
Nucleosome remodeling to facilitate TF binding was also observed during differentiation 
of hematopoietic stem cells (HSCs) to erythrocytes (Hu et al. 2011), where the BRG1 
subunit of the chromatin-remodeling BAF complex, recruited by GATA1, facilities 
nucleosome repositioning at GATA1 binding sites. This leads to a longer nucleosome-
free region, by shifting flanking nucleosomes, at which the TF TAL1 binds and regulates 
gene expression. This is another example of interplay between TFs and chromatin 
remodeling, where binding of pioneer factors like PU.1 and GATA1 precedes chromatin 
remodeling, which in turn allows other TFs to bind. 
The temporal relationship between chromatin modifications and TF binding and its 
impact on changes in gene regulation in response to stimuli was also investigated in 
dendritic cells stimulated with the pathogen component LPS (lipopolysaccharide) (Garber 
et al. 2012). A high throughput ChIP (HT-ChIP) approach coupled with multiplexed 
genome-wide sequencing was used to map binding sites for 25 TFs, Pol II, and 3 
chromatin modifications at 4 time-points. H3K4me1 was used to define enhancers and 
H3K4me3 to define promoters. H3K4me3 was found to be relatively static, while 
H3K27ac was more variable and correlated with Pol II binding. However, TF binding 
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was found to be much more dynamic than the histone modifications examined. 
Concordant with the model described by Heinz et al (2010), above, TFs that work at 
different levels were identified: the pioneer factors PU.1 and Cebpb were bound prior to 
cell stimulation, and binding remained static during the stimulus response and correlated 
with the baseline epigenetic state of the cell (Garber et al. 2012). A second layer of TFs, 
designated “primer” factors, was bound prior to stimulation but correlated with future 
gene induction potential in response to stimulus – “priming” the genes for response. 
Finally, a third layer of TFs, including STATs, bound dynamically in response to 
stimulus and targeted subsets of genes that carry out specific biological functions. Genes 
that were induced in response to stimuli were bound by a larger number of TFs than 
genes that did not respond, indicating co-ordinated regulation by multiple TFs. 
The studies above indicate that differential TF binding can be regulated by differences in 
chromatin modifications at different genomic loci, and at loci that are active or expressed 
in different cell types, as well as by differences in nucleosome positioning. Differences in 
the shape and magnitude of chromatin features at TFBSs and TSSs are also associated 
with differences in gene expression (Kundaje et al. 2012). TSSs have inherent and known 
directionality, and asymmetrical distributions in chromatin modifications are commonly 
seen surrounding TSSs (e.g. Barski et al. 2007). Heterogeneous and asymmetric patterns 
in nucleosome positioning and chromatin modifications can be identified at anchors, 
including TSSs and TFBSs, using the unsupervised clustering algorithm CAGT 
(Clustered AGgregation Tool) (Kundaje et al. 2012).  Two major patterns of nucleosome 
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positioning are seen around TSSs: TSSs whose nucleosomes are positioned upstream of 
the TSS and show low nucleosome occupancy downstream have comparatively high gene 
expression levels, while TSSs that show the opposite pattern are characterized by lower 
gene expression. TFBSs also frequently show asymmetric, heterogeneous, and cell-type-
specific patterns in nucleosome positioning and chromatin modifications, with only four 
exceptions out of 148 TFBS datasets (Kundaje et al. 2012). These different asymmetric 
patterns were observed for multiple chromatin modifications, including both activating 
and repressive modifications, but the patterns for different chromatin modifications were 
not necessarily correlated with each other: for example, at promoters, H3K4me1 and 
H3K4me3 were anti-correlated. Thus, in the most commonly observed cluster at 
promoters bound by the Pol II subunit POLR2A, H3K4me1 signal was low upstream of 
the summit and increased steadily in the downstream direction, while H3K4me3 signal 
showed the opposite, almost mirror-image, pattern. An anti-correlated pattern was also 
seen between co-localized repressive modifications H3K27me3 and H3K9me3 
surrounding TSSs. Furthermore, asymmetry in nucleosome positioning around a TFBS 
does not preclude symmetric signals for particular histone modifications, and a large 
fraction of TFBSs and POLR2A binding sites occur at “switch points” between different 
chromatin modifications on either side of the binding site (Kundaje et al. 2012). These 
findings indicate very complex relationships between chromatin landscape and binding of 
TFs and other DNA-binding proteins, which are likely to have functional importance in 
regulating gene expression. 
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1.E.2 Chromatin remodeling responses to hormone signaling 
Chromatin remodeling is an important aspect of reconfiguring the epigenetic state across 
the genome during development and differentiation, and is reflected in cell type-specific 
chromatin modification and nucleosome positioning patterns in differentiated cells, in 
particular at enhancers, as described above. Chromatin remodeling also occurs in 
response to short term stimulation by hormones (Biddie 2011), including in rat liver in 
response to GH signaling (Chia and Rotwein 2010).  
GH-induced chromatin remodeling has been observed in the form of changes in H3 and 
H4 acetylation at selected GH-responsive, STAT5b-activated promoters in livers of 
Hypox rats treated with GH (Chia and Rotwein 2010).  The Igf1 promoter, unlike certain 
other GH-responsive genes examined, is poised for expression prior to GH stimulation, as 
indicated by high baseline levels of H3K4me1, and high levels of RNA polymerase II, 
p300, and Med1/Trap220 bound at the promoter in a preinitiation complex. H3K4me1 
and K4me3 levels declined at the Igf1 promoter but not at the other promoters following 
GH stimulation. Histone acetylation marks active enhancers and promoters, and 
H3K4me1 and H3K4me3 often mark poised enhancers and promoters, as described in 
section 1.D.2 above. Hence, the induction of histone aceylation at Igf1 and other GH 
responsive genes indicates chromatin remodeling into an ‘active’ epigenetic state upon 
GH stimulation, and in the case of Igf1, resolution from a poised to an active state. 
DNase-seq analysis (Ling et al. 2010 and Chapter 4) showed that GH treatment changes 
chromatin accessibility genome-wide in mouse liver, including several Igf1-associated 
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DHSs in male liver that are suppressed by treatment with the female-like GH pattern, but 
the study did not interrogate specific chromatin modifications.  
Hormone-responsive nuclear receptors 
The nuclear receptor (NR) superfamily of TFs is well-known for its chromatin 
remodeling activity. It includes TFs that respond to hormones, such as estrogen receptor 
(ER), glucocorticoid receptor (GR), progesterone receptor (PR), and androgen receptor 
(AR)  (reviewed by Biddie et al. 2010), as well as TFs that respond to structurally diverse 
drugs and other foreign chemicals (Hernandez et al. 2009; Chai et al. 2013).  
Glucocorticoid receptor (GR) and Progesterone receptor (PR) 
Both GR and PR induce de novo chromatin remodeling at the MMTV gene promoter in 
response to hormone activation (Richard-Foy and Hager 1987; Truss et al. 1995; Deroo 
and Archer 2001; Vicent et al. 2011). The Swi/Snf complex, an ATP-dependent 
chromatin remodeling complex, has been implicated in GR-mediated regulation of 
selected genes (Deroo and Archer 2001). Chromatin remodeling by Swi/Snf is required 
for dexamethasone induction of at least 40% of GR-stimulated genes, highlighting the 
importance of the Swi/Snf complex for hormone response (John et al. 2008). ChIP-chip 
analysis of GR binding sites at select genomic regions, along with DNase 
hypersensitivity analysis, showed that GR binding occurs at both hormone-induced and 
constitutive DHSs, and not all of the hormone-induced DHSs required Swi/Snf activity 
(John et al. 2008).  GR binding is thus associated with at least two different mechanisms 
of chromatin remodeling.  However, subsequent genome-wide analysis of GR binding  
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and DNase-seq in multiple cell types showed that the vast majority of new GR binding 
sites induced by ligand activation occur at sites that are in a preexisting accessible 
chromatin state (as measured by DNase hypersensitivity) (John et al. 2011). The subset of 
GR binding sites that were inaccessible prior to hormone stimulation were partitioned 
according to the specific GR motif sequence that matched the binding site, and these 
motif classes were ranked by the fraction of GR binding sites containing each motif that 
were accessible before hormone stimulation. The ranking revealed a relationship between 
the specific GR binding element motif and the proportion of such sites requiring 
chromatin remodeling, indicating local sequence-specific differences in hormone 
responsiveness of chromatin structure at regulatory sites (John et al. 2011). Chromatin 
accessibility of GR binding sites is dependent on AP1, which acts as a pioneer factor for 
GR binding (Biddie et al. 2011). 
A recent study profiled DNase hypersensitivity, nucleosome positioning, PR binding, and 
localization of chromatin remodeling enzymes genome-wide in breast cancer cells before 
and after treatment with progestins (Ballare et al. 2013).  By integrating DNase-seq and 
MNase-seq data, it was determined that PR binding frequently occurs at PRbs (PR 
binding sites) that are accessible to DNase I, but are enriched for nucleosomes, prior to 
hormone stimulation. Histones H1 and H2A/H2B, but not H3/H4, are displaced following 
hormone treatment, and this chromatin remodeling is accompanied by increased DNase 
hypersensitivity.  Thus, even though hormone-induced GR binding sites were largely 
accessible prior to hormone induction (John et al. 2011), analysis of  nucleosome 
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positioning by MNase digestion may nevertheless reveal sites that undergo hormone-
induced remodeling. Nucleosome remodeling at PRbs is a requirement for hormone-
responsive regulation of associated genes, but the extent of remodeling is not correlated 
with the increase in gene expression (Ballare et al. 2013). A chromosomal conformation 
capture (3C) assay confirmed one instance of a hormone-stimulated interaction between a 
PRbs located at the EFGR promoter and a PRbs located at an enhancer (defined by the 
presence of H3K4me1) located 52 kb upstream of the TSS. Hormone-mediated chromatin 
remodeling can thus occur at a distal regulatory site that physically interacts with a 
hormone-responsive gene.  
Estrogen receptor (ER) and Androgen receptor (ER) 
Early high throughput ER mapping studies in estradiol-stimulated breast cancer cells 
revealed the existence of distal ER binding sites and implicated the pioneer factor 
FOXA1 (Magnani et al. 2011) in facilitating binding (Carroll et al. 2005). A subsequent 
genome-wide study confirmed distal binding by ER, including binding sites as far as 200 
kb from target gene TSSs,  and demonstrated a correlation between ER binding and target 
gene expression (Carroll et al. 2006). Two modes of ER-mediated down-regulation were 
observed: early-down regulated genes appeared to be down regulated by physiological 
squelching, whereby multiple TFs compete for cofactors that are present in a limiting 
concentration in the cell; and late-down regulated genes required direct binding by ER 
and may therefore be regulated by estrogen-induced repressors or corepressors. Motif 
discovery at ER binding sites identified Forkhead and other cooperating factors, and 
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binding by FOXA1 and other factors were confirmed by ChIP experiments at 26 ER 
binding sites.  
FOXA1 has also been implicated as a pioneer factor in AR binding in LNCaP prostate 
cancer cells (Lupien et al. 2008). Cell-type-specific binding of FOXA1 was observed 
primarily at distal regulatory sites in MCF7 breast cancer cells, where genes bound by 
both ER and FOXA1 were more likely to be up- or down-regulated by estrogen 
treatment, as compared to genes bound by either factor alone. Comparing MCF7 and 
LNCaP cells, FOXA1 binding is very cell-type-specific, with EREs (estrogen response 
elements) enriched at MCF7-specific FOXA1 binding sites and AREs (androgen 
response elements) enriched at LNCaP-specific FOXA1 binding sites. Conversely, the 
majority of enhancers that bind both FOXA1 and ER are MCF7-specific, while enhancers 
that bind FOXA1 and AR are LNCaP-specific. Target genes of FOXA1 binding sites 
overlapping ER or AR were also enriched for genes regulated by estradiol or 
dihydrotestosterone (DHT), respectively, showing that differential recruitment of FOXA1 
is a mechanism by which cell-type-specific hormone-mediated gene regulation is 
achieved (Lupien et al. 2008). This cell-type-specific recruitment of FOXA1 was also 
associated with cell-type-specific H3K4me1 and H3K4me2 marks. When FOXA1 was 
down regulated using an siRNA, DNase hypersensitivity was decreased at FOXA1 
binding sites consistent with the proposed role of FOXA1 in chromatin opening, 
however, H3K4 methylation was unaffected.  Thus, the cell-type-specific pioneer factor 
activity of FOXA1 in this system involves chromatin opening but not H3K4 methylation. 
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H3K4 methylation was instead necessary for FOXA1 recruitment, as shown by decreased 
FOXA1 binding when the H3K4 demythlase KDM1 was overexpressed.  
A later study found that cell-type-specific FOXA1 binding sites are enriched for 
H3K4me2 and also H2A.Z, which mark enhancers, and depleted of DNA methylation 
(Serandour et al. 2011). To examine the kinetics of chromatin remodeling and FOXA1 
binding, H3K4me2 and DNA methylation were monitored in a time course study of  six 
FOXA1 binding sites in P19 cells treated  with retinoic acid to induce differentiation. At 
all but one site, FOXA1 binding preceded H3K4 dimethylation and DNA demethylation. 
DNA demethylation, in turn, was shown to be a prerequisite for enhancer activity, as 
measured by luciferase reporter assays, and stabilized FOXA1 binding. Thus, chromatin 
remodeling in association with FOXA1 binding is a dynamic response to retinoic acid 
stimulation. FOXA1-mediated, hormone-dependent chromatin remodeling at ER binding 
sites was demonstrated in FAIRE-seq experiments; FOXA1 was shown to be necessary 
for chromatin opening at ER binding sites that are inaccessible prior to hormone 
treatment (Hurtado et al. 2011). Moreover, FOXA1 is required for the action of 
tamoxifen, which inhibits estrogen-ER activity in breast cancer cells. Not all ER binding 
sites co-occur with FOXA1 binding, suggesting roles for additional pioneer factors, such 
as AP2 transcription factors (Jozwik and Carroll 2012). 
The relationship between H3K4me2, DNase hypersensitivity and cell-type-specific 
hormone-responsive FOXA1 binding was investigated further by He et al (2012). At both 
AR and ER binding sites, DNase hypersensitivity increases when the receptors are bound 
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(He et al. 2012), showing that DNase hypersensitivity is dynamic and a good predictor of 
TF binding. Further analysis supported the physiological squelching hypothesis for 
estrogen-mediated early-down regulation proposed earlier (Carroll et al. 2006). Linear 
regression of FOXA1 ChIP-seq tag counts in estrogen sitmulated vs. untreated cells 
showed that FOXA1 binding with stimulation was no different at DHSs whose 
accessibility is unchanged by estrogen stimulation as compared to DHSs that become less 
accessible upon estrogen stimulation (hormone-diminished DHSs) (He et al. 2012). In 
contrast, binding of the ER coactivator NCOA3 was lower in hormone-diminished DHSs 
compared to unchanged DHSs, suggesting that NCOA3 is less available for binding at 
hormone-diminished DHSs upon estrogen stimulation. 
Distinct H3K4me2 profiles are seen at ER, AR, and FOXA1 binding sites. In uninduced 
LNCaP cells, at sites bound by AR but not FOXA1, H3K4me2 formed a broad 
monomodal peak, compared to a bimodal peak at FOXA1 binding sites or androgen-
induced AR binding sites.  In MCF7 cells, only FOXA1-only binding sites showed a 
bimodal H3K4me2 peak, both before and after estrogen treatment (He et al. 2012). Thus, 
AR, but not ER, appears to have nucleosome remodeling activity in response to hormone 
stimulation. However, silencing of FOXA1 has a significant impact on the genome-wide 
locations of AR binding: some sites lose AR binding, but a larger number of new AR 
binding sites are induced upon FOXA1 silencing, with a similar effect seen on GR 
binding sites (Sahu et al. 2011). The induced AR binding sites are enriched for the motif 
for CTCF, an insulator protein that plays a role in chromatin looping. These results 
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indicate a complex regulatory role for FOXA1. At select AR target genes, treatment with 
circumin, which has been suggested to inhibit NR function and promote cell death, leads 
to decreased recruitment of histone acetyl transferases and subsequent histone acetylation 
at regulatory enhancers (Shah et al. 2012). This is proposed to be accomplished via 
inhibition of p300 histone acetylase activity by covalent bonding between circumin and 
p300 (Marcu et al. 2006). Treatment with circumin also decreased recruitment of pioneer 
factors GATA2 and FOXA1 (Shah et al. 2012). Together, impairment of histone 
acetylation and pioneer factor binding inhibit AR binding in response to hormone 
treatment, leading to suppressed tumor growth. Thus, tumor progression may be 
suppressed therapeutically by changing chromatin remodeling and pioneer factor 
recruitment induced by hormone signaling. 
The results described above show that the different hormone-activated regulatory 
pathways involve different interactions between chromatin environment, hormone-
activated nuclear receptors, and other TFs. In all cases, hormone-activated NRs bind to 
sites that are in an accessible chromatin state after hormone stimulation, and in the case 
of PR, AR and ER, hormone treatment increases binding site accessibility.  While PR and 
AR appear to have chromatin remodeling activity, ER does not, and AR, GR and ER bind 
sites that have been remodeled by other pioneer factors such as AP1 and FOXA1. 
FOXA1 and FOXA2 in liver 
FOXA1 binding facilitates recruitment of other TFs to the Alb gene enhancer during liver 
differentiation (Zaret 1999) and FOXA1 and FOXA2 open compacted chromatin in vitro 
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(Cirillo et al. 2002; Sekiya et al. 2009).  FOXA1 and FOXA2 are required for sexual 
dimorphism in susceptibility to hepatocellular carcinoma, by mediating estrogen-
dependent resistance to tumorigenesis and androgen-mediated promotion of 
tumorigenesis (Li et al. 2012), suggesting they may play a more global role in regulating 
sex-dependent gene expression in liver. 
Binding sites for FOXA2 and tissue-specific factors were mapped genome-wide in islets 
and liver, and examined for their relationship with H3K4me1 distribution and target gene 
expression (Hoffman et al. 2010). In liver, both bimodal and monomodal patterns of 
H3K4me1 marks occur at FOXA2 binding sites and at binding sites for HNF4α, but the 
bimodal loci are associated with more highly expressed genes and more likely to confer 
liver-specificity. Comparing K4me1 patterns at TF binding sites in liver and islet cells, 
peaks that are bimodal in liver and monomodal in islets are associated with liver-specific 
genes, and similarly for bimodal peaks in islets and islet-specific genes. Bimodal K4me1 
loci in liver are also most likely to be co-occupied by FOXA2 and HNF4α. MNase 
digestion followed by qPCR to map the position of nucleosomes at select sites that were 
bimodal in one tissue and monomodal in the other confirmed that the bimodal K4me1 
peak corresponds to nucleosome depletion at the peak center. Thus, FOXA2 may mediate 
nucleosome remodeling to activate liver-specific and islet-specific enhancers. However, 
only about half of all FOXA2 binding genome-wide occurs at nucleosome-bound sites, 
including some sites that exhibit a bimodal K4me1 distribution (Li et al. 2011). Hence, 
just as presence of a DHS does not necessarily imply a nucleosome-free region (Ballare 
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et al. 2013), a dip in K4me1 cannot be taken to be definitive evidence for nucleosome 
repositioning. 
 
1.E.3 Genomics and epigenomics of liver sexual dimorphism 
Transcription factor binding 
To examine genomics of sex-dependent gene regulation in liver, several of the 
transcription factors described in section 1.C that are known to be involved in sex-biased 
liver gene expression have recently been mapped by ChIP-seq in order to elucidate their 
actions genome-wide. The results from these studies confirmed predictions from the 
DNase-seq study and also provided many new insights. 
STAT5 and BCL6 – dynamic binding to overlapping motifs 
BCL6 is a repressor (Chang et al. 1996; Seyfert et al. 1996) that is expressed more highly 
in male liver than female liver (Meyer et al. 2009). BCL6 and STAT5 bind very similar 
sequences (Hartatik et al. 2001). BCL6 cycles dynamically with STAT5 binding and 
contributes to GH-regulated gene expression (Chen et al. 2009; Meyer et al. 2009; Chia 
and Rotwein 2010). STAT5 and BCL6 binding sites were classified based on the 
presence or absence of BCL6 binding in male, and whether STAT5 binding was male-
enriched, female-enriched, sex-independent, or absent (Zhang et al. 2012). Continuous 
GH treatment in male liver, which feminizes gene expression (Holloway et al. 2006) and 
open chromatin (Ling et al. 2010 and Chapter 4) by suppressing male-biased and 
inducing female-biased genes and DHSs, also feminizes STAT5 binding activity as seen 
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in EMSA analysis  (Zhang et al. 2012). The dynamic nature of STAT5 binding in 
response to plasma GH pulses and GH-free interpulse intervals seen in studies of select 
genes was confirmed on a genome-wide scale; sites bound during GH pulses, that also 
exhibited residual binding during low-GH intervals, were more likely to be strong 
STAT5 binding sites. However, there was no relationship between the number of BCL6 
binding sites and STAT5 activity status in male liver. TFs implicated by motif analysis to 
co-occur with male-enriched STAT5 binding site included HNF6/CDP and PBX1, in 
agreement with earlier analysis of motifs associated with male-biased DHS (Ling et al. 
2010 and Chapter 4). The de novo discovered motifs for HNF6/CDP and for 
HNF4/PPAR exhibited differences in the sequence motif between different classes of 
STAT5/BCL6 binding sites  (Zhang et al. 2012), which could reflect binding of different 
family members at each class of binding sites, post-translational or other differences in 
the binding TFs, or binding in different TF complexes, leading to subtle differences in 
sequence specificity (Arvey et al. 2012).  
Genes associated with male-enriched STAT5 binding are enriched for genes down 
regulated in male liver following Hypox, as defined in section 1.C.2 (Wauthier et al. 2010 
and Chapter 3), while genes associated with female-enriched STAT5 binding were 
enriched for genes down regulated following Hypox in female but not in male liver 
(Zhang et al. 2012). Since Hypox ablates GH, which eliminates liver STAT5 activity, 
these results are consistent with GH-activated STAT5 being a major regulator of sex-
biased gene expression in mouse liver. BCL6 binding is enriched at female-biased gene 
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targets, in particular when the gene is also targeted by STAT5 in a female-enriched or 
sex-independent manner (Zhang et al. 2012). Sex-biased STAT5 binding occurs at sites 
with sexually dimorphic chromatin accessibility, BCL6 binding does not. In particular, 
male-enriched and female-enriched STAT5 binding sites show the same level of 
chromatin accessibility (DNase hypersensitivity) in male liver, with male-enriched sites 
being more closed in female liver and female-enriched sites more open in female liver. 
Conversely, while male-enriched and female-enriched STAT5 sites show similar levels 
of the repressive modification H3K27me3 in female liver, H3K27me3 marks are elevated 
in male liver at female-enriched sites and slightly lower in male liver at male-enriched 
sites (Zhang et al. 2012). These results indicate differences in the role played by 
chromatin modifications in male-biased and female-biased gene regulation. 
CUX2 – a female-specific repressor 
CUX2 binding sites were mapped genome-wide in mouse liver in male and female liver 
(Conforto et al. 2012) to test the hypothesis that the female-specific repressor CUX2 (Laz 
et al. 2007) suppresses male-biased genes in female liver by a mechanism analogous to 
the repression of female-biased genes in male liver by BCL6. ChIP-seq binding data for 
CUX2 was integrated with microarray experiments comparing the impact of CUX2 down 
regulation in female liver, as well as CUX2 overexpression in male mouse liver. 
Consistent with its highly female-specific expression, CUX2 binding was largely absent 
in male mouse liver, whereas ~1500 peaks of CUX2 binding were identified in female 
liver. The finding that CUX2 motifs are enriched at male-biased DHS (Ling et al. 2010 
and Chapter 4) was confirmed, and CUX2 binding is also enriched at sites of male-
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enriched STAT5 binding (Zhang et al. 2012), consistent with the earlier finding (Ling et 
al. 2010 and Chapter 4) that both CUX2 and STAT5 motifs, among others, are enriched 
among the same set of male-biased DHS. CUX2 overexpression in male liver impacted 
both male-biased and female-biased genes, suppressing 35% of male-biased genes and 
inducing 36% of female-biased genes. Complementary findings were obtained in studies 
using CUX2-siRNA (Conforto et al. 2012). However, CUX2 binding in female liver was 
enriched at male-biased genes suppressed by over expression of CUX2 but not at the 
female-biased genes induced by CUX2 over-expression, suggesting that CUX2-mediated 
induction of female-biased genes is largely an indirect effect. However, the authors did 
observe CUX2 binding close to some female-biased genes, suggesting a potential 
activating role for CUX2 in addition to its repressive role. 
Sex-differences in chromatin structure 
In studies to be described in chapter 5 of this dissertation, STAT5, BCL6 and CUX2 
binding data described above were integrated with histone modification maps in male and 
female liver to further elucidate the relationship between these factors and chromatin 
structure at their respective binding sites and target genes. Comparison between male and 
female liver showed that while sex-biased DHS differ in their chromatin state 
environment, sex-biased gene TSSs largely do not. However, the subset of sex-biased 
genes with the largest sex-difference in gene expression do exhibit nearby sex-differences 
in chromatin marks. Moreover, these highly sex-biased genes are most likely to be 
targeted by STAT5 in a sex-biased manner. BCL6, on the other hand, preferentially 
targets female-biased genes that lack nearby sex-differences in chromatin marks, and 
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BCL6 predominantly binds at regulatory sites that are sex-independent in both DNase 
accessibility and in chromatin modifications.  
Differences were also observed in mechanisms of sex-biased gene regulation in male and 
female liver.  Sex-biased K27me3 is a characteristic of a subset of female-biased genes 
but not of male-biased genes, indicating that K27me3 is involved in silencing of female-
biased genes in male liver. Male-biased DHS are characterized by a sexually dimorphic 
K4me1 pattern surrounding the DHS peak, with a bimodal peak in male liver and 
monomodal peak in female liver. This differential pattern is most pronounced at sites that 
bind FOXA1/FOXA2 in a male-enriched manner, followed by sex-independent 
FOXA1/FOXA2 binding sites.  Sex-biased FOXA1/FOXA2 binding is correlated with 
sex-biased K4me1 and K27ac marks, which is also a characteristic of GH-responsive sex-
biased DHS. These findings suggest that GH may act to generate male-biased DHS via 
the actions of the pioneer factors FOXA1/FOXA2, which may be recruited by male-
biased K4me1, much in the way that FOXA1 is recruited to sites exhibiting cell type-
specific K4me1 and K4me2 in breast and prostate cancer cells, as described in section 
1.E.1 on ER and AR signaling above. The difference in K4me1 profile between male-
biased and female-biased DHS suggests sex-dependent nucleosome positioning at male-
biased but not female-biased DHS. This, in turn, may explain the difference between 
DNase hypersensitivity at male-enriched and female-enriched STAT5 binding sites 
observed by (Zhang et al. 2012): in male liver, male-enriched and female-enriched 
STAT5 binding sites exhibit similar levels of DNase accessibility, whereas in female 
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liver, male-enriched STAT5 binding sites exhibit much lower accessibility than female-
enriched STAT5 binding sites.  
 
In conclusion, hormone-mediated regulation involves complex interplay between 
transcription factors and chromatin structure. Insights into some of these mechanisms, 
both in stimulus-responsive gene regulation as well as  cell type- and tissue-specific gene 
expression, have been made via genomics methods utilizing high-throughput mapping of 
open chromatin regions and transcription factor binding, and epigenomics to chart 
chromatin modifications. In the system of GH-mediated sex-dependent liver gene 
expression, several factors have been identified that play a crucial role in GH-mediated 
regulation of sex-biased genes, in particular STAT5. The first goal in this dissertation, 
described in Chapter 2, was to computationally predict active STAT5 binding sites 
associated with select well-characterized GH-responsive genes. The second goal (Chapter 
3) was to characterize the impact of GH signaling globally on mouse liver gene 
expression. The third goal (Chapter 4) was to determine whether sex-differences are 
evident in chromatin accessibility, responsive to GH, and associated with sex-differences 
in gene expression. The final goal (Chapter 5) was to characterize sex-differences in liver 
chromatin structure by specific chromatin modifications, and identify relationships 
between these chromatin modifications and TF binding and gene regulation. 
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In the following chapters, the terms “sex-biased” and “sex-specific” are used 
interchangeably to refer to genes or sites that differ significantly − in gene expression, 
DNase hypersensitivity, or TF binding, as appropriate − between male and female liver.
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Chapter 2  
Computational prediction of STAT5 binding sites at growth hormone-regulated 
genes in rat liver1 
2.A Abstract 
 
Phylogenetic footprinting was used to predict functional transcription factor binding sites 
(TFBS) for signal transducer and activator of transcription (STAT) 5, a growth hormone 
(GH)-activated transcription factor, in three GH-responsive genes IGF-I, SOCS2, and 
HNF6. Each gene, including upstream (100 kb) and downstream (25 kb) regions, was 
aligned across four species and searched for conserved STAT5-binding sites using TFBS 
position weight matrices. Predicted sites were classified as paired or single and whether 
or not they matched the STAT5 consensus sequence TTCN3GAA. Fifty-seven of the 
predicted genomic regions were assayed by chromatin immunoprecipitation from male 
rat liver with high levels of active STAT5. STAT5 binding was enriched at eight genomic 
regions of IGF-I, including three novel regions in the second intron, and at four regions 
of SOCS2, including three novel upstream sites. STAT5 binding to HNF6 was modestly 
enriched at one consensus and two novel, nonconsensus sites. Overall, 14 of the 17 
identified sites were paired sites. Analysis of the verified STAT5 binding sites indicated 
that STAT5 TFBS matrix 459 in combination with a STAT5 consensus sequence was the 
                                                 
1 A modified version of this chapter was published in Molcular Endocrinology. Laz E.V., Sugathan 
A., and D. J. Waxman (2009). “Dynamic in vivo binding of STAT5 to growth hormone-regulated 
genes in intact rat liver. Sex-specific binding at low-  but not high-affinity STAT5 sites.”  Mol 
Endocrinol 23:1242. All experimental work was carried out by Dr. Ekaterina Laz, as noted in 
appropriate places in this chapter.  
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best predictor of STAT5 binding to these three genes. Using these criteria, multiple novel 
STAT5 binding sites were identified and then verified in several other GH-inducible 
genes, including MUP genes, where male-specific gene expression was associated with 
male-specific binding to multiple low-affinity STAT5 sites. 
 
2.B Introduction 
Growth hormone (GH), a pituitary-secreted polypeptide hormone, regulates a variety of 
metabolic processes, including fatty acid oxidation, amino acid uptake and protein 
synthesis (Le Roith et al. 2001). The primary targets of GH include liver, muscle and 
adipose tissue. GH is secreted from the pituitary in a sex-specific manner in rodents and 
humans (Tannenbaum and Martin 1976; Eden 1979; MacLeod et al. 1991; Pincus et al. 
1996). In adult male rats, peaks of GH secretion occur every 3 to 4 hr and are separated 
by periods when GH is virtually undetectable (‘episodic’ GH profile), while in adult 
female rats, plasma GH peaks are more irregular and basal levels of GH are elevated 
compared to males (‘continuous’ GH profile) (Tannenbaum and Martin 1976; Eden 
1979). These sexually dimorphic plasma GH profiles establish and maintain sex 
differences in longitudinal bone growth, as well as sex differences in the expression of a 
large number of genes in the liver (Shapiro et al. 1995; Ahluwalia et al. 2004; Waxman 
and O'Connor 2006). 
GH binding to its receptor on the cell surface stimulates transphosphorylation of the GH 
receptor-associated Janus kinase 2 (JAK2) and subsequent activation of several 
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intracellular signaling pathways (Herrington and Carter-Su 2001; Zhu et al. 2001; Pilecka 
et al. 2007; Rosenfeld et al. 2007), including that mediated by signal transducer and 
activator of transcription (STAT) 5b. STAT5b is the key mediator of GH signaling in the 
liver (Udy et al. 1997; Teglund et al. 1998; Davey et al. 1999; Holloway et al. 2007) and 
is activated by JAK2-dependent phosphorylation of tyrosine residue 699, which enables 
STAT5b to dimerize and translocate to the nucleus, where it binds to specific DNA 
response sequences and activates transcription of target genes (Hennighausen and 
Robinson 2008). DNA response elements for STAT5b and a closely related family 
member, STAT5a, collectively referred to as STAT5, can be represented by the 
consensus sequence TTCN3GAA (Ehret et al. 2001). STAT5 is sensitive to the signal 
dynamics of GH stimulation (pulsatile vs. near continuous) (Gebert et al. 1999a; Gebert 
et al. 1999b), and therefore displays differential responsiveness to plasma GH stimulation 
in male and female rat liver (Waxman et al. 1995b). In male rats, the pool of liver STAT5 
protein is repeatedly activated by each incoming plasma GH pulse; thus, there is a strong 
positive correlation between the plasma GH profile and the activity of STAT5 in the 
liver, with STAT5 activity levels being high during the upswing of a GH secretory 
episode and undetectable during the plasma GH trough periods (Choi and Waxman 2000; 
Tannenbaum et al. 2001). Female rats have substantially lower liver STAT5 activity 
compared with male peak levels, but their basal (interpeak) STAT5 activity, although 
low, is measurably higher than the basal level in males (Choi and Waxman 1999). 
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Insulin-like growth factor-1 (IGF-1) is a direct target of liver STAT5 (Woelfle et al. 
2003a; Woelfle et al. 2003b; Chia et al. 2006; Eleswarapu et al. 2008). IGF-1 mediates 
the effects of GH on somatic growth and tissue maintenance and also has GH-
independent functions (Le Roith et al. 2001; Yakar et al. 2002; Woelfle et al. 2005). The 
majority of circulating IGF-1 is produced in the liver where its expression is directly 
stimulated by GH (Daughaday and Rotwein 1989; Yakar et al. 1999). Using chromatin 
immunoprecipitation (ChIP), two DNA regions, each containing a pair of STAT5 binding 
sites, have been identified in the rat IGF1 locus: region RE-1/RE-2, located 75 kb 
upstream of the transcription start site (TSS), and region GHRE-1/GHRE-2, located in 
the first intron (Woelfle et al. 2003b; Chia et al. 2006). In rats that have been 
hypophysectomized – pituitary gland removed, so GH is not released – STAT5 rapidly 
binds to these two regions in liver following treatment with a supraphysiological dose of 
GH, which induces transcription of the IGF1 gene (Woelfle et al. 2003b; Chia et al. 
2006). The two 5’ distal STAT5 binding sites (RE-1/RE-2) were also identified in the 
human IGF1 gene through mapping of STAT5-binding enhancers (Wang and Jiang 
2005). In addition, three novel IGF1 regions containing a total of five conserved STAT5 
binding sites were identified by ChIP analysis of GH-treated mouse liver (Eleswarapu et 
al. 2008). 
STAT5 binding sites have been identified in liver for a limited number of other GH-
inducible genes. SOCS2 encodes a GH-inducible negative regulator of JAK/STAT 
signaling that acts on GH receptor and other cytokine receptor signaling pathways 
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(Flores-Morales et al. 2006; Rico-Bautista et al. 2006). A GH-response element 
containing a pair of STAT5 binding sites that is conserved between rat and human 
SOCS2 was identified in the rat (Vidal et al. 2007). As shown by ChIP analysis, GH 
rapidly stimulates binding of STAT5 to this region in the liver of hypophysectomized 
rats, coincident with the induction of SOCS2 gene transcription (Vidal et al. 2007). 
Hepatocyte nuclear factor 6 (HNF6) may also be a direct target of GH-activated STAT5 
(Lahuna et al. 2000). HNF6 is a female-predominant, liver-enriched transcription factor 
that regulates the transcription of a variety of genes (Lannoy et al. 1998; Rastegar et al. 
1998; Rastegar et al. 2000), including certain sex-dependent, GH-responsive CYP genes 
(Lahuna et al. 1997; Delesque-Touchard et al. 2000; Wiwi and Waxman 2005). A 
consensus STAT5 binding site in the HNF6 promoter that forms a GH-induced DNase I 
footprint was shown to bind STAT5 in vitro by electrophoretic mobility shift assay 
(EMSA), and this STAT5 binding site was required for GH-stimulated transcription of an 
HNF6 promoter-reporter gene construct (Lahuna et al. 2000). 
The known STAT5 binding sites in the IGF1, SOCS2 and HNF6 genes were all identified 
under non-physiological conditions, i.e. in the livers of hypophysectomized rats or mice 
given a supraphysiological dose of GH, or in vitro. Conceivably, additional binding sites 
might be bound by STAT5 in liver in vivo, and the extent to which these sites are 
occupied might differ between males and females, due to the sex differences in plasma 
GH profiles. Furthermore, STAT5 binding to chromatin may vary during the course of a 
naturally occurring plasma GH pulse in response to changes in intranuclear 
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concentrations of tyrosine phosphorylated STAT5. These and related issues are examined 
in the present study. I used a phylogenetic footprinting approach to predict STAT5 
binding sites in the genomic regions surrounding the IGF1, SOCS2 and HNF6 genes. Dr 
Ekaterina Laz experimentally verified these sites by ChIP analysis using livers of intact 
male and female rats. On the basis of these findings, a refined approach is used to predict, 
and then verify, liver STAT5 binding sites in several other primary GH target genes. We 
successfully identify previously known as well as novel STAT5 binding sites at these 
genes, and show that presence of a consensus STAT5 binding site is one of the most 
important predictors of STAT5 binding, however both presence of a consensus site and 
phylogenetic conservation are weak predictors of binding, illustrating that more complex 
factors, such as chromatin environment, may play a role in determining which putative 
STAT5 binding sites are active and functional in regulating gene expression. 
 
2.C Materials and Methods 
2.C.1 Prediction of STAT5 binding sites 
A computational phylogenetic footprinting method was developed to predict the 
occurrence of STAT5 binding sites that are conserved across the rat (rn4), mouse (mm8), 
human (hg18) and dog (canFam2) genomes for the IGF1, SOCS2, and HNF6 genes. 
Sequences encompassing 100 kb of upstream region, the full coding sequence region, and 
either 3 kb (IGF1 and SOCS2, due to sequence length limitations) or 25 kb (HNF6) 
downstream of the coding sequence, were first scanned individually for each species for 
52 
 
 
 
the occurrence of STAT5 binding sites, i.e., genomic sequences that match position 
weight matrices (PWMs) that describe a binding site for STAT5. A total of nine PWMs 
were used, five of which were obtained from the TRANSFAC database (Matys et al. 
2006). One of the TRANSFAC matrices, derived from a study of STAT5 binding to 
synthetic oligonucleotides (Soldaini et al. 2000), includes sequences that contain a 
STAT5 consensus site as well as sequences that bind STAT5 but do not match the 
STAT5 consensus sequence TTCN3GAA. In order to better detect non-consensus STAT5 
binding sites, this matrix was separated into two, by generating one PWM from the 
oligonucleotides that contain paired STAT5 binding sites with one consensus sequence 
(M00AS01), and a second PWM from paired sites with no consensus sequence 
(M00AS02). Two other matrices were generated from a set of published STAT5 binding 
sequences (Soldaini et al. 2000) that were not represented in any of the TRANSFAC 
STAT5 matrices – one for paired STAT5 binding sites with a 7 bp spacer sequence 
(M00AS03), and another for paired STAT5 binding sites that were weak binders 
(M00AS04). The nine STAT5 matrices used in this study are shown in Table 2-1. 
The matrix scanning tool Possum (Fu et al. 2004) was used to find sites in each genomic 
sequence that match one or more of the nine STAT5 matrices, using the default threshold 
log-likelihood ratio score of 5. Sequences from the four species examined were then 
aligned in order to identify hits that are conserved across species, which was 
accomplished as follows. Pairwise alignments were generated for the entire upstream, 
gene body, or downstream sequence, between rat and each of the other three species 
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using two different algorithms for rapid global alignment, AVID (Bray et al. 2003) and 
LAGAN (Brudno et al. 2003). VISTA (Mayor et al. 2000) was then used to identify 
conserved regions in each pairwise alignment. Conserved regions were defined as 
segments > 100 nt in length that are at least 70% identical between the two sequences. 
Since the two alignment algorithms produce different alignments, each genomic region 
corresponding to a predicted STAT5 site in the rat sequence was evaluated individually 
to choose the pairwise alignment (AVID or LAGAN) that produced the best alignment in 
that genomic region, for each of the other three species. The best alignment was defined 
based on the following criteria in a hierarchical manner, comparing the reference 
sequence (rat) with the aligned sequence in the species being compared: 1) number of 
predicted STAT5 binding sites in the reference sequence that are also predicted in the 
aligned sequence; 2) whether the aligned sequence is identical to the reference sequence; 
3) number of gaps in the alignment; 4) % identity. Sites that were shared across all four 
species were considered to be most likely to be functional in STAT5 binding. Each 
predicted STAT5 binding site was classified according to whether it contains the 
consensus STAT5 binding sequence TTCN3GAA in rat, which was used as the reference 
species. STAT5 binding sites were also classified as “single” or “paired”. A paired site 
was defined as one that has an overall length that is greater than twice the length of a 
single binding site for STAT5 (12 nts, including 3 nt flanking sequence), with a 
maximum intervening sequence length of 50 nt. Predicted STAT5 sites less than 50 nt 
apart, whether on the forward or reverse strand, were concatenated and classified as 
paired sites.  
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2.C.2 Experimental methods, carried out by Dr Ekaterina Laz of this laboratory 
For the experiments shown in Fig. 2-1, a high STAT5 activity adult male rat liver sample 
was used for initial screening. STAT5 activity for each sample was determined using 
EMSA analysis of a strong STAT5 response element (Fig. 2 in Laz et al. 2009). 
Chromatin was purified from freshly isolated liver nuclei that were immediately cross-
linked with formaldehyde using a procedure adapted from that for mouse liver (Chaya 
and Zaret 2004), followed by sonication. For all other analyses, cross-linked samples 
were prepared from frozen livers and then sonicated. All animal protocols were approved 
by the Boston University Institutional Animal Care and Use Committee. Chromatin 
immunoprecipitation was carried out as described in Laz et al., 2009. Real-time PCR 
results for each STAT5 binding region for a given liver sample were derived from 
averages of duplicate or triplicate immunoprecipitation samples. Data were normalized to 
input and are presented as fold increase over negative control. For a negative control, an 
amplicon centered within a 2,300 bp segment in the 5’ distal region of the rat IGF1 gene 
was used, which is devoid of any predicted STAT5 binding sites (genomic coordinates 
are listed in Supplemental Table S3 of Laz et al. 2009). Data obtained in ChIP analysis 
carried out using normal rabbit IgG in place of STAT5 antibody N-20 corresponds to a 
second control, and is presented in Fig. 2-1 and Fig. 2-2 for each qPCR primer pair. 
EMSA analysis of STAT5 binding sites was performed as described previously (Choi and 
Waxman 1999) with modifications. Dissociation constant (Kd) values were determined 
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by EMSA analysis of STAT5 binding to oligonucleotides representing sites 224 and 199 
of rat SOCS2 and site 304 of rat IGF1.  
2.C.3 Evaluation of matrices and parameters used for prediction of STAT5 binding sites 
A total of 79 prospective STAT5 binding sites in IGF1, SOCS2 and HNF6 were tested 
experimentally. These 79 sites include the sites for which real-time PCR primer pairs 
were designed (primary sites) plus any adjacent sites present in rat and located close 
enough to the primary site (within 150 nt) to be indistinguishable by ChIP. For primary 
sites that tested positive (i.e., showed ChIP enrichment), only those adjacent sites that 
contained a consensus STAT5 binding sequence and were identified by STAT5 matrix 
M00459 were considered. In the case of weak primary binding sites (sites GHRE-
1/GHRE-2, 217, 232 of IGF1 and sites 148, 157 and 181 of HNF6), the adjacent sites had 
to be located within 300 nt of the end of each amplicon, since a more distant site could be 
contributing to a weak signal. Each of the 79 sites was classified according to the 
following 18 possible predictors of binding: presence of a paired STAT5 site; presence of 
at least one consensus STAT5 site in rat; presence of at least one consensus STAT5 site 
in any species; STAT5 site found in three other species; STAT5 site found in at least two 
other species; STAT5 site found in at least one other species; region of STAT5 site is 
conserved in three other species; region of STAT5 site is conserved in at least two other 
species; region of STAT5 site is conserved in at least one other species; and STAT5 site 
that is recognized by each of the 9 STAT5 binding site matrices. The 79 tested sites were 
classified as true positives (TP), false positives, (FP), true negatives (TN), and false 
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negatives (FN) according to each of the 18 predictors individually, and the sensitivity 
(TP/(FN + TP)), specificity (TN/(FP + TN)), positive predictive value (PPV = TP/(TP + 
FN)), negative predictive value (NPV = TN/(FN + TN)), and accuracy ((TP + TN)/(TP + 
TN + FP + FN)) were calculated for each predictor (Table 2-4). The best individual 
predictors were determined by plotting Sensitivity vs. (1 – Specificity) in an ROC plot 
(Figure 2-3). The two predictors with the best combination of sensitivity and specificity, 
i.e., values closest to the (0, 1) point on the ROC plot, were then identified. The 
sensitivity, specificity, positive predictive value, negative predictive value, and accuracy 
were calculated for the combination of these predictors − i.e., positive predictions 
required to meet both criteria, and negative otherwise. To gauge how applying these 
conditions (consensus site and matrix 459) might improve predictions that are found in 4 
species, 3 or more species, or 2 or more species, the program was run a second time on 
the same three genes IGF1, SOCS2, and HNF6, using only matrix 459 and with a 
consensus site filter. Table 2-6 shows how many such sites predicted using the more 
refined criteria had been tested, and how many sites tested positive. 
2.C.4 Prediction of STAT5-binding sites in additional early GH response genes 
Matrix 459 was used to predict STAT5-binding sites in seven additional rat genes, 
CALD1, GADD45G, NREP, SULT2A1, RGS3, SPIN2A and SPIN2B, and in the MUP 
gene family, as described above for IGF1, SOCS2, and HNF6. Sequences comprising 100 
kb upstream of the coding sequence, the coding sequence and 25 kb downstream of the 
coding sequence of each gene were scanned for matrix 459 sites, and for all genes except 
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the SPIN2 and MUP genes, rat, mouse, human and dog sequences were aligned. In the 
case of the SPIN2 genes, sequences for SPIN2A (NM_012657), SPIN2B (NM_182474), 
and SPIN2C (NM_031531) were aligned, with SPIN2B as the reference sequence. Five 
MUP genes were analyzed: OBP3 (NM_147215), MUP5 (AB039828), MUP4 
(NM_198784), LOC259245 (NM_147213), and LOC259246 (NM_147214), with OBP3 
taken as the reference sequence; these MUP genes had unique probes and were similarly 
regulated by GH in a rat microarray study (Wauthier and Waxman 2008). Sites 
containing a STAT5 binding consensus sequence were selected, and the sites were then 
classified as paired or single. 
 
2.D Results 
2.D.1 Prediction and experimental evaluation of STAT5 binding sites for IGF1, SOCS2 and 
HNF6 
A summary of STAT5 binding sites predicted using a set of nine STAT5 TFBS matrices 
is presented in Table 2-2 (all sites), along with the number of sites that were conserved in 
the other three species considered (mouse, human, dog). A majority (88%) of the 
predicted STAT5 sites fall into the “paired 0 consensus” and “single non-consensus” 
categories, i.e. they do not contain the STAT5 binding site consensus sequence 
TTCN3GAA. To test the STAT5 binding site predictions, we primarily considered sites 
found in all 4 species. Predicted STAT5-binding sites were tested by Dr Ekaterina Laz by 
ChIP using rat liver chromatin prepared from an untreated male with high liver STAT5 
58 
 
 
 
activity. A total of 26, 16 and 22 predicted STAT5 sites were tested in the IGF1, SOCS2 
and HNF6 genes, respectively (coordinates of sites and amplicons listed in Table S3 of 
Laz et al. 2009). Eight regions in the IGF1 gene (corresponding to a total of 10 STAT5 
sites) were enriched at least two-fold over the negative control, which is located within a 
2,300 nt segment in the 5’ distal region of rat IGF1 gene that is devoid of any predicted 
STAT5 binding sites. (Fig. 2-1A). The highest enrichment (24-fold) was observed for 
region 296, which contains three consensus STAT5 binding sites. Three of the 8 regions 
are novel STAT5 binding regions (regions 217, 232 and 260) (Table 2-3).  
In the case of SOCS2, five regions (corresponding to six predicted sites) were enriched 
>2-fold compared with the negative control for binding in vivo (Fig. 2-1B). However, the 
weak ChIP signal of site 225 likely comes from the adjacent strong STAT5 site 224, as 
site 225 does not bind STAT5 in vitro (Fig. 4 and Laz et al. 2009). Site 224 was 
previously shown to bind STAT5 in the livers of hypophysectomized rats treated with 
GH (Vidal et al. 2007), while the other three regions represent novel STAT5 binding 
sites. In the case of HNF6, three STAT5-binding regions exhibited a 1.9 to 3-fold 
enrichment over the negative control (Fig. 2-1C). HNF6 region 181 was previously 
shown to bind STAT5 in a GH-dependent manner by EMSA analysis (Lahuna et al. 
2000), while the other two HNF6 regions, 148 and 157, are novel and contain paired non-
consensus STAT5 sites (Table 2-3). The enrichment of STAT5 binding to these regions 
of HNF6 is considerably lower than that for the strongest STAT5 binding regions in the 
IGF1 and SOCS2 genes (Fig. 2-1). A fourth HNF6 region, 234, was ~2-fold enriched in 
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STAT5 binding with respect to the IgG control but was only 1.4-fold enriched relative to 
the negative control and was not considered further.  
2.D.2 Sex-dependence of STAT5 binding in vivo – by Dr Ekaterina Laz 
Predicted sites that were positive for STAT5 binding were investigated for sex-dependent 
binding by Dr. Laz. Liver samples from individual male and female rats were used in 
STAT5 ChIP analysis to investigate the relationship between the temporal pattern of liver 
STAT5 activation (Choi and Waxman 2000; Tannenbaum et al. 2001) and STAT5 
binding to chromatin, quantified by real-time PCR. Dr. Laz assayed four males with high 
STAT5 activity, four males with intermediate STAT5 activity, two males with no 
detectable STAT5 activity, and four female livers with low but detectable STAT5 
activity. Clear differences in STAT5 binding were observed when comparing male liver 
samples where STAT5 activity was high vs. intermediate vs. very low or undetectable, as 
well as in the set of male vs. female samples. Results are shown in Fig. 3 in (Laz et al. 
2009). The majority of STAT5 binding regions were occupied in male samples with high 
STAT5, exhibited lower STAT5 binding in the intermediate STAT5 activity male group, 
and no STAT5 binding in the STAT5 activity-deficient male group. Since there is a 
strong positive correlation between the plasma GH profile and liver STAT5 activity in 
the liver (Choi and Waxman 2000; Tannenbaum et al. 2001), these results indicate that 
STAT5 cycles off of its chromatin binding sites during the plasma GH interpulse period. 
STAT5 binding in female liver samples, where STAT5 activity was marginally higher 
than that of the STAT5-negative males, was indistinguishable from that of the STAT5-
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negative males, except at IGF1 sites 196 and 304 and SOCS2 sites 224 (and 225). Dr. Laz 
determined that SOCS2 site 224 and IGF1 site 304 are high affinity binding sites while 
SOCS2 site 199, which shows high STAT5 binding in high STAT5 activity males but low 
STAT5 binding in females, is a low affinity binding site. These results show that high 
affinity binding sites are capable of binding STAT5 both in male liver, during a plasma 
GH pulse, and in female livers, where STAT5 activity is low but more persistent.  
 
2.D.3 Evaluation of STAT5 binding site prediction 
Overall, 17 of the 64 STAT5 sites tested (27%) bound STAT5 in STAT5-positive males 
(Fig. 2-1 and Table 2-2). I investigated which features distinguish predicted sites that 
bind STAT5 from those that do not. This evaluation was based on the 64 STAT5 binding 
sites indicated in Fig. 2-1, plus 15 additional sites that were conserved in fewer than 4 
species but were located in close proximity to the 64 sites and therefore were 
indistinguishable from them by ChIP. These 79 sites were classified according to 18 
possible predictors of STAT5 binding – a paired site, presence of a consensus sequence 
in rat or in other species, site predicted in three other species, or in two or more, or one or 
more species, site found in a region that is conserved between rat and three, two or more, 
or one or more species, or a site that is matched by each of the nine available STAT5 
matrices. Measures of accuracy of prediction – sensitivity, specificity, positive predictive 
value (PPV), negative predictive value (NPV), and accuracy – were calculated for each 
predictor (Table 2-4). The individual predictors with the best combination of sensitivity 
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and specificity were found to be 1) the presence of at least one consensus site in rat, and 
2) a match with matrix 459. These two predictors also had the best accuracies and the 
best combinations of PPV and NPV (Table 2-5). This finding is consistent with the fact 
that matrix 459 is the only one among the nine STAT5 binding site matrices that 
specifically describes a binding site for STAT5b, whereas all the other matrices describe 
binding sites for STAT5a (Table 2-1). Liver tissue contains substantially more STAT5b 
than STAT5a (Ripperger et al. 1995; Park et al. 1999); hence, a majority of liver STAT5 
binding is expected to involve STAT5b. When the presence of a consensus STAT5 site in 
rat and matrix 459 were combined as a single predictor, the specificity, accuracy, and 
PPV all increased, while the sensitivity and NPV remained the same as those for the 
consensus site alone (Table 2-5). The combination of both conditions – presence of a 
consensus STAT5 sequence and recognition by STAT5 matrix 459 – thus appears to be 
the best predictor for STAT5b binding to these sites. Prediction was carried out a second 
time in the same three genes for sites conserved in at least three species, this time using 
only matrix 459 and requiring presence of a consensus sequence in rat. No additional 
sites were tested, and therefore the evaluation of the refined criteria was based on sites 
that had been previously selected for experimental validation. Out of the previously 
identified sites that tested positive, 8 out of 10 IGF1 sites, 2 out of 3 SOCS2 sites, and 0 
out of 1 HNF6 site were correctly predicted. The positive sites corresponded to 71% of 
all sites predicted by the refined method that had been tested, as compared to ~27% in the 
initial analysis based on all nine STAT5 matrices. Decreasing the minimum number of 
species sharing a site to two resulted in the correct prediction of all 14 validated 
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consensus STAT5 sites, which corresponded to 61% tested sites that were predicted using 
the new criteria (Table 2-6). These two conditions can therefore be applied to shortlist the 
predicted STAT5 candidate sites for experimental validation.  
2.D.4 Identification of STAT5 binding sites in other GH-responsive genes 
The above two conditions – presence of STAT5 consensus site and matrix 459 – were 
used to predict STAT5 binding sites in a series of GH-responsive genes, previously 
identified in rat liver by microarray analysis (CALD1, GADD45G, NREP, SULT2A1, 
RGS3, SPIN2A, SPIN2B and five members of the MUP gene family) (Wauthier and 
Waxman 2008). These genes are all down-regulated in hypophysectomized compared to 
intact male rat liver and are rapidly induced (within 30 to 90 min) by a single, 
physiological GH injection, making them candidates for direct STAT5 target genes 
(microarray data is shown in Table S8 of Laz et al. 2009). ChIP analysis revealed strong 
STAT5 binding to two sites in RGS3 (sites 113 and 122) and to four sites in the SPIN2 
genes (Fig. 2-2A, sites 12, 21, 26 and 54) (Table 2-3). At least two functional STAT5 
binding sites were found for the MUP genes (sites 8/9 and site 50, Fig. 2-2B). Due to the 
high sequence similarity between MUP genes, site 50 could not be assigned to a specific 
MUP gene. STAT5 binding to both MUP binding sites was male-specific (Fig. 2-2C), 
consistent with the strong male-specificity of MUP gene expression in rat liver (Kulkarni 
et al. 1985; Janeczko et al. 1990; Wauthier and Waxman 2008). None of the predicted 
STAT5 sites tested for CALD1 (4 sites), GADD45G (2 sites), NREP (1 site) or SULT2A1 
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(1 site) bound STAT5 (data not shown), suggesting they may respond to GH by a 
STAT5-independent mechanism.  
 
2.E Discussion 
STAT5b is an important mediator of GH action in the liver, where it regulates the 
transcription of many genes either directly or indirectly. In rat liver, at least 20% of the 
genes acutely stimulated by GH and a majority of the genes acutely suppressed by GH 
are apparently dependent on STAT5b for their up- or down-regulation, respectively (Ono 
et al. 2007; Vidal et al. 2007). This study investigated the utility of phylogenetic 
footprinting for discovery of STAT5 binding sites in GH-responsive genes. In addition, 
the dynamic effect of plasma GH profiles on STAT5 binding to chromatin was 
investigated in intact male and female rat liver. I used a computational approach to 
predict STAT5 binding sites, where sequences associated with each gene and its flanking 
DNA (100 kb upstream sequence and up to 25 kb downstream sequence) were first 
scanned for STAT5 binding sites. Long genomic sequences were analyzed because of the 
emerging evidence that STAT5 often binds to genes outside of the traditional promoter 
region (Nelson et al. 2004; Chia et al. 2006; Eleswarapu et al. 2008), and such sites were 
identified in the present study. Unlike previous studies, where only the consensus 
sequence TTCN3GAA was considered in predicting STAT5 binding sites (Nelson et al. 
2004; Vidal et al. 2007; Eleswarapu et al. 2008), my approach utilized PWMs, including 
matrices based on non-consensus STAT5 sequences (Soldaini et al. 2000). The relevance 
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of non-consensus STAT5 sequences is supported by a recent identification of a STAT5 
binding region containing multiple non-consensus STAT5 sequences in the promoter of 
C3ar1 (Basham et al. 2008). Since regulatory elements are often conserved between 
species (Park et al. 1999; Prakash and Tompa 2005), predicted rat STAT5 sites that were 
conserved across the other three species examined (mouse, human and dog) were given 
preference for experimental verification. Dr Ekaterina Laz evaluated STAT5 binding in 
intact, untreated male rats and we tested the hypothesis that STAT5 binding to chromatin 
in liver in vivo is dynamically responsive to plasma GH pulsation. We identified multiple 
STAT5 binding regions in each gene (Table 2-3). Several STAT5 binding regions were 
reported previously for IGF1 (Eleswarapu et al. 2008), but only one STAT5 region was 
previously identified for SOCS2 (Vidal et al. 2007) and for HNF6 (Lahuna et al. 2000). 
Thus, these three genes, as well as several other GH-responsive genes examined here 
(Fig. 2-2), all contain multiple STAT5 binding sites. Notably, all of the sites identified 
previously for IGF1, SOCS2 and HNF6 under non-physiological conditions or in vitro 
were found to bind STAT5 in liver in vivo in males killed at the time of a plasma GH 
pulse.  
 
The majority of the STAT5 binding sites identified in IGF1, SOCS2 and HNF6 were 
paired sites, containing either one or two consensus sequences (Table 2-3). STAT5 may 
bind to these sites in tandem, as tetramers, which are expected to have a higher overall 
binding affinity. In vitro binding studies demonstrate, however, that STAT5b, which is 
the major (>90%) STAT5 form in liver (Ripperger et al. 1995; Park et al. 1999), is less 
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likely to form tetramers on DNA than STAT5a (Verdier et al. 1998; Soldaini et al. 2000). 
Nevertheless, three very strong STAT5 binding sites (site 296 in IGF1 and sites 193 and 
224 in SOCS2) are paired sites containing 2-3 STAT5 consensus sequences. In the case 
of RGS3 and the SPIN2 genes, the STAT5 sites identified were all paired sites, while 
STAT5 binding sites associated with MUP genes were single consensus sites. In the case 
of RGS3 and the SPIN2 genes, which are also rapidly induced by a physiological pulse of 
GH in rat liver (Wauthier and Waxman 2008), the STAT5 sites identified were all paired 
sites. For HNF6 site 12, its paired 2 consensus site did not bind STAT5. The three 
STAT5 binding regions identified for HNF6 represent a small percentage of the sites 
tested (14%, compared to 38% and 25% for IGF1 and SOCS2, respectively). STAT5 
binding at all three regions was weak in comparison to the strong STAT5 binding regions 
associated with IGF1 and SOCS2. STAT5 binding HNF6 at region 181, the strongest 
HNF6 binding site identified, was conserved in only 3 of the 4 species (absent in mouse), 
in contrast to the conservation across all four species of the strongest binding regions in 
IGF1 and SOCS2. Conceivably, HNF6 may be regulated by other, stronger STAT5 
binding sites that were not identified in the present study. These could include STAT5 
sites not conserved across species, in view of the fact that site 181 was not conserved in 
the mouse yet was the strongest of the three HNF6 sites identified. 
 
The overall validation rate of this approach was only 27%, illustrating that phylogenetic 
conservation is insufficient to accurately predict STAT5 binding, consistent with a later 
genome-wide study that found only 10-22% of binding sites for the liver-enriched TFs 
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HNF4α and CEBPA are conserved between mouse, human and dog (Schmidt et al. 
2010), illustrating that many functional TF binding sites are species-specific.  I examined 
the predictors and found that although some predicted and functional binding sites did not 
match the consensus sequence of TTCNNNGAA – three of the non-consensus sites 
enriched by STAT5 ChIP competed for STAT5 binding in vitro (HNF6 sites 148 and 
157, and IGF1 site 232), supporting our finding that these sites bind STAT5 in vivo – 
presence of a consensus site turned out to be one of the best predictors for STAT5 
binding, and a better predictor than phylogenetic conservation of the genomic locus. The 
highest positive predictive value was achieved when STAT5 site predictions were based 
on the following two criteria: 1) presence of a consensus STAT5 binding sequence, and 
2) recognition by STAT5 matrix 459. Each of these criteria preformed much better than 
phylogenetic conservation, as shown in Table 2-4; however, this evaluation is biased, 
since predictions that were conserved across species had been preferentially selected for 
experimental verification. When combined, two best criteria predicted all of the IGF1, 
SOCS2 and HNF6 STAT5 binding sites that had been experimentally verified, with the 
exception of non-consensus STAT5 sites, which would be missed using this approach. 
Three of the non-consensus sites enriched by STAT5 ChIP competed for STAT5 binding 
in vitro (HNF6 sites 148 and 157, and IGF1 site 232), supporting our finding that these 
sites bind STAT5 in vivo. However, even with these restrictions, only 9 out of 29 
additional tested predictions at 12 more genes were found to bind in vivo, showing that 
other influences not considered in this study, such as chromatin environment, may be 
important. In this study I considered the entire coding region of genes of interest, along 
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with 100kb upstream and 3-25kb downstream; among the successfully predicted STAT5 
binding sites were the previously published sites located up to 75kb upstream of the IGF1 
gene, as well as novel sites located in intron 2 of IGF1 and 6 kb to 16 kb upstream of 
SOCS2.  Thus, STAT5 can bind very distally from target genes, showing that promoter-
based approaches are insufficient for this TF, and the broad region that needs to be 
considered illustrates the necessity of genome-wide approaches.  
 
Finally, experimental comparison by Dr Ekaterina Laz of STAT5 binding in the livers of 
male rats with different content of active STAT5 showed no binding at any tested region 
in STAT5-negative males. Since STAT5 activity in male liver exhibits strong positive 
correlation with the plasma GH profile (Choi and Waxman 2000; Tannenbaum et al. 
2001), these findings indicate that STAT5 binding to chromatin is dynamic, i.e., is 
directly induced by, and cycles on and off in response to each plasma GH pulse. Few of 
the STAT5 binding regions of IGF1 and SOCS2 that were occupied in high STAT5 
activity male liver were also occupied in female liver and the three regions of IGF1 and 
SOCS2 that bound STAT5 in female liver were among the strongest binding regions in 
males (IGF1 sites 296 and 304, and SOCS2 site 224). Considering that the levels of 
active STAT5 in female rat liver are much lower than in males at the peak of GH 
secretion (Tannenbaum et al. 2001), the STAT5 activity level in female liver may simply 
be too low for STAT5 to bind at the other sites. Indeed, Dr Laz’ determination of the Kd 
values for STAT5 binding revealed that site 224 of SOCS2 and site 304 of IGF1 have 10 
and 4 times, respectively, higher affinity for STAT5 than SOCS2 site 199, where STAT5 
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binding was only observed in males. This finding indicates that sex-specific STAT5 
binding, e.g. linked to the expression of sex-specific genes, is more likely to occur at low-
affinity STAT5 sites than at high-affinity sites. This hypothesis is further supported by 
the finding that the male-specific STAT5 binding sites in MUP genes bind STAT5 with 
low affinity (Fig. 6D in Laz et al. 2009). Other factors, such as differences in chromatin 
structure or the presence or absence of proteins that modulate STAT5 binding to DNA, 
might also contribute to the sex differences in STAT5 binding seen at some sites. Despite 
the sex-independent gene expression of IGF1 and SOCS2, a majority of their associated 
STAT5 binding sites bound STAT5 in a male-specific manner. Conceivably, IGF1 and 
SOCS2 transcription could be primarily regulated by STAT5 binding to the sites that 
show high STAT5 binding in both male and female liver, i.e., the high affinity sites. 
Although the occupancy of those sites by STAT5 in female liver is somewhat lower than 
in males, it is presumably more persistent due to the persistence of low level GH 
signaling to STAT5 in females (Choi and Waxman 1999). Further experiments will be 
required to answer these questions.  
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Table 2-1. Position weight matrices for STAT5 binding sites. 
For each PWM, each row represents a single nucleotide position. For each row, columns 
indicate the frequency with which the nucleotide A, C, G, or T (from left to right) is 
observed at that position. 
Matrix ID Matrix Description 
 
M00457 
(TRANSFAC) 
 
7 6 8 7 
18 2 7 3 
14 4 4 11 
0 0 0 33 
0 1 0 32 
0 32 1 0 
0 15 6 12 
10 6 8 9 
8 0 25 0 
0 0 33 0 
33 0 0 0 
33 0 0 0 
13 7 4 8 
2 11 0 19 
8 8 6 8 
 
 
Single STAT5a-binding site 
- 33 sites selected from random 
oligonucleotides for STAT5a 
homodimers binding 
- Source: (Soldaini et al. 2000) 
M00459 
(TRANSFAC) 
9 6 14 11 
24 2 8 8 
16 1 3 26 
0 0 0 46 
0 0 0 46 
0 46 0 0 
0 28 1 17 
7 11 8 20 
10 2 34 0 
0 0 46 0 
46 0 0 0 
46 0 0 0 
17 5 5 19 
8 10 1 27 
8 11 7 17 
 
Single STAT5b-binding site 
- 46 sites selected from random 
oligonucleotides for STAT5b 
homodimers binding 
- Source: (Soldaini et al. 2000) 
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Table 2-1. Position weight matrices for STAT5 binding sites. (continued) 
M00493 
(TRANSFAC) 
23 26 17 33 
54 11 17 19 
37 5 13 46 
2 2 2 93 
11 4 2 82 
3 93 2 2 
5 57 8 30 
29 22 20 29 
 
STAT5a-binding half-site 
- 39 sites selected for STAT5a binding 
from random oligonucleotides 
presented in both orientations to an 
HMM training algorithm 
- Source: (Ehret et al. 2001) 
 
M00499 
(TRANSFAC) 
21 32 31 16 
40 15 11 34 
18 29 18 35 
0 0 0 100 
0 0 0 100 
5 95 0 0 
2 35 6 56 
29 21 21 29 
 
STAT5a-binding half-site 
- 62 compiled genomic half-sites for 
STAT5a 
- Source: (Ehret et al. 2001) 
M00460 
(TRANSFAC) 
1 1 0 35 
6 1 1 29 
2 35 0 0 
2 19 9 7 
8 16 6 7 
15 5 14 3 
1 0 35 1 
30 0 2 5 
36 0 1 0 
11 7 4 15 
6 8 7 16 
6 9 11 9 
6 14 10 7 
7 8 12 10 
10 7 8 12 
1 3 0 33 
10 2 2 23 
4 31 0 2 
4 23 6 4 
8 8 10 11 
13 9 11 4 
6 3 26 2 
18 3 11 5 
16 3 18 0 
 
Paired STAT5a-binding site 
- 46 sites selected from random 
oligonucleotides for STAT5a 
homotetramer binding 
- Source: (Soldaini et al. 2000) 
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Table 2-1. Position weight matrices for STAT5 binding sites. (continued) 
M00AS01 3 2 4 6 
7 5 2 5 
1 6 3 9 
0 0 0 18 
0 0 0 18 
0 18 0 0 
0 12 3 4 
4 8 4 3 
7 4 7 1 
0 0 18 0 
18 0 0 0 
18 0 0 0 
6 3 2 8 
4 4 1 10 
1 4 6 6 
4 8 4 3 
3 6 5 5 
5 4 4 6 
0 4 0 15 
4 3 2 10 
3 14 0 2 
2 5 7 5 
4 5 3 7 
6 6 4 3 
5 1 13 0 
9 3 6 0 
11 2 5 0 
4 4 5 2 
0 6 5 2 
2 3 3 0 
 
Paired 1 consensus STAT5a-binding site 
with 5-6 nt spacer sequence 
- 15 STAT5a tetramer-selected DNAs 
with one consensus STAT5 site and 
5 or 6 nt spacer sequence 
- STAT5 binding sites from 4 genes: 
Spi2.1, TCR Jy1, Bcl-x, murine Bcl-x 
- Source: (Soldaini et al. 2000) 
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Table 2-1. Position weight matrices for STAT5 binding sites. (continued) 
M00AS02 2 7 5 8 
9 5 6 2 
6 3 4 9 
1 1 0 20 
6 1 1 14 
2 20 0 0 
2 8 6 6 
5 11 2 4 
9 3 8 2 
1 0 20 1 
15 0 2 5 
21 0 1 0 
7 6 2 7 
3 4 6 9 
5 6 7 4 
3 8 7 4 
4 5 8 5 
6 3 4 9 
1 0 0 21 
6 0 1 15 
2 19 0 1 
2 18 1 1 
4 5 7 6 
8 4 8 2 
2 2 16 2 
12 0 5 5 
10 1 11 0 
5 3 13 1 
2 11 9 0 
4 10 7 0 
 
Paired 0 consensus STAT5a-binding site 
with 6 nt spacer sequence 
- 22 STAT5a tetramer-selected DNAs 
with no consensus STAT5 site and 6 
nt spacer sequence 
- Source: (Soldaini et al. 2000) 
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Table 2-1. Position weight matrices for STAT5 binding sites. (continued) 
M00AS03 0 5 0 1 
3 2 4 0 
2 1 2 4 
0 0 0 9 
1 0 1 7 
0 9 0 0 
1 5 1 2 
5 1 0 3 
5 3 1 0 
0 0 8 1 
9 0 0 0 
9 0 0 0 
3 1 3 2 
0 1 1 7 
3 1 4 1 
1 4 1 3 
2 2 3 2 
3 5 1 0 
5 0 1 3 
0 0 0 9 
1 0 2 6 
2 7 0 0 
0 3 3 3 
1 1 4 3 
4 0 3 2 
1 1 6 1 
6 0 2 1 
4 1 3 1 
2 0 6 1 
5 3 1 0 
1 2 3 0 
 
Paired 1 or 0 consensus STAT5a-binding 
site with 7 nt spacer sequence 
- 3 STAT5a tetramer-selected DNAs 
with 1 consensus STAT5 site 
- 3 STAT5a tetramer-selected DNAs 
with no consensus STAT5 site 
- STAT5-binding sites from 3 genes: 
β-casein, porcine β-casein, pim-1 
- 7 nt spacer sequence 
- Source: (Soldaini et al. 2000) 
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Table 2-1. Position weight matrices for STAT5 binding sites. (continued) 
M00AS04 3 2 1 0 
0 2 3 1 
1 2 1 2 
0 0 0 6 
0 0 0 6 
0 6 0 0 
1 5 0 0 
1 0 4 1 
3 0 3 0 
0 0 6 0 
6 0 0 0 
6 0 0 0 
1 1 0 4 
1 1 1 3 
1 0 1 4 
0 5 1 0 
2 1 1 2 
2 1 1 2 
1 0 3 2 
5 0 1 0 
0 5 1 0 
0 2 1 3 
4 2 0 0 
3 0 1 2 
0 0 5 1 
4 1 1 0 
2 1 3 0 
1 0 4 0 
1 3 1 0 
1 3 1 0 
Weak STAT5a-binding paired sites 
- 6 weak STAT5a tetramer binding 
DNAs 
- 6 nt spacer sequence 
- Source: (Soldaini et al. 2000) 
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Table 2-2. Summary of predicted STAT5 binding sites. 
For experimental validation, preference was given to the sites conserved in all 4 species 
(rat, mouse, human, and dog).  Adjacent sites located in the proximity of amplicons for 
other sites were in many cases not considered if not found in all 4 species.   
 
 Type Predictions 
Te
st
ed
 
Ve
rif
ie
d 
c  
  All  
sites a 
Sites found in all 
4 species b 
IGF1 Paired 2 consensus 2 2 2 2 
 Paired 1 consensus 32 12 10 5 
 Paired 0 consensus 207 25 11 1 
 Single consensus 18 4 3 2 
 Single non-consensus 115 16 0 0 
 Total 374 59 26 10 
SOCS2 Paired 2 consensus 2 1 2 2 
 Paired 1 consensus 11 1 1 1 
 Paired 0 consensus 135 13 8 0 
 Single consensus 12 2 3 1 
 Single non-consensus 80 3 2 0 
 Total 240 20 16 4 
HNF6 Paired 2 consensus 1 0 1 0 
 Paired 1 consensus 17 3 4 1 
 Paired 0 consensus 163 16 16 2 
 Single consensus 9 1 1 0 
 Single non-consensus 91 9 0 0 
 Total 281 29 22 3 
 
a – STAT5 sites predicted for the rat genes based on set of nine TFBS matrices. 
b – Predicted rat STAT5 sites that are also present in mouse, human and dog. 
c – Verification is based on in vivo results presented in Fig. 2-1 and in vitro binding data 
in Fig. 4 of (Laz et al. 2009) 
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Table 2-3. Summary of STAT5 binding sites for rat genes enriched in ChIP assays 
 
Site Classificationa Sequence,b 5’-3’ Chromosomal locationa Verified by 
EMSA 
IGF-I on Chr7(+) 
RE-1c Paired 1 consensus tctgtgttagtcaggaaaaTTCTAAGAA 
   actgcctccagagagagg 
24,458,482–24,458,527 Yes (Chia et 
al. 2006) 
RE-2 c Single consensus tttTTCTTAGAAgta 24,458,733–24,458,747 Yes (Chia et 
al. 2006) 
GHRE-1 c Paired 1 consensus ccgctcaccttgggggccTTCCTGGAAgaa 24,535,315–24,535,344 Yes 
GHRE-2 c Single consensus tgcTTCTTAGAAtga 24,535,399–24,535,413 Yes (Woelfle 
et al. 2003b) 
217 Paired 2 consensus catTTCTTTGAAgtgcaaggagTTCCTGGAAcct 24,538,140–24,538,173 Yes 
232 Paired 0 consensus Ggatcccaagaaaaacccttcccttgc 24,544,749–24,544,775 Yes 
260 Paired 1 consensus cattttaaacgtaagTTCTGAGAActg 24,557,417–24,557,443 Yes 
263c Paired 1 consensus tctTTCAGGGAAatctaggaatatcagaaa 24,558,319–24,558,348 Yes 
296c Paired 2 consensus ggcaactgtgaataagtttTTCGAAGAA 
   ttg(6)gacttctgaggcaacggtctcca 
   gTTCTCAGAAaggaaaTTCGCAGAAgtg 
24,575,406–24,575,493 Yes 
304c Paired 1 consensus tgaTTCCTAGAAaagatgacctcacccaac 24,580,690–24,580,719 Yes 
SOCS2 on Chr7(−) 
193 Paired 2 consensus atattattggaaatc(4)ctctgacaagca 
   ctgtactaggaa(29)ttgTTCTTGGAA 
   tgt(18)tgcTTCTCTGAAgttcaggtgc 
   tcggtctacaaaatgtgatctatgtggaaag 
32,623,539–32,623,677 Yes 
199 Paired 1 consensus tgcTTCTCAGAAtccgatgactaagccaggaatag 32,620,436–32,620,470 Yes 
221 Single consensus agaTTCCAAGAAaac 32,611,389–32,611,403 Yes 
222 Paired 0 consensus tagaattttctaaagagaaaaaaattactgcggataa 32,611,262–32,611,298 No 
224c Paired 2 consensus gcggtcacgtgaggcggaTTCCTGGAAagTTCCTGGAA 
   agcggcctccgcagcggc 
32,610,008–32,610,063 Yes 
225 Paired 0 consensus tccttctcggcgtcgggaaatcttcggagcac 
   (16)ctgttatccaaatttataatcctaataacct 
32,609,489–32,609,567 No 
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Table 2-3. Summary of STAT5 binding sites for rat genes enriched in ChIP assays (continued) 
HNF6 on Chr8(+) 
148 Paired 0 consensus Tgatacccagaattctattgaccatgg 79,632,576–79,632,602 Yes 
157 Paired 0 consensus tttccatcattaatgtcattactacgaacta(10) 
   tgtcgttgggagccgagtttcacggtattg 
79,636,722–79,636,792 Yes 
181 c Paired 1 consensus gagccgggggcagcaggaTTCTAAGAAaga 79,644,216–79,644,245 Yes 
RGS3 on Chr5(+) 
113 Paired 1 consensus ttgtgtgctcagaccataTTCTCAGAAtaa 79,706,585–79,706,614 ND 
122 Paired 1 consensus ggcctcatggcctcctatttgtggaagcaca 
   ggatagtgactTTCCAAGAActgctctttgtttctctca 
79,724,023–79,724,092 ND 
SPIN2d on Chr6 
12 (2c) Paired 1 consensus gatTTCTGGGAAcatggactcatagtccct 128,461,625–128,461,654 ND 
21 (2b) Paired 0 consensus attgtcccagaaatccacttcctctcagatcctcagaaatg 128,378,512–128,378,552 ND 
26 (2a) Paired 1 consensus tgatTTCTCAGAAcatggattagtagaagcg 128,436,433–128,436,463 ND 
54 (2b) Paired 1 consensus cgcttctactaatccatgTTCTGAGAAatca 128,386,919–128,386,949 ND 
MUPs on Chr5(−) 
8 (OBP3) Single consensus gtcTTCTGAGAAtcc 78,179,829–78,179,843 Yes 
9 (OBP3) Single consensus caaTTCATGGAAatt 78,179,664–78,179,678 Yes 
29 Single consensus Various Various (see Table S3 in Laz 
et al. 2009) 
Yes 
50 Single consensus gtcTTCTGAGAAtcc Various see Table S3 in Laz 
et al. 2009) 
Yes 
Chr, Chromosome. ND, not determined. 
aClassification and chromosomal location of STAT5 binding sites are based on predictions made with all nine STAT5 TFBS matrices. The 
nt numbering is based on rat genome assembly rn4. 
bConsensus STAT5 binding sequence (TTCNNNGAA) within a predicted STAT5 binding site is shown in uppercase letters. Numbers in 
parentheses indicate the nucleotide length of the intervening sequence that is not recognized by a STAT5 binding matrix. 
cSTAT5 binding sites identified in the present study that were also previously identified (Lahuna et al. 2000; Woelfle et al. 2003b; Wang 
and Jiang 2005; Chia et al. 2006; Vidal et al. 2007; Eleswarapu et al. 2008). 
dNumber in parentheses indicates the SPIN2 gene located closest to the STAT5 binding site shown. 
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Table 2-4. Summary statistics for the 18 predictors for STAT5 binding sites.  
True positives (TP), true negatives (TN), false positives (FP), false negatives (FN), 
sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), 
and accuracy (Acc) for each of the 18 prediction criteria for STAT5 binding sites are 
listed. 
 
Predictor TP TN FP FN Sensitivity* Specificity† PPV‡ NPV§ Acc**
Paired 15 7 54 3 0.83 0.11 0.22 0.70 0.28 
≥ 1 consensus site          
      in rat 15 45 16 3 0.83 0.74 0.48 0.94 0.76 
      in any species 15 29 32 3 0.83 0.48 0.32 0.91 0.56 
Site found in          
      3 other species 13 15 46 5 0.72 0.25 0.22 0.75 0.35 
      ≥2 other species 17 10 51 1 0.94 0.16 0.25 0.91 0.34 
      ≥1 other species 18 4 57 0 1.00 0.07 0.24 1.00 0.28 
Region conserved in          
      3 other species 11 39 22 7 0.61 0.64 0.33 0.85 0.63 
      ≥2 other species 14 31 30 4 0.78 0.51 0.32 0.89 0.57 
      ≥1 other species 18 1 60 0 1.00 0.02 0.23 1.00 0.24 
Matrix          
      457 17 38 23 1 0.94 0.62 0.43 0.97 0.70 
      459 17 45 16 1 0.94 0.74 0.52 0.98 0.78 
      460 11 44 17 7 0.61 0.72 0.39 0.86 0.70 
      493 10 42 19 8 0.56 0.69 0.34 0.84 0.66 
      499 10 27 34 8 0.56 0.44 0.23 0.77 0.47 
      AS01 8 51 10 10 0.44 0.84 0.44 0.84 0.75 
      AS02 6 39 22 12 0.33 0.64 0.21 0.76 0.57 
      AS03 4 45 16 14 0.22 0.74 0.20 0.76 0.62 
      AS04 5 43 18 13 0.28 0.70 0.22 0.77 0.61 
* Sensitivity = TP/(FN + TP) 
† Specificity = TN/(FP + TN) 
‡ PPV = TP/(TP + FP) 
§ NPV = TN/(FN + TN) 
** Acc = (TP + TN)/(TP + TN + FP + FN) 
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Table 2-5. Summary statistics for the two best individual predictors for STAT5 
binding sites.   
True positives (TP), true negatives (TN), false positives (FP), false negatives (FN), 
sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), 
and accuracy (Acc) (see definitions in Table footnotes) for the two best individual 
predictors and the combination of the two: positive both criteria were met, negative 
otherwise.   
  
Predictor(s) TP TN FP FN Sensitivity* Specificity† PPV‡ NPV§ Acc** 
≥ 1 consensus site in rat  15 45 16 3 0.83 0.74 0.48 0.94 0.76 
Matrix 459 17 45 16 1 0.94 0.74 0.52 0.98 0.78 
Matrix 459 + consensus site 15 50 11 3 0.83 0.82 0.58 0.94 0.82 
 
* Sensitivity = TP/(FN + TP) 
† Specificity = TN/(FP + TN) 
‡ PPV = TP/(TP + FP) 
§ NPV = TN/(FN + TN) 
** Acc = (TP + TN)/(TP + TN + FP + FN) 
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Table 2-6. Numbers of STAT5 binding site predictions in IGF1, SOCS2, and HNF6 
using matrix 459 only, and numbers that had been tested experimentally.  
A: Sites predicted in all 4 species. B: Sites predicted in 3 or more species. C: Sites 
predicted in 2 or more species. Tested and bound sites are subsets of sites that had been 
predicted using all nine PWMs and without the consensus site filter, shown in Table 2-2. 
 
A. 
  All 4 species, 
consensus 
Tested 
experimentally Bound % 
IGF1 12 10 8 80.0 
SOCS2 3 3 2 66.7 
HNF6 1 1 0 0.0 
Total 16 14 10 71.4 
 
B. 
  ≥ 3 species, 
consensus 
Tested 
experimentally Bound % 
IGF1 14 10 8 80.0 
SOCS2 6 3 2 66.7 
HNF6 1 1 0 0.0 
Total 21 14 10 71.4 
 
C. 
  ≥ 2 species, 
consensus 
Tested 
experimentally Bound % 
IGF1 29 12 9 75.0 
SOCS2 14 6 4 66.7 
HNF6 12 5 1 20.0 
Total 55 23 14 60.9 
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Figure 2-1. STAT5 binding regions identified by ChIP. 
Chromatin samples prepared from untreated male liver with a high content of active 
STAT5 were precipitated with STAT5 antibody or normal rabbit IgG, and the abundance 
of STAT5 binding regions predicted in the IGF-I (A), SOCS2 (B), or HNF6 (C) loci was 
quantified by real-timem PCR. Data were normalized to input DNA and expressed for 
each region as fold increase over the negative control (region within a 2300-bp segment 
in the 5’ distal region of rat IGF-I, which is devoid of any predicted STT5 binding sites). 
Data are mean ± range values for two independent determinations. In cases where 
predicted STAT5 sites were in close proximity, a single PCR amplicon was used to 
interrogate both sites, as indicated (e.g. IGF-I sites 245 and 246, SOCS2 sites 221 and 
222, etc.). Genomic locations of the sites positive for STAT5 binding are shown below 
each graph, as visualized on the UCSC genome browser. Red indicates sites present in all 
four species; green indicates sites present in three of the four species considered. 
Numbers in parentheses indicate the number of species (of four total) in which the local 
genomic region encompassing the site is at least 70% identical. All STAT5 sites shown 
on the genome browser window except for IGF-I site GHRE-2, SOCS2 sites 193 and 221, 
and HNF6 site 181 are present in all four species (rat, mouse, human, and dog). 
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Figure 2-1. STAT5 binding regions identified by ChIP. 
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Figure 2-2. STAT5-binding regions identified in RGS3, SPIN2, and MUP genes. 
Cross-linked chromatin samples prepared from frozen untreated male liver with high 
content of active STAT5 were precipitated with STAT5-antibody or normal rabbit IgG, 
and the abundance of STAT5 binding regions predicted in the RGS3 and SPIN2 (A) or 
MUP (B) loci was quantified by real-time PCR. Data and normalized and expressed as in 
Fig. 2-1 and shown as mean ± range of two determinations for each predicted STAT5 
site. Text in parenthesis in A indicates which of the three SPIN2 genes (SPIN2A, SPIN2B, 
and SPIN2C) this site is located closest to. Text in parentheses in B indicates whether the 
STAT5 binding site was assayed for a single MUP gene (gene OBP3) or for several MUP 
genes together (MUP). ActB is a region within the third intron of β-actin that served as an 
additional negative control; this region is devoid of any predicted STAT5 binding sites, 
and β-actin is not regulated by GH. Genomic locations of the sites positive for STAT5 
binding are shown below each graph, as in Fig. 2-1. Below A, numbers in parentheses 
indicate the number of species (for RGS3 sites) or the number of genes (for SPIN2 sites) 
in which the local genomic region encompassing the site is at least 70% identical. The 
SPIN2 region STAT5 sites shown on the genome browser window are present in all three 
SPIN2 genes, except for SPIN2 site 12, which is found in SPIN2B only. Below B, the 
MUP region RefSeq genes shown correspond to the eight known rat MUP genes; these 
are given various MUP, OPB, and LOC designations, as indicated. The STAT5-positive 
MUP sites designated 29 and 50 were interrogated with generic MUP region primers; 
each amplicon amplifies genomic sequences associated with six distinct sites, numbered 
29A through 29F and 50A through 50F, as shown. Sites 8 and 9 are close, but distinct 
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STAT5 sites that were interrogated by PCR primers mapping to the specific genomic 
region as indicated. C, STAT5 binding to the indicated MUP region sites (see B) was 
analyzed by ChIP in the sets of male and female chromatin samples prepared from 
individual untreated adult female and male rats with high liver STAT5 activity. The 
abundance of STAT5 binding regions was quantified and expressed as described in Fig. 
2-1. Data are the mean ± sem for each group (n = 3). Dashed horizontal lines indicate 
ChIP activity of the negative control.  
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Figure 2-2. STAT5-binding regions identified in RGS3, SPIN2, and MUP genes. 
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Figure 2-3. ROC plot of Sensitivity versus (1 – Specificity) for all individual 
predictors for STAT5 binding sites. 
The best predictors are those closest to (0,1); the two best individual predictors, matrix 
459 and the presence of a STAT5 binding consensus sequence in rat, are circled. 
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Chapter 3  
Intrinsic sex differences in the early growth hormone responsiveness of sex-specific 
genes in mouse liver2 
3.A Abstract 
Sex differences in liver gene expression are dictated by sex differences in circulating GH 
profiles. Presently, the pituitary hormone dependence of mouse liver gene expression was 
investigated on a global scale to discover sex-specific early GH response genes that could 
contribute to sex-specific regulation of downstream GH targets and to ascertain whether 
intrinsic sex differences characterize hepatic responses to plasma GH stimulation. Global 
RNA expression analysis identified two distinct classes of sex-specific mouse liver 
genes: genes subject to positive regulation (class I) and genes subject to negative 
regulation by pituitary hormones (class II). Genes activated or repressed in 
hypophysectomized (Hypox) mouse liver within 30-90 min of GH pulse treatment at a 
physiological dose were identified as putative direct targets of GH action (early response 
genes). Intrinsic sex differences in the GH responsiveness of a subset of these early 
response genes were observed. Notably, 45 male-specific genes, including five encoding 
transcriptional regulators that may mediate downstream sex-specific transcriptional 
responses, were induced by GH within 30 min in Hypox male but not Hypox female 
mouse liver. The early GH response genes were enriched in 29 male-specific targets of 
                                                 
2 A modified version of this chapter was published in Molecular Endocrinology. Wauthier V., Sugathan A., 
Meyer R.D., Dombkowski A.A., and D.J. Waxman (2010) “Intrinsic sex differences in the early growth 
hormone responsiveness of sex-specific genes in mouse liver.” Mol Endocrinol 24:667. All experimental 
work was carried out by Dr. Valerie Wauthier, and portions of the computational analysis were carried out 
by Dr Valerie Wauthier and Dr. Alan Dombkowski, as noted in appropriate places in this chapter.  
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the transcription factor myocyte enhancer factor 2, whose activation in hepatic stellate 
cells is associated with liver fibrosis leading to hepatocellular carcinoma, a male-
predominant disease. Thus, the rapid activation by GH pulses of certain sex-specific 
genes is modulated by intrinsic sex-specific factors, which may be associated with prior 
hormone exposure (epigenetic mechanisms) or genetic factors that are pituitary-
independent, and could contribute to sex differences in predisposition to liver cancer or 
other hepatic pathophysiologies. 
 
3.B Introduction 
Sex-specific gene expression in the liver is a characteristic of >1000 genes and affects a 
wide range of biological processes, including steroid, lipid and foreign compound 
metabolism (Clodfelter et al. 2006; Yang et al. 2006; Wauthier and Waxman 2008). This 
sexual dimorphism is determined by sex differences in circulating GH profiles (MacLeod 
et al. 1991; Mode and Gustafsson 2006; Waxman and O'Connor 2006; Waxman and 
Holloway 2009). In many species, including rats, mice, and humans, the temporal pattern 
of pituitary GH secretion is sex-dependent (episodic in males and more frequent in 
females) and leads to sex differences in downstream signaling pathways in liver and 
perhaps other target tissues. In mice, GH is secreted in episodic bursts ranging up to 100 
ng/ml in both sexes; however, female mice have more frequent peaks than males over a 
given time period (MacLeod et al. 1991). This differential frequency of plasma GH 
stimulation is an essential element for sex-specific liver gene expression (Waxman and 
O'Connor 2006).  
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GH signaling is initiated by the binding of GH to the extracellular domain of GH 
receptor, which activates multiple intracellular signaling pathways, including signaling 
by the transcription factor STAT5b (O'Shea et al. 2002). Liver sexual dimorphism is 
ablated in male mice with STAT5b deficiency (Clodfelter et al. 2006; Holloway et al. 
2007). Liver STAT5b is directly responsive to the male plasma GH profile, as 
demonstrated by the direct correlation between the occurrence of a plasma GH pulse and 
the presence of activated STAT5b in the nucleus in male rats, with active STAT5b being 
low or undetectable during the GH-free interpulse intervals (Choi and Waxman 2000). In 
contrast, in adult female rats, the near continuous presence of GH in circulation partially 
down-regulates GH singaling to STAT5b in hepatocytes, resulting in activated STAT5b 
levels that are generally low compared with peak male levels (Choi and Waxman 1999). 
Nuclear STAT5b activity is also reported to exhibit sexual dimorphism in mouse liver 
(Sueyoshi et al. 1999). The strong, repeated activation of liver STAT5 by each incoming 
plasma GH pulse that occurs in male but not female rats (Waxman et al. 1995b; Choi and 
Waxman 2000) enables STAT5 to bind dynamically to chromatin in males at both low- 
and high-affinity binding sites, whereas in females, STAT5 binding to chromatin displays 
selectivity for high-affinity binding sites (Laz et al. 2009). Although STAT5b is required 
for sexual dimorphism of the liver, it is not sufficient, on its own, to establish and 
maintain sex-specific liver gene expression (Choi and Waxman 2000; Verma et al. 2005). 
This finding suggests a requirement for additional factors, some of which may 
themselves be targets of STAT5b. This possibility, that GH and STAT5b activate indirect 
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regulatory pathways and mechanisms, is consistent with the rather slow feminization of 
male-specific gene expression seen in intact male mice given a continuous GH infusion 
(female-like GH pattern) (Holloway et al. 2006). 
 
Global gene expression studies have provided important insights into the cellular and 
molecular mechanisms that determine liver sexual dimorphisms. In one study, GH was 
shown to play a global regulatory role in sexually dimorphic gene expression in rat liver 
(Ahluwalia et al. 2004). Another study revealed a key role for STAT5b in sexual 
dimorphic gene expression in mouse liver, as demonstrated by the near global loss of sex-
specific gene expression in STAT5b-deficient male mice (Clodfelter et al. 2006). A 
specific role for STAT5a, a minor liver STAT5 form, has been observed in female mouse 
liver (Clodfelter et al. 2007). Genes directly activated (Vidal et al. 2007) or repressed 
(Ono et al. 2007) by GH/STAT5b have been identified in rat liver; however, sex-specific 
early GH response genes were not investigated. In rats, hypophysectomy has a major 
impact on liver gene expression (Flores-Morales et al. 2001), including sex-specific gene 
expression (Wauthier and Waxman 2008). In the mouse, the impact of pituitary hormone 
ablation and the effects of GH restoration at a supra-physiological dose have been 
investigated for select genes using traditional assays of gene expression (Holloway et al. 
2006); however, the global impact of hypophysectomy on sex-specific genes, and the 
ability of short-term physiological GH replacement to reverse the effects of pituitary 
hormone ablation, have not been investigated. Finally, although several in vitro and in 
vivo studies have suggested sex differences in the intrinsic GH responsiveness of certain 
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sex-specific genes and signaling pathways (Waxman et al. 1995a; Pampori and Shapiro 
1999; Thangavel et al. 2004; Thangavel et al. 2006; Dhir et al. 2007), such intrinsic sex 
differences have not been investigated on a genome-wide scale.  
 
The present study utilized genome-wide expression microarrays: 1) to investigate the 
pituitary hormone dependence of liver sexual dimorphism and to identify sex-specific 
early GH response genes in a mouse model; and 2) to discover any intrinsic sex 
differences in the responsiveness of mouse liver to GH pulse stimulation. These studies 
utilized the hypophysectomized (Hypox) mouse model to eliminate potentially 
confounding effects of sex steroids or other pituitary-dependent factors. Importantly, GH 
was used at a physiological replacement dose to avoid artifacts that may be associated 
with the >10 to 100-fold supra-physiological doses of GH that have been widely used in 
earlier studies monitoring GH-induced changes in liver gene expression. Our findings 
reveal early GH responses in male liver that are not seen in female liver and that affect 45 
male-specific genes, 29 of which are targets of the transcription factor Mef2. 
 
3.C Materials and Methods 
3.C.1 Experimental methods, carried out by Dr Valerie Wauthier of this lab 
Experimental design – Expression microarrays were used to investigate the impact of 
hypopohysectomy on mouse liver gene expression, with a focus on sexually dimorphic 
gene expression, and to establish the short-term responsiveness of these genes to a 
physiological replacement dose of GH. RNA was isolated from livers of adult mice that 
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were: intact males and intact females; Hypox males and Hypox females; Hypox male and 
Hypox female mice treated with a single GH pulse and killed either 30 min later or 90 
min later; and Hypox male and Hypox female mice treated with 2 GH injections, spaced 
4 h apart, and killed 30 min after the second GH injection (Hypox + 2 GH).  
 
Male and female crl:CD1 (ICR strain) mice were untreated or hypophysectomized at 8 
wk of age. Hypox male and female mice were given a single i.p. injection of rat GH and 
killed 30 or 90 min later. Other Hypox male and Hypox female mice were given two i.p. 
injections of GH, spaced 4 hr apart, and killed 30 min after the second GH injection. 
Total liver RNA was isolated from individual livers for the following ten groups of mice 
(n=6-8 mice/group): Sham surgery-treated and vehicle-injected males and females (M-
Sham, F-Sham); male and female hypophysectomized mice (M-Hypox; F-Hypox); M-
Hypox and F-Hypox mice given a single GH injection and killed 30 or 90 min later (M-
Hypox + GH (30); F-Hypox + GH (30); M-Hypox + GH (90); F-Hypox + GH (90); and 
M-Hypox and F-Hypox mice given two GH injections spaced 4 hr apart and killed 30 
min after the second injection (M-Hypox + 2 GH; F-Hypox + 2 GH). RNA integrity was 
validated using an Agilent Bioanalyzer 2100. 
3.C.2 Microarrays and data analysis, with Dr. Valerie Wauthier and Dr. Alan Dombkowski. 
Liver RNA pools were prepared by Dr Valerie Wauthier for two independent sets of 
biological replicates and used in 11 sets of competitive hybridization experiments in a 
loop design: 1) M-Sham vs. F-Sham; 2) M-Hypox vs. M-Sham; 3) M-Hypox + GH (30) 
vs. M-Hypox; 4) M-Hypox + GH (90) vs. M-Hypox; 5) M-Hypox + 2 GH vs. M-Hypox; 
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6) F-Hypox vs. F-Sham; 7) F-Hypox + GH (30) vs. F-Hypox; 8) F-Hypox + GH (90) vs. 
F-Hypox; 9) F-Hypox + 2 GH vs. M-Hypox; 10) M-Hypox vs. F-Hypox; and 11) M-
Hypox + GH (30) vs. F-Hypox + GH (30). Hybridization of fluorescent labeled RNA to 
Agilent Whole Mouse Genome oligonucleotide microarrays (Agilent Technology, Palo 
Alto, CA; catalog # G4122F) was carried out (Holloway et al. 2008), with dye swapping 
to eliminate dye bias, giving a total of 22 microarrays. Linear and LOWESS 
normalization and data analysis by Dr. Alan Dombkowski employed Rosetta Resolver 
software (Weng et al. 2006). The full set of normalized expression ratios and p-values is 
available as GEO series GSE17644 at http://www.ncbi.nlm.nih.gov/geo.  
 
Dr. Wauthier and I identified differentially expressed genes and patterns of differentially 
expressed genes as follows. A filter (p < 0.005) was applied to the p-values to determine 
the significance of each gene’s differential expression for each of the 11 microarray 
experiments. A fold change filter of 2.0-fold was combined with the above p-value filter 
to reduce the false discovery rate (FDR) to 0.78%. A system of binary and decimal flags, 
termed TFS (Total flagging sum) (Clodfelter et al. 2006), whereby each probe was 
assigned one of three possible digits for up-regulation, down-regulation, or no regulation, 
was applied for clustering the probes (genes) based on expression ratios obtained in all 
eleven microarray comparisons (Fig. S1 in Wauthier et al. 2010). 
3.C.3 Microarray probe annotation 
Microarray probe coordinates provided by Agilent were converted into mouse genome 
version mm9 coordinates using the UCSC genome browser’s liftOver tool. The genomic 
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sequences defined by the genomic coordinates were aligned with the probe sequences 
using Smith-Waterman local alignment using JAligner (Moustafa 2007), with gap open 
penalty 10 and gap extension penalty 0 in order to allow for long intervening intronic 
sequences that are present in the genomic sequence but not in the microarray probe 
sequence. Any probe sequences (length 60 nt) that did not have at least 56 nt identical to 
the genomic sequence were remapped to the genome using BLAT (Kent 2002). The 
UCSC genome browser’s annotation tables were then searched for transcripts that 
overlapped with the genomic coordinates. Annotations that had 60 nt of exonic sequence 
overlapping with the genomic coordinates were chosen; if there were none, the minimum 
number of overlapping exonic nts was relaxed to 56. For each probe, RefSeq annotations 
were given first priority, followed by non-RefSeq mRNA, Ensembl, spliced EST, and 
finally unspliced ESTs annotations, in order of decreasing priority. Accession numbers 
were obtained for 39,355 out of the 41,174 probes, of which 33,011 had corresponding 
gene names. An additional 3,570 probes were assigned gene names using the microarray 
probe annotation tool AILUN (http://ailun.stanford.edu/) (Chen et al. 2007), which maps 
microarray probes to Entrez genes. In each case where two or more probes assigned the 
same gene name gave the same pattern of regulation, as indicated by assignment to the 
same TFS group (i.e., redundant probes), only the probe with the best p-value was 
retained. Probes associated with the same gene name but different TFS group were not 
considered redundant and were retained. The number of regulated probes i.e., that met 
p<0.005 and >2 fold-change in at least one microarray comparison, was thus reduced 
from 7,775 to 7,046 by eliminating redundant probes. The 729 redundant probes 
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(identified in Table S1 in Wauthier et al. 2010) provide independent confirmation of the 
microarray results reported for the corresponding genes. 
3.C.4 Hierarchical clustering and heat maps  
After eliminating redundant probes, 1,380 genes were identified as sex-specific based on 
p<0.005 and fold change >2 in the untreated male/female comparison. The 1,380 sex-
specific genes were clustered by hierarchical clustering, by gene and by sample based on 
Pearson’s correlation of log ratios, as implemented using the hierarchical clustering 
module of GenePattern (Reich et al. 2006). Clustering was performed separately for two 
groups of arrays: the three Male vs Female comparisons (Sham, Hypox, and Hypox + GH 
(30)) and the two Hypox vs Sham comparisons (Male and Female) in one group; and the 
two Hypox vs Sham comparisons and the six GH-treated vs Sham comparisons in a 
second group. Heat maps were generated for each set of arrays using the GenePattern 
hierarchical clustering visualizer. 
3.C.5 Gene Set Enrichment Analysis (GSEA)  
GSEA (Subramanian et al. 2005) was used to identify sets of regulated genes that have a 
common transcription factor binding set motif using the full set of 837 C3 motif gene sets 
of the Molecular Signatures Database (http://www.broadinstitute.org/gsea/index.jsp). 
These motif gene sets are comprised of genes for which a binding site motif is found 
within a 4kb window centered on the transcription start site and is conserved across four 
species: mouse, human, dog and rat (Xie et al. 2005). Each of the 11 microarray data sets 
was analyzed as a pre-ranked dataset, with probes ranked according to the corresponding 
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Rosetta fold-change values. An FDR cutoff of 0.05 and an NES (normalized enrichment 
score) cutoff of +3 (up regulated genes) or -3 (down regulated genes) were used to 
identify the enriched gene sets for each condition. For enriched gene sets with FDR < 
0.05 but |NES| < 3, most of the core enrichment genes – the genes that contribute to the 
enrichment score – did not meet the microarray p-value threshold of 0.005. Motif gene 
sets for only one transcription factor, Mef2, were enriched with FDR < 0.05 and |NES| > 
3 in at least two of the 11 microarray data sets and were therefore considered for further 
analysis. Chi-square tests were carried out to determine the statistical significance of 
differences in composition of male-specific, female-specific, and sex-independent genes 
for the Mef2 gene sets that are up regulated in a given condition, compared to the 
composition for all genes up or down regulated in that condition. The 41 Mef2 target 
genes up regulated in two or more GH treatment time points were further analyzed for 
enrichment of Gene Ontology, protein domain, pathway, and functional categories using 
DAVID (http://david.abcc.ncifcrf.gov). Categories enriched in the Mef2 target gene list 
with a p-value < 0.01 compared to the species background were considered significant. 
3.C.6 Comparison between mouse and rat  
Sex-differences in liver gene expression and response to hypophysectomy and GH 
treatment seen in the present study were compared to those reported previously in a study 
of Hypox rat liver (Wauthier and Waxman 2008). 11,295 genes were common to the 
mouse and rat microarray platforms used in these two studies, defined as microarray 
probes with the same gene name. Cross-species comparisons at p<0.005 and fold change 
>2 showed very little overlap in the listings of sex-specific genes between mouse and rat 
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liver, with only 6% of sex-specific mouse genes and 8% of sex-specific rat genes 
showing the same specificity in the other species. Therefore, a threshold of p<0.005 was 
applied irrespective of fold change, to account for the possibility that conserved genes 
may show greater response in one species than another due to platform-dependent or 
biological differences. The sex-specificities of the 11,295 common genes were compared 
in mouse and rat, and genes that showed the same sex-specificity in both species were 
compared for responsiveness to hypophysectomy across species (class I, class II, or non-
responsive, defined in section 3.D.3 of Results). Finally, genes that were class I male-
specific in both species (male-specific genes that are down regulated in 
hypophysectomized males) were compared for induction by GH treatment of Hypox 
males in each species. When comparing sex-specificity, genes represented by probes that 
exhibited both male-specificity and female-specificity in either species were excluded 
from consideration, giving 268 sex-specific genes common to mouse and rat, and 
similarly when comparing class I vs class II genes. To compare the response of class I 
male-specific genes to GH treatment in Hypox males, genes were considered induced if 
they were up-regulated in any of the three (mouse) or two (rat) GH time points, as long as 
they did not show the opposite response at other GH time points. 
 
3.D Results 
3.D.1 Experimental design  
Expression microarrays were used to investigate the impact of hypophysectomy on 
mouse liver gene expression, with a focus on sexually dimorphic gene expression, and to 
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establish the short-term responsiveness of these genes to a physiological replacement 
dose of GH. RNA was isolated from livers of adult mice that were: intact males and 
intact females; Hypox males and Hypox females; Hypox male and Hypox female mice 
treated with a single GH pulse and killed either 30 min later or 90 min later; and Hypox 
male and Hypox female mice treated with 2 GH injections, spaced 4 h apart, and killed 
30 min after the second GH injection (Hypox + 2 GH). 7,046 microarray probes met the 
threshold criteria for differential expression (average expression ratio >2-fold and a 
significance of p<0.005) for at least one of the eleven data sets after elimination of 
redundant probes (listed in Table S1 in Wauthier et al. 2010). 
3.D.2 Sex-specificity in intact and hypophysectomized mouse liver  
Sex-specific expression in intact mouse liver was found for 1,380 (20%) of the regulated 
genes, 864 male-specific and 516 female specific (Table 3-1). Overall, 94% of the genes 
showing sex-specificity in mouse liver are pituitary hormone dependent and perhaps GH 
dependent, with 95% of male-specific and 91% of female-specific gene expression being 
abolished by hypophysectomy, and many of the 71 genes retaining sex-specificity 
showing a reduced ratio (Table 3-1). This conclusion was also evident from the 
hierarchical clustering of sex-specific genes (Fig. 3-1A): the Hypox male vs Hypox 
female array formed a branch on its own, reflecting the major effect of hypophysectomy 
on sex-specificity. Sex-specific genes not affected by hypophysectomy (i.e., pituitary 
hormone independent genes) include the Y chromosome-encoded male-specific genes 
Ddx3y, Eif2s3y, Jarid1d/Kdm5d and Uty, and the female-specific genes Xist and Tsix, 
which are involved in X-inactivation. 
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3.D.3 Sex-specific response to hypophysectomy 
Hypophysectomy had a significantly greater impact on sex-specific gene expression in 
male than in female mouse liver (Fig. 3-1A, lane 1 vs. lane 2). Substantial fractions of the 
male-specific genes (70%) and female-specific genes (53%) whose expression changed 
following hypophysectomy were affected in Hypox males only (Table 3-2), with male-
specific genes showing decreased expression, and female-specific genes showing 
increased expression. Of the many fewer genes whose expression changed in Hypox 
female liver only, 50 of 58 male-specific genes were increased in expression while 77 of 
81 female-specific genes were decreased (Table 3-2). Thus, the male pituitary hormone 
profile maintains the expression of these male-specific genes and suppresses the 
expression of the female-specific genes in male liver, while the female pituitary hormone 
profile maintains female-specific gene expression and suppresses male-specific gene 
expression in female liver. These findings indicate that while male and female plasma 
GH profiles both make substantial contributions to liver sex-specificity in rats (Wauthier 
and Waxman 2008), the male plasma GH profile dominates in mice.  
 
Classification of sex-specific genes – Two distinct classes of sex-specific genes were 
identified: genes whose expression decreases after hypophysectomy, indicating pituitary 
hormone is required for full expression (class I sex-specific genes), and genes whose 
expression increases after hypophysectomy, indicating repression by pituitary hormone 
(class II sex-specific genes) (Table 3-3). A large majority (88%) of the male-specific 
genes affected by hypophysectomy are class I genes (i.e. are induced by the male 
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pituitary hormone profile), with only 10% being class II genes. In contrast, a majority 
(64%) of the pituitary-dependent female-specific genes are class II genes (i.e. are 
suppressed by male pituitary hormone profile). 
 
The class I and class II sex-specific genes were further subdivided based on their 
responses to hypophysectomy in males and females (Table 3-3). The largest of male-
specific genes are Class IA male genes (479 genes), which are positively regulated by the 
male but are not regulated by the female pituitary hormone profile. Class IB male genes 
require pituitary hormone for full expression in both sexes (112 genes). The other groups, 
Class IC, Class IIA, and Class IIB, make up a much smaller percentage of male-specific 
genes. Class IC male genes are positively regulated by the male pituitary hormone profile 
and are repressed by the female pituitary hormone profile. Class IIA male genes do not 
require the male pituitary hormone profile for expression but are repressed by the female 
pituitary hormone pattern, while class IIB male genes are repressed by pituitary 
hormones in both sexes. Female-specific genes were classified similarly, as shown in 
Table 3-3. Class IIA female genes are repressed by the male but not by the female 
pituitary hormone pattern and make up the largest group of female-specific genes (183 
genes). Thus, both male-specific and female-specific genes are predominantly dependent 
on the male pituitary hormone pattern. 
3.D.4 Clustering by significance and differential expression 
The 7,046 genes that met the threshold criteria for at least one of the eleven data sets 
were clustered using a binary flagging system (Clodfelter et al. 2006), whereby each gene 
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is assigned to a specific category, based upon whether it is up-regulated, down-regulated, 
or not regulated (with fold-change > 2 and p < 0.005) in each of the eleven microarrays. 
Select gene groups are discussed below. 
 
Sex difference in response to short-term GH pulse treatment – In order to test the 
hypothesis that a subset of the sex-specific genes affected by hypophysectomy are direct 
targets of GH that can be detected as a rapid response to GH treatment, Hypox mice were 
injected with GH and killed 30 minutes or 90 minutes after a single pulse, or 30 minutes 
after two pulses 2 hours apart. A majority of the class I sex-specific genes (74%) did not 
respond to short-term GH treatment; these genes may be regulated by GH indirectly 
(hence no rapid response to GH), or may require pituitary hormone(s) other than GH for 
expression. However, 147 class I male-specific genes were induced by short-term GH 
treatment in livers of Hypox mice in a sex-dependent manner: 45% of the 147 class I 
male-specific genes were induced in Hypox males only, and 24% induced in Hypox 
females only (Table S4A of Wauthier et al. 2010), genes listed in Table S4C of (Wauthier 
et al. 2010). GH induction of 12 out of 17 induced class I female-specific was also sex-
dependent. Sex-differences were also apparent from the time course of induction of the 
male-specific genes, which was more rapid in Hypox males than in Hypox females (Fig. 
3-2; Table S4B in (Wauthier et al. 2010)): 46 of the 70 class I male genes induced in 
Hypox males only were induced after one GH injection, whereas the class I male genes 
that responded to GH in Hypox females only were not induced until after the second GH 
injection (i.e., 4.5 hr after the first GH injection). The pattern was similar for male-
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specific genes induced by GH in both Hypox males and Hypox females. In contrast, the 
time course of response to short-term GH treatment was very similar in males and 
females for class I female-specific genes (Table S4B in Wauthier et al. 2010). These sex-
differences in early GH responsiveness were evident from Fig. 3-1B, where the three 
GH-treated Hypox male arrays clustered together, and were most similar to Hypox 
females given 2 GH injections, indicating that genes that respond to GH after a single 
injection in Hypox males require two injections in Hypox females.  
 
These findings indicate that the liver maintains intrinsic sex differences in GH 
responsiveness several weeks after hypophysectomy, i.e., despite the chronic absence of 
GH and other pituitary-dependent hormones (e.g., sex steroids). This sex difference in 
GH responsiveness was confirmed by a direct microarray comparison of the rapid (30 
min) GH pulse-induced changes in liver gene expression seen in Hypox male vs. Hypox 
female mice. 
 
Rapid repression of sex-specific genes by GH pulse treatment – Rapid down regulation of 
gene expression is often difficult to detect by microarray analysis of mature RNAs due to 
the delay imposed by the intrinsic stability of pre-existing RNAs. Nevertheless, 15 of the 
male-specific genes and 37 of the female-specific genes that were up regulated in Hypox 
mouse liver (class II genes) were down-regulated by short-term GH treatment in either 
one or both sexes (Table S4E in Wauthier et al. 2010). Down-regulation was not apparent 
until 4.5 h after the first GH injection. Several of the short-term GH down regulated class 
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IIA female genes are also de-repressed in male mouse liver upon ablation of STAT5b 
(Clodfelter et al. 2006), suggesting STAT5b mediates the short-term suppression by GH. 
These genes include Gadd45b, Odz3, Rab30 (Clodfelter et al. 2006) and Tox, which 
encodes a class IIA female-specific transcription factor (Laz et al. 2007). 
 
GH responsiveness of sex-independent genes – No major sex differences were apparent in 
the time course of GH responsiveness of the sex-independent genes (Table S6 in 
Wauthier et al. 2010) Of note, six genes were up-regulated within 30 min and then 
remained elevated in both males and females; four of these genes encode well-established 
targets of STAT5: Igf1, Cish, Socs2, and a Socs2-like sequence. The other two, Phlda1 
and an uncharacterized transcript (AK053952), may be novel targets of STAT5. Phlda1 
encodes a proline-histidine rich nuclear protein that may play an important role in the 
anti-apoptotic effects of Igf1 (Toyoshima et al. 2004). 
3.D.5 DNA-binding proteins and transcriptional regulators 
41 male-specific genes and 28 female-specific genes were identified as DNA-binding 
proteins and transcriptional regulators by their Gene Ontology descriptors (Table S8 in 
Wauthier et al. 2010), including seven male class IA genes that were induced by GH 
within 30-90 min in male but not female liver, that could mediate the downstream 
transcriptional effects of GH on other sex-specific genes. These genes include Foxg1, a 
co-repressor of the androgen receptor that is overexpressed in hepatoblastoma (Adesina 
et al. 2007; Obendorf et al. 2007), and Vgll2, a transcriptional cofactor required for 
skeletal muscle muscle differentiation (Chen et al. 2004). The genes Onecut1 and Mbd1 
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were down-regulated in both Hypox male and Hypox female liver and were up regulated 
in both sexes within 90 min of GH treatment (Table S9 in Wauthier et al. 2010). Onecut1 
encodes the liver-enriched transcription factor HNF6, and Mbd1 encodes a methyl-CpG 
binding domain protein that can repress transcription from methylated gene promoters 
and contributes to epigenetic gene silencing (Sakamoto et al. 2007). 
3.D.6 Gene set enrichment analysis 
GSEA was used to investigate whether any of the 11 microarray data sets shows 
enrichment for known transcription factor motifs, as determined using a set of 837 motif 
gene sets, comprised of genes for which a conserved motif is found within a 4 kb window 
centered on the transcription start site (Xie et al. 2005). Twelve motif gene sets associated 
with the transcription factor Mef2 (Potthoff and Olson 2007) were enriched among genes 
up regulated in 3 of the 11 microarray datasets: Hypox males + 30 min GH treatment, 
Hypox males + 2 GH (4.5 hr GH time point), and Hypox female + 2 GH, all compared to 
the corresponding hypophysectomized controls (Table 3-4). Moreover, GH induced a 
similar number of Mef2 target genes in Hypox males at the 90 min time point as at the 
other two time points (Table S10B in Wauthier et al. 2010). Examination of the 41 Mef2 
target genes induced at two or more of the six GH time points (30 min, 90 min and 4.5 hr, 
in both males and females) (Table S11 in Wauthier et al. 2010) revealed that 29 Mef2 
target genes (71%) were male-specific, all but one being class I male-specific genes. In 
contrast, only 25% of the non-Mef2 target genes showing the same pattern of up 
regulation by GH were male-specific (Table 3-5). The Mef2 target genes induced by GH 
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are involved in diverse processes, most notably muscle cell development and 
differentiation (Table S12 in Wauthier et al. 2010). 
3.D.7 Comparisons of sex-specificity between mouse and rat 
Genes common to the present mouse microarray platform and the rat microarray platform 
used in (Wauthier and Waxman 2008) were compared for liver sex-specificity and 
response to hypophysectomy and GH treatment across species (listed in Table S14 in 
Wauthier et al. 2010). 268 of the genes common to both species showed the same sex-
specificity at p<0.005 (12% and 20% of the sex-specific genes in mouse and rat liver, 
respectively; Fig. 3-3A). Many sex-specific genes are assigned species-specific gene 
names (e.g., members of the Cyp and Mup gene families), and this contributes to the low 
number of genes showing species-conserved sex specificity. To compare responses to 
hypophysectomy across species, the 268 sex-specific genes were classified as class I, 
class II, or non-responsive to hypophysectomy. Approximately half of the 268 sex-
specific genes belong to the same class in both species (Fig. S3-3B), and showed class 
patterns similar to all sex-specific genes in the species (Fig. 3-4). Of the 37 genes that are 
class I male-specific genes in both species, 13 genes were induced by GH in Hypox male 
mice, and 8 genes were induced by GH in Hypox male rats.  
 
3.E Discussion 
A large-scale gene expression study was conducted to investigate the pituitary hormone 
dependence of sex-specific gene expression in mouse liver and to identify sex-specific 
early GH response genes that might contribute to downstream signaling pathways. Sex-
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specific liver gene expression was shown to be highly pituitary hormone dependent, as 
indicated by the near global loss (94%) of sexual dimorphism in Hypox mice. Two 
distinct classes of sex-specific mouse liver genes were identified. Class I sex-specific 
genes, which are positively regulated by the pituitary gland, as shown by their down 
regulation following hypophysectomy, comprise 88% of the pituitary-dependent genes 
that are male-specific but only 34% of those that are female-specific. In contrast, class II 
sex-specific genes, which are pituitary hormone repressed, comprise 64% of the female-
specific genes but only 10% of the male-specific class II genes. Furthermore, the male 
pituitary hormone profile was shown to have a greater influence on mouse liver sexual 
dimorphism than the female hormone profile, as indicated by the greater impact of 
hypophysectomy on the expression of sex-specific genes in males. Finally, an intrinsic 
sex difference in the GH pulse responsiveness of the liver was identified, with a subset of 
sex-specific genes responding rapidly to a physiological pulse of GH in Hypox male but 
not Hypox female mouse liver. It should be noted that the absence of other pituitary-
dependent hormones might influence the GH response profiles reported in this study. 
 
The global role of the pituitary gland in regulating mouse liver sexual dimorphism 
through both positive regulation (class I genes) and negative regulation (class II genes) 
shown here is consistent with the dominant role of plasma GH profiles in determining 
liver sex specificity (Ahluwalia et al. 2004; Laz et al. 2004). GH induced a subset of class 
I sex-specific genes within 30-90 min; these genes are putative direct targets of GH. 
Several of the early GH response genes are transcription factors, which could mediate the 
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inductive effects of GH on downstream sex-specific genes. Class I genes induced after a 
second GH injection may be primary response genes whose induction is delayed, or could 
be secondary GH response genes. Some of the class I genes that did not respond to GH 
during the time frame of our experiments (4.5 hr) might have a requirement for pituitary 
hormones other than GH. However, many of the class I sex-specific genes are likely to be 
regulated by GH indirectly, as indicated by the finding that several days of continuous 
GH stimulation are required to feminize liver gene expression in intact male mice 
(Holloway et al. 2006). Genes that are up regulated in Hypox mouse liver (class II genes) 
and repressed by short-term GH treatment are candidates for direct targets of the 
inhibitory action of GH. Although direct suppression by GH was observed for relatively 
few class II sex-specific genes, this may be the result of mRNA half-lives that are longer 
than the 4.5 hr time frame of our GH treatment experiments. Class II sex-specific genes 
that responded to GH slowly or not at all in the present study may be secondary GH 
response genes or perhaps may be repressed via the action of other pituitary hormones. 
Intrinsic sex differences in the inhibitory action of GH on sex-specific genes were also 
apparent.  
 
The rapid induction by GH of liver gene expression (including sex-specific gene 
expression) may be mediated by STAT5b, which was previously shown to be essential 
for liver sexual dimorphism by microarray analysis (Clodfelter et al. 2006) and in studies 
of the effect of GH pulse replacement in Hypox STAT5b-deficient mice (Davey et al. 
1999; Holloway et al. 2006). Consistent with this hypothesis, several genes with 
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characterized STAT5 response elements, including Igf1 (Eleswarapu et al. 2008), Cish 
(Verdier et al. 1998), Spi2.1 (Serpina3 family) (Wood et al. 1997) and Onecut1/Hnf6 
(Lahuna et al. 2000; Laz et al. 2009), were rapidly induced by GH. The rapid induction 
by GH of certain female-specific genes could be mediated by STAT5a, a minor liver 
STAT5 form that is >90% identical to STAT5b but is apparently more important for sex-
specific gene expression in female than male mouse liver (Clodfelter et al. 2007). The 
short-term GH inhibitory effects on certain sex-specific genes may be dependent on 
STAT5b, which can effect rapid GH suppression in rat liver (Ono et al. 2007). Class II 
male-specific genes may be directly repressed by STAT5b during each plasma GH pulse 
and then de-repressed during the plasma GH-free interpulse interval, as suggested by the 
rapid down-regulation of class II male-specific hnRNAs in Hypox rat liver following GH 
pulse treatment (Wauthier and Waxman 2008). In this manner, GH may both activate and 
repress sex-specific genes via the same transcription factor, namely STAT5b. 
 
GSEA analysis was carried out to identify other transcription factors that might be 
involved in the short-term responses to GH. These analyses identified the transcription 
factor Mef2 (myocyte enhancer factor 2), which regulates processes such as neural 
survival and muscle differentiation (Potthoff and Olson 2007). Mef2 target genes were 
induced at all three GH treatment time points in Hypox males, but induction was delayed 
until the 4.5 hr time point in Hypox females, consistent with the sex-difference in short-
term GH-responsiveness discussed above. Strikingly, the GH-responsive Mef2 target 
genes were substantially enriched in class I male-specific genes (28 out of 41 GH-
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responsive Mef2 target genes) and account for 17% of all short-term GH-responsive class 
I male-specific genes (Table S10D in Wauthier et al. 2010). The functional significance 
of the rapid activation of Mef2 target genes by GH in male liver is unknown. Two of the 
four vertebrate Mef2 genes, Mef2a and Mef2d, are expressed at significant levels in 
mouse liver and the other two forms are expressed at low levels, as judged by their 
microarray signal intensities. The Mef2 genes themselves did not respond to GH 
treatment, suggesting that GH may regulate Mef2 activity post-translationally, e.g., by 
phosphorylation. Other studies have reported that Mef2a, Mef2c and Mef2d RNA and 
protein are present in hepatic stellate cells, which comprise 5-8% of resident liver cells 
and are activated in a Mef2-dependent manner to a myofibroblast-like phenotype under 
pathological conditions leading to liver fibrosis and cirrhosis (Sato et al. 2003; Wang et 
al. 2004). The association of Mef2-regulated genes with myofibroblast/smooth muscle 
function is consistent with the preferential expression of Mef2 protein in this liver cell 
type and with the activation of these Mef2 genes under conditions of hepatic stellate cell 
activation (Wang et al. 2004). Furthermore, hepatic stellate cells are strongly activated in 
hepatocellular carcinoma, where Mef2 protein is highly expressed (Bai et al. 2008), 
suggesting that Mef2 plays a key role in hepatocellular carcinoma pathogenesis. In this 
context our observation that male liver is more responsive to rapid GH induction of Mef2 
target gene expression is intriguing, insofar as it suggests that GH activation of Mef2 
signaling could be an important factor in the widespread greater susceptibility of males to 
liver cancer (De Maria et al. 2002). Although STAT5 is a known mediator of GH-
mediated gene regulation in the liver, its target genes were not enriched in our GSEA 
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analysis, which was limited to transcription factors whose conserved binding sites are 
within 2 kb of the transcription start site, which is frequently not a characteristic of 
STAT5 binding sites (Nelson et al. 2004; Laz et al. 2009 and Chapter 2). The mechanism 
whereby GH induces Mef2 target genes in liver is unknown. The Mef2 target genes up 
regulated by GH are involved in diverse processes, most notably muscle cell 
development and differentiation (Table S12 in Wauthier et al. 2010). Of note, during 
muscle cell differentiation, p38 signaling leading to the activation of Mef2 converges 
with Igf1 activation of PI-3 kinase/AKT signaling at the level of chromatin to induce 
Mef2 target gene expression (Serra et al. 2007). Conceivably, there may be similar 
cooperation between Mef2 and Igf1 in the induction of GH-responsive genes in liver.  
 
Hypophysectomy is presently shown to have a greater impact on sex-specific gene 
expression in male than in female mouse liver. Given the central role of pituitary GH 
secretory profiles in establishing and maintaining liver sexual dimorphism, discussed 
above, this implies that in the mouse, the male plasma GH profile is the dominant 
determinant of liver sexual dimorphism. This conclusion is consistent with our earlier 
finding that loss of GH-activated STAT5b has a much greater impact on sex-specific 
gene expression in male than in female mouse liver (Clodfelter et al. 2006). By contrast, 
in the rat model, hypophysectomy of males had a greater effect on the expression of 
male-specific genes, whereas hypophysectomy of females had a greater impact on 
female-specific genes (Wauthier and Waxman 2008), indicating that both the male and 
the female GH profile make important contributions to liver sexual dimorphism in that 
111 
 
 
 
species. This species difference likely results from the distinct plasma GH profiles of rats 
and mice, with GH circulating in a near continuous manner in female rats, whereas in 
female mice the plasma GH profile is highly pulsatile, albeit with noticeably shorter 
interpulse intervals than in male mice (MacLeod et al. 1991). It is unclear, however, how 
these species differences in plasma GH profiles might contribute to the species-dependent 
effects of hypophysectomy reported here.  
 
A subset of the sex-specific genes responded to GH rapidly in Hypox male but not Hypox 
female mice. Given that this sex difference was seen in mice deficient in pituitary-
dependent hormones, including gonadal hormones, for a period of several weeks, leading 
to the conclusion that intrinsic sex differences characterize the liver's response to GH. 
These intrinsic sex differences could result from an epigenetic memory set by the distinct 
male and female pituitary hormonal environments prior to hypophysectomy. 
Alternatively, they might be mediated by sex-specific genes encoding other modulatory 
factors that are expressed in the liver in a pituitary-independent manner, which would 
enable them to continue to impose their modulatory effects on pituitary/GH-responsive 
sex-specific genes post hypophysectomy. Indeed, several of the sex-specific genes whose 
expression is pituitary hormone-independent are chromatin modifying enzymes, e.g., the 
Y-chromosome genes Jarid1d, a histone H3 lysine 4 demethylase (Lee et al. 2007), and 
Uty, which exhibits 84% sequence similarity to the histone H3 lysine 27 demethylase Utx 
(Hong et al. 2007). Five of the male-specific genes rapidly induced by GH within 30 min 
in Hypox males but not Hypox females code for transcription factors. Further studies will 
112 
 
 
 
be required to determine if any of these factors contribute to the GH-dependent regulation 
of downstream sex-specific genes, and to elucidate the cellular and molecular 
mechanisms that dictate the intrinsic sex-differences in GH responsiveness of the liver. 
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Table 3-1. Sex specificity of liver-expressed genes in intact and Hypox mice. 
The 7046 liver-expressed genes meeting the criteria described in Materials and Methods 
(section 3.C.2) are listed based on the sex specificity of their expression in intact mice 
and secondarily based on the sex specificity of their expression in Hypox mice. 
 
Sex-specificity in 
intact mouse liver 
Sex-specificity in 
Hypox mice 
Gene count % 
Male-specific    
 Female 9 1 
 Male 36 4 
 Nonspecific 819 95 
 Total 864  
Female-specific   
 Female 35 7 
 Male 9 2 
 Nonspecific 472 91 
 Total 516  
Sex-independent   
 Female 99 2 
 Male 135 2 
 Nonspecific 5432 96 
 Total 5666  
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Table 3-2. Impact of hypophysectomy on liver gene expression. 
The 7046 liver-expressed genes meeting the criteria described in Materials and Methods 
were initially sorted by sex-specificity in intact, untreated mice and secondarily by 
response to hypophysectomy in males inly, in females only, and in both males and 
females. Percentages are calculated based on the 683 male-specific genes and 346 
female-specific genes that respond to hypophysectomy. Many of the other sex-specific 
genes are affected by hypophysectomy but do not reach the threshold of more than 2.0-
fold change in expression and P < 0.005; however, those genes lose their sex specificity 
in hypophysectomized mice (<2.0-fold sex difference). 
 
Effect of Hypox on 
gene expression 
Changed in  
M-Hypox only 
 Changed in  
F-Hypox only 
 Changed in both 
M-Hypox and  
F-Hypox 
Gene 
count
% Gene 
count
% Gene 
count 
%
Male-specific genes  
    Increase 1 0 50 7 21 3
    Decrease 479 70 8 1 112 16
    Total 480 58 145a 
Female-specific 
genes 
 
    Increase 183 53 4 1 39 11
    Decrease 2 1 77 22 20 6
    Total 185 81 80b  
a Includes 12 male-specific genes down-regulated in M-Hypox and up-regulated in F-
Hypox. 
b Includes 21 female-specific genes down-regulated in F-Hypox and up-regulated in M-
Hypox.  
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Table 3-3. Classification of pituitary hormone-dependent and male- and female-specific genes. 
The 1029 sex-specific genes affected by hypophysectomy in males only, in females only, or in both males and females (Table 
3-2) were classified based on whether expression is suppressed (class I) or induced (class II) by hypophysectomy in males and 
females. The subclass indicates if the impact of hypophysectomy is seen in only one sex (A) or in both sexes (B). Subclass C 
includes genes that responded to hypophysectomy in both sexes but in the opposite direction. Percentages (column 2) are based 
on 683 male-specific and 346 female-specific genes. Columns 4 and 5 indicate whether the genes are down-regulated, up-
regulated, or not changed significantly (dash) after hypophysectomy. 
 
Sex specificity: 
class 
Gene 
count 
Sub-
class 
Response in 
M-Hypox 
Response in 
F-Hypox 
Gene 
count 
Examples (genes) 
Male-specific 
class I 
603 (88%) IA Down − 479 Ckmt2, Cml4, Gstp1, Myh1 
 IB Down Down 112 Cyp7b1, Elovl3, Hsd3b4, 
Mup1/3/4/5 
 IC Down Up 12 Acta1, Cyp4a12a, Myh4 
Male-specific 
class II 
71(10%) IIA − Up 50 Alas2, Mcm10, Nox4 
 IIB Up Up 21 Gsta1/Gsta2, Grem2, Lpl 
    683 totala  
Female-specific 
class I 
118 (34%) IA − Down 77 A1bg, Cyp3a41, Fmo3, Trim24 
 IB Down Down 20 Ly6c2, Mfsd2, Ptgds 
 IC Up Down 21 Acot3, Cyp2g1, Npal1 
Female-specific 
class II 
222 (64%) IIA Up − 183 Cyp2b9, Cyp4a10, Hao3, Nnmt, 
Tox 
 IIB Up Up 39 Cyp4a14, Serpinb1a, Serpinb1b 
    346 totala  
 a Gene totals include nine other male-specific genes and six other female-specific genes.  
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Table 3-4. GSEA results for Mef2 gene sets enriched among genes up regulated by 
short-term GH treatment in M-Hypox and/or F-Hypox mouse liver. 
Shown are NES (normalized enrichment score), p-value, and FDR for 12 Mef2 motif 
gene sets.  Mef2 was the only motif gene set enriched at least 2 of the 11 microarray 
experiments, with FDR < 0.05 and |NES| >= 3. 
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Table 3-4. GSEA results for Mef2 gene sets enriched among genes up regulated by short-term GH treatment in M-Hypox 
and/or F-Hypox mouse liver. 
Gene set name Sequence Logo 
M-Hypox+GH30 vs M-
Hypox 
M-Hypox+2GH vs M-
Hypox 
F-Hypox+2GH vs F-
Hypox 
NES p-value FDR NES p-value FDR NES p-value FDR 
V$MEF2_01 4.24 0 0 3.79 0 3.6E-3 4.01 0 1.1E-3
V$MEF2_02 4.37 0 0 3.79 0 6.0E-3 4.74 0 0 
V$RSRFC4_01 4.18 0 2.9E-4 3.61 0 0.011 4.58 0 0 
V$RSRFC4_Q2 4.23 0 0 3.58 0 9.9E-3 4.58 0 0 
CTAWWWATA_V$RSRFC4_Q2 4.05 0 7.8E-4 3.74 0 4.3E-3 5.27 0 0 
V$HMEF2_Q6 
 
3.47 1.2E-3 0.048    4.00 0 1.1E-3
V$MEF2_03 3.86 0 2.9E-3    3.64 0 7.1E-3
V$MEF2_Q6_01 4.08 0 7.0E-4    4.25 0 0 
YTATTTTNR_V$MEF2_02 3.75 0 8.5E-3    4.24 0 0 
TAAWWATAG_V$RSRFC4_Q2       4.17 0 1.8E-4
V$AMEF2_Q6       3.45 0 0.020
V$MMEF2_Q6       3.43 0 0.021
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Table 3-5. Sex-specificities of Mef2 target genes and non-Mef2 target genes up-
regulated in at least two GH-treated conditions 
Shown are proportions of GH-induced Mef2 target genes (left) and non Mef2 target 
genes (right) that are male-specific, female-specific, and sex-independent. Proportions of 
sex-specificities of Mef2 target genes were significantly different from those for non-
Mef2 target genes (p-value ≈ 0 using Chi-squared test). 
 
  # Mef2 target genes # non-Mef2 target genes 
Genes up-
regulated in total 
% male-
specific
% female-
specific 
% sex-
independe
nt 
total % male-specific 
% female-
specific 
% sex-
independ
ent 
2 or more 
conditions 41 71% 0% 29% 252 25% 7% 68% 
3 or more 
conditions 22 82% 0% 18% 97 42% 10% 47% 
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Figure 3-1. Heat maps representing expression of 1,380 sex-specific genes clustered by 
gene and by sample.  
Genes are depicted based on their average expression ratios across the 11 microarray 
experiments. Colors range from bright green (up-regulation) to bright red (down-
regulation). Hierarchical clustering was performed based on Pearson’s correlation of log 
ratios. A. Heat map showing expression of the 1,380 sex-specific genes in the three Male 
vs Female comparisons (Sham, Hypox, and Hypox + GH (30 min)) and the two Hypox vs 
Sham comparisons (Male and Female).  B. Heat map showing expression of the 1,380 
sex-specific genes in the two Hypox vs Sham comparisons and the six GH-treated vs 
Sham comparisons.  The dendrogram at top identifies arrays that show the greatest 
similarity in their patters of expression. 
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Figure 3-1. Heat maps representing expression of 1,380 sex-specific genes clustered 
by gene and by sample. 
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Figure 3-2. Class I male-specific genes that respond to GH rapidly in M-Hypox and F-
Hypox liver. 
Shown are the numbers of genes that are rapidly induced by a pulse of GH (within 30 or 
90 min), or not until 30 min after a second pulse of GH given 4 h after the first pulse. The 
class I male-specific genes are divided into groups based on whether they are induced by 
short-term GH treatment in Hypox males only, Hypox females only, or in both sexes, as 
indicated on the x-axis. Early GH induction responses dominated in Hypox males, 
whereas the GH responses seen in Hypox females were almost exclusively late responses. 
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Figure 3-3. Comparison of sex-specificities and response to hypophysectomy in mice 
and rats. 
Genes that were sex-specific at p<0.005 in either species were considered. A, Proportions 
of sex-specific genes in one species that are of the same or opposite sex-specificity or 
non-sex-specific in the other species. B, Classification of the 268 common sex-specific 
genes into class I and class II in mice, and proportions of these that are the same class, 
opposite class, or do not respond to Hypox, in rats. 
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Figure 3-3. Comparison of sex-specificities and response to hypophysectomy in mice 
and rats. 
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Figure 3-4. Proportions of sex-specific genes in mouse and rat that belong to Class I, 
Class II, or do not respond to Hypox.  
A, All sex-specific genes at p<0.005 and fc>2. B, Genes of the same sex-specificity in 
both species, at p<0.005.  In mice, more male-specific genes belong to class I than class 
II, while more female-specific genes belong to class II than class I; in rats, both male-
specific and female-specific genes are predominantly class I genes. Consequently, the set 
of female-specific mouse class II genes showed the lowest agreement with rat (see Fig. 3-
3B). 
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Figure 3-4. Proportions of sex-specific genes in mouse and rat that belong to Class I, 
Class II, or do not respond to Hypox. 
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Chapter 4  
Unbiased, genome-wide in vivo mapping of transcriptional regulatory elements 
reveals sex differences in chromatin structure associated with sex-specific liver gene 
expression3 
 
4.A Abstract 
A simple and efficient method was used to identify condition-specific transcriptional 
regulatory sites in vivo to help elucidate the molecular basis of sex-differences in 
transcription, which are widespread in mammalian tissues and affect normal physiology, 
drug response, inflammation and disease. To systematically uncover transcriptional 
regulators responsible for these differences, DNase hypersensitivity analysis coupled with 
high-throughput sequencing was used to produce condition-specific maps of regulatory 
sites in male and female mouse liver, and for livers of male mice feminized by 
continuous infusion of growth hormone (GH). 71,264 hypersensitive sites were 
identified, with 1,284 showing robust sex-differences. Continuous GH infusion 
suppressed the vast majority of male-specific sites and induced a subset of female-
specific sites in male liver. Broad genomic regions (up to ~100kb) showing sex-
dependent hypersensitivity and similar patterns of GH response were also identified. A 
strong association was observed of sex-specific sites with sex-specific transcription; 
however, a majority of sex-specific sites were >100kb from sex-specific genes. By 
                                                 
3 A modified version of this chapter was published in Molecular and Cellular Biology. Ling, G., 
Sugathan, A., Mazor, T., Fraenkel., E., and D.J. Waxman (2010). “Unbiased, genome-wide in 
vivo mapping of transcriptional regulatory elements reveals sex differences in chromatin structure 
associated with sex-specific liver gene expression.”  Mol Cell Biol 30:5531. All experimental work 
was carried out by Dr. Guoyu Ling, as noted in appropriate places in this chapter. 
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analyzing sequence motifs within regulatory regions, two known regulators of liver 
sexual dimorphism were identified, and several new candidates for further investigation 
were discovered. This approach can readily be applied to mapping condition-specific 
regulatory sites in mammalian tissues under a wide variety of physiological conditions. 
 
4.B Introduction 
Sexual dimorphism in gene expression is common in mammalian somatic tissues (Isensee 
and Ruiz Noppinger 2007), and has broad implications for human health. Sex differences 
in gene expression may contribute to differences between men and women in the 
prevalence, extent, and progression of disease, including autoimmune diseases (Whitacre 
2001), kidney disease (Rinn and Snyder 2005), cardiovascular disease (Silander et al. 
2008) and liver diseases, including hepatocellular carcinoma (El-Serag 2004; Yokoyama 
et al. 2005). In addition, sex differences in pharmacokinetics and pharmacodynamics are 
common and may affect drug response (Waxman and Holloway 2009). Sex differences in 
gene expression have been widely studied in liver, where they affect >1,000 transcripts 
(Clodfelter et al. 2006; Yang et al. 2006; Wauthier and Waxman 2008) and impact 
physiological and pathophysiological functions ranging from lipid and fatty acid 
metabolism to xenobiotic metabolism and disease susceptibility (Waxman and Holloway 
2009). In liver, sex differences in gene expression are primarily determined by growth 
hormone (GH) signaling (Cesena et al. 2007; Hosui and Hennighausen 2008), which 
shows important sex-differences that reflect the sex-differences in plasma GH profiles 
seen in many species, including rats, mice and humans (Waxman and O'Connor 2006).  
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The underlying mechanisms of sexual dimorphism in mammalian tissues have been only 
partly elucidated at the molecular level. In male rat liver, intermittent plasma GH pulses 
repeatedly activate the latent cytoplasmic transcription factor STAT5b, whose activity is 
essential for liver sex differences (Clodfelter et al. 2006). The more continuous, female-
like pattern of pituitary GH secretion can be mimicked by continuous GH infusion of 
male mice, which abolishes the normal male, pulsatile, plasma GH profile and feminizes 
liver transcript patterns by suppressing many male-specific genes and inducing many 
female-specific genes (Holloway et al. 2006). In spite of these findings, the molecular 
mechanisms whereby STAT5b and other transcription factors regulate liver sex 
specificity have remained elusive (Lichanska and Waters 2008; Waxman and Holloway 
2009).  
 
DNase I hypersensitivity (DHS) analysis is a powerful tool to identify functional DNA 
elements involved in gene regulation. The temporal and spatial association of DHS sites 
with tissue-specific and developmentally regulated gene expression has long been 
established (Gross and Garrard 1988), and several instances have been reported where 
sex differences in DNase hypersensitivity characterize genes that show sex-dependent 
transcription. Early studies identified a male-predominant DHS site in mouse liver 
upstream of C4a (Sex-limited protein), where an open chromatin structure correlated with 
a male-predominant pattern of gene expression (Hemenway and Robins 1987), and 
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examples of sex-regulated DHS sites have been reported for two sex-specific cytochrome 
P450 (Cyp) genes in rat liver (Strom et al. 1994; Gao et al. 2008).  
 
In order to identify sex differences in mouse liver chromatin structure on a global scale, 
DHS analysis was combined with ultra high throughput sequencing (DNase-seq) to probe 
open chromatin structure at single bp resolution (Crawford et al. 2006; Sabo et al. 2006; 
Boyle et al. 2008; Song and Crawford 2010). The results show that DNase-seq, whose 
application until now has been limited to cultured cell lines, can readily be used to map 
DHS sites in mammalian liver, despite the added complexity of multiple cell types. High 
resolution, genome-wide DHS maps were obtained for both male and female mouse liver 
under physiological conditions, and it is demonstrated that these maps can be utilized to 
identify transcriptional regulators of sex-biased liver gene expression. More than 70,000 
DHS sites were characterized, and encompass a large fraction (~70-90%) of binding sites 
for six liver transcription factors identified earlier by ChIP-seq. 1,284 DHS sites were 
identified that show robust sex differences and may contribute to sex-dependent gene 
expression, ~20% of which mapped within 100 kb of a sex-specific liver gene. In 
addition, a subset of the sex-dependent DHS sites is shown to respond to continuous GH 
treatment in male mice, likely representing functional DNA elements that mediate 
hormone-dependent, sex-dependent gene expression. Finally, analysis of the sex-
dependent DHS sequences for enriched motifs identified binding sites for two 
transcription factors, STAT5b and HNF4α, known to be essential for sex-specific liver 
gene expression (Clodfelter et al. 2006; Holloway et al. 2007; Holloway et al. 2008), as 
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well as binding sites for several novel factors, not previously implicated in liver sexual 
dimorphism. These findings highlight the utility DNase-seq for elucidating condition-
specific transcriptional regulatory sites associated with complex biological processes in 
mammalian tissue in vivo on a genome-wide scale. 
 
4.C Materials and methods 
4.C.1 Mouse studies and experimental methods, carried out by Dr. Guoyu Ling 
Adult male and female ICR mice (CD-1 mice) were purchased from Taconic Farms, Inc. 
(Germantown, NY) or Charles River Laboratories (Wilmington, MA), and were housed 
in the Boston University Laboratory of Animal Care Facility in accordance with 
approved protocols. Livers were collected from 8-wk old mice euthanized by CO2 
asphyxiation followed by cervical dislocation. Continuous GH treatment of 7-week male 
mice and feminization of liver gene expression was verified by real-time PCR. Nuclei 
were isolated from pools of 2-5 livers and DNase I digestion was performed as described 
(Sabo et al. 2006) with some modifications. Illumina sequencing (see below) was carried 
out for each of two independent pools of biological replicates (n=4-5 livers for each sex 
in each replicate). 
 
For in vivo transfection assays, genomic regions corresponding to six individual DHS 
sites were PCR-amplified from ICR mouse genomic DNA and cloned into a vector 
designated pAlbpmo, that includes a minimal mouse Alb promoter driving expression of 
a Firefly luciferase gene. The DHS regions were cloned into pAlbpmo, upstream of the 
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Alb promoter. A Renilla luciferase reporter vector was constructed in a similar way by 
inserting an Alb enhancer into a modified reporter vector containing the same mouse 
minimal Alb promoter. Plasmids were injected into male and female mice and livers were 
harvested 7 days after injection to assay reporter activity. 
All experimental methods are described in detail in (Ling et al. 2010). 
4.C.2 Illumina sequencing 
Sequences of DNase I-released DNA fragments were sequenced using an Illumina 
Genome Analyzer II instrument (Illumina, Inc., San Diego, CA). Sample preparation was 
performed by Tali Mazor as described in Ling et al., 2010. The sequencing reads were 
aligned to mouse genome mm9 using Illumina's Eland extended software with a 
maximum of 2 mismatch allowed in the first 25 bp. A total of 36 million, 32 million, and 
28 million reads were sequenced from the male, female, and GH-treated male samples, 
respectively, with ~82% mapped to unique genomic positions (Table S2 in Ling et al. 
2010). All high-throughput sequencing data are available on the GEO database (accession 
GSE-21777). 
 
4.C.3 Identification of DHS sites  
PeakSeq (Rozowsky et al. 2009) was modified as outlined below and used to identify 
DHS sites in male, female, and GH-treated male mouse liver nuclei in comparison to 
control samples; the control samples consisted of sonicated mouse genomic DNA, as well 
as DNase I-digested mouse genomic DNA, and were processed in parallel to the DNase 
I-digested nuclei. Sex-specific DHS sites, and sites induced or suppressed in male liver 
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by continuous GH treatment were also identified. The PeakSeq algorithm was modified 
as follows: (a) sequence read numbers from the two samples being compared were 
square-root normalized to improve the linearity of the data for calculation of the scaling 
factor by linear regression (Fig. 4-3); (b) when comparing sequence reads from male vs. 
female liver, or from male vs. continuous GH-treated male liver, only putative peak 
regions were included in linear regression due to the presence of varying amounts of 
background between samples (Table 4-1); (c) a minimum threshold of 7 sequence reads 
for autosomes and 5 sequence reads for sex chromosomes was applied to all putative 
DHS peaks to eliminate unusually long (>10 kb) peaks with few sequence reads; and (d) 
putative peaks that were <100 bp in length were extended to 100 bp and then evaluated 
for statistical significance. Further details are provided in Supplementary Methods and 
Results of (Ling et al. 2010). 
 
Low stringency peaks listed in Table 4-2 consist of all sex-independent and sex-specific 
peaks that met the combined thresholds of p<0.01 and >2-fold difference in the relevant 
comparison between combined samples (based on the sequence reads of biological 
replicate 1 and the sequence reads of biological replicate 2).  For sex-independent DHS 
sites, standard stringency peaks were defined as those that were identified in at least two 
of the three combined samples (Male, Female, and GH-treated male) compared to 
control. For sex-specific sites, standard stringency sites were defined as those that are 
identified in the combined samples and in at least one of the two individual replicates. 
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For both sex-independent and sex-specific sites, high stringency DHS sites were those 
that were identified in both sets of biological replicates.  
 
4.C.4 Association of DHS sites with genes, H3K4 methylation, and FoxA2 binding sites  
DHS sites were classified as intergenic, coding, or associated with promoter regions 
based on mapping to known genes, mRNAs, and spliced and unspliced ESTs in the 
UCSC genome browser. To compare DHS sites with liver gene expression, the locations 
of sex-independent and sex-specific DHS sites were mapped to sex-specific and sex-
independent genes expressed in mouse liver (Wauthier et al. 2010, Chapter 3). ChIP-seq 
data for H3K4-me1, H3K4-me3, and FOXA2 binding in female mouse liver (Robertson 
et al. 2008) were compared to locations of sex-independent and sex-specific DHS sites. 
The association of DHS sites with the above two histone modifications was calculated by 
determining the numbers of DHS sites that have a histone modification site within 150 bp 
of either side of the DHS site. To generate distribution plots, distances from the 
midpoints of DHS sites to sequence tags previously determined by ChIP-seq for H3K4-
me1, H3K4-me3 and FOXA2 were computed.  
4.C.5 Gene expression data  
Liver gene expression data was obtained from an earlier study (Wauthier et al. 2010, 
Chapter 3), where a total of 1,380 transcripts showed significant differences in expression 
between male and female liver. After removing microarray probes that do not map to any 
known gene, probes that map to the same transcript as another probe, and probes 
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mapping to chromosomes for which no DNase hypersensitivity data is presented (chrY, 
chrUn, and chrN_random), a total of 1,209 genes showing >2-fold sex-differences in 
expression at p<0.005 remained (sex-specific genes), as well as 21,153 sex-independent 
genes. Of these, 343 sex-specific genes and 7,341 sex-independent genes met the 
additional criterion of microarray signal intensity ≥500 in liver. 
 
4.C.6 Identification of broad DHS regions  
SICER (Zang et al. 2009), an algorithm that uses a clustering approach to identify 
extended enriched domains from histone modification ChIP-seq data, was applied to 
detect broad regions of the genome that are enriched for DNase-seq reads in male or 
female liver samples compared to control. Genomic regions that show sex-dependent 
DNase hypersensitivity were defined as those that were significantly enriched in male 
compared to female, or in female compared to male, DNase-digested liver nuclei. 
Similarly, genomic regions that respond to continuous GH treatment were identified by 
comparing the untreated male samples to the GH-treated male samples. A window size of 
200 bp and a gap size 1200 bp were used, and significant regions were chosen that met 
FDR < 10-3 and fold-difference ≥ 2 for the pair of liver samples being compared.  
 
4.C.7 Enriched transcription factor binding sites in sex-specific DHS sites  
THEME, a hypothesis-based algorithm that tests whether a given motif separates a 
foreground set of sequences from a background set (Macisaac et al. 2006), was used to 
identify enriched motifs in the following 18 sets of sites compared to sex-independent 
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sites: (A) male-specific sites either (i) within 10 kb or (ii) up to 50 kb from the 
transcription start site (TSS) of a sex-specific gene; (B) male-specific sites within 10 kb 
or 50 kb of a sex-independent gene; and (C) male-specific sites distant from any gene; 
each group of DHS sites was divided into subgroups that respond and subgroups that do 
not respond to continuous GH treatment in males at p<0.01 and fold-difference >2, and 
similarly for female-specific DHS sites. Transcription factor binding profiles for 97 
families of transcription factors were generated by clustering the vertebrate transcription 
factor position-specific scoring matrices (PSSMs) from the TRANSFAC and JASPAR 
databases (Matys et al. 2006; Bryne et al. 2008). The corresponding 97 motifs were 
considered enriched if they met the following conditions: cross-validation error <0.4, p-
value <0.001, normalized log-likelihood ratio score > 0.4, and enrichment compared to 
sex-independent sites > 2. Motifs with total information content < 8 bits were eliminated 
from further consideration. To identify the transcription factor(s) associated with each 
motif, the refined family binding profiles were matched back to the TRANSFAC and 
JASPAR databases using STAMP (Mahony and Benos 2007), and the top factor(s) that 
matched with an E-value < 10-8 were identified. One exception was motif 44, for which 
the best matches, to Fox factors, had an E-value < 10-6. Discovered motifs were clustered 
by hierarchical clustering by Pearson correlation of fold enrichment over sex-independent 
sites in each of the 18 sets of sex-specific sites using the hierarchical clustering module of 
the GenePattern suite of tools (Reich et al. 2006).  
 
4.D Results 
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4.D.1 Generation of liver DHS maps  
DNase-seq was used to generate genome-wide DHS maps for liver tissue obtained from 
male and female mice, and from male mice given a continuous infusion of GH for 7 days, 
which feminizes the pattern of liver gene expression (Holloway et al. 2006). Mouse liver 
nuclei prepared from two independent pools of biological replicates were digested with 
DNase I under optimized conditions (see Materials and Methods), and fragments released 
from hypersensitive regions were separated from randomly cut DNA fragments, which 
tend to be much larger in size (Sabo et al. 2006). DNase-released fragments ranging from 
~100-300 bp were sequenced using Illumina sequencing technology. The final combined 
data set is comprised of 29 million sequence reads mapped to unique locations in the 
mouse genome for male liver and 26 million reads for female liver; 23 million additional 
sequence reads were obtained for continuous (7 day) GH-treated male liver (~82% 
uniquely mappable reads) (Table S2 in Ling et al. 2010). The resultant DHS maps are of 
high quality, as seen in Fig. 4-1A for the Alb gene region. Eight DHS regions were 
identified within ~47 kb of the Alb gene TSS, with very low background between peaks 
of hypersensitivity. In addition to the DHS sites at -0.1 kb, -3.5 kb, -10.8 kb and -13.7 kb 
relative to the Alb TSS, previously identified using classical Southern blotting methods 
(Liu et al 1988), DHS sites were identified at four upstream locations, from -22 kb to -47 
kb (Fig. 4-1A). Closer examination of the -13.7 kb DHS site revealed a typical structure 
for a DHS peak, with a roughly symmetric distribution of positive and negative strand 
digestion sites that clearly define the DHS peak boundary (Fig. 4-2). Using DNase I 
digested genomic DNA as a control, I identified 71,264 DHS sites in male and female 
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liver, covering 1.8% of the mouse genome. 48,762 of the DHS sites were high stringency 
sites (confirmed in both sets of biological replicates), and the total number of DHS sites 
increased to 110,785 when using the combined data sets (Table 4-2 and Table S5 in Ling 
et al., 2010). Stringency levels of peaks are described in Methods section 4.C.3 and in 
Table 4-2. There is a high degree of overlap between DHS sites and transcription factor 
binding sites identified by ChIP-chip or ChIP-seq analysis of mouse liver (Table 4-3), 
ranging from 67% for CEBPA (Schmidt et al. 2010) to 93% for FXR/NR1H4 (Thomas et 
al. 2010). Thus, the DHS sites identified here likely include a large fraction of the active 
regulatory elements in liver tissue.  
4.D.2 DHS sites showing sex specificity and responsiveness to GH 
I hypothesized that liver chromatin is characterized by sex differences in accessibility to 
DNase, and that these differences relate to the observed sex differences in liver gene 
expression. I further anticipated that continuous GH treatment of male mice, which 
feminizes the overall pattern of liver gene expression (Holloway et al. 2006), will alter 
the sex-dependent patterns of chromatin accessibility. By comparing the DHS profiles of 
male and female mouse liver I identified genomic regions showing significantly greater 
DNase I fragment release from male compared to female mouse liver nuclei, i.e., male-
specific DHS sites; correspondingly, female-specific DHS sites showed significantly 
greater DNase I cleavage in female liver. 850 male-specific peaks and 434 female-
specific peaks were identified as high stringency sex-specific DHS sites based on their 
confirmation in each of two independent biological replicates (Table 4-2); examples are 
shown in Fig. 4-1B and Fig. 4-1C and in Fig. S4 in (Ling et al. 2010). A total of 4,182 
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sex-specific DHS sites were identified at lower stringencies (Table 4-2 and listed in 
Tables S5B-S5E in (Ling et al. 2010)). Continuous GH treatment of male mice 
suppressed 82% of the high stringency male-specific DHS sites and induced 26% of the 
high stringency female-specific DHS sites, whereas <3% of sex-independent DHS sites 
were GH-responsive at p<0.01 and fold-difference >2 (Table 4-4). When weaker (low 
stringency) GH responses are included, 98% of male-specific DHS sites were suppressed 
and 44% of female-specific DHS sites were induced (Table S5H in Ling et al. 2010).  
 
Examination of the distribution of the 1,284 high stringency sex-specific sites across 
chromosomes revealed greater enrichment of female-specific DHS sites on chromosomes 
5 and X, and enrichment of male-specific DHS sites on chromosomes 3 and 18, 
compared to the overall list of DHS sites (Table S6 in Ling et al. 2010). Overall, 65% of 
sex-specific DHS sites are in the coding region or within 5 kb of the TSS of a known 
transcript, as compared to 78% of sex-independent DHS sites (Fig. S5 in Ling et al. 
2010). The median lengths of sex-specific and sex-independent DHS were similar, 466-
575 bp and 437-483 bp, respectively (Table S7 in Ling et al. 2010), corresponding to the 
depletion of ~2 nucleosomes.  
4.D.3 Association of liver DNase hypersensitivity with liver gene expression 
In CD4+ T cells, the probability that a given gene harbors a 5’-proximal DHS site 
increases with the level of gene expression (Boyle et al. 2008). I observed the same trend 
in mouse liver, where the proportion of sex-independent genes that have a DHS site 
within 200 bp of the TSS increased with increasing intensity of gene expression, leveling 
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off at ~90% (Fig. 4-4A). In contrast, the proportion of genes that show sex-specific 
expression (Wauthier et al. 2010) and have a 5’-proximal DHS site increased more 
gradually with increasing expression (Fig. 4-4B; p = 0.0006). The overall lower 
percentage of sex-specific genes with a 5’-proximal DHS site might indicate that these 
genes are more commonly regulated by distal elements. Alternatively, the sex-
independent genes might simply be close to more non-functional DHS sites than are sex-
specific genes.  
 
Next, I tested the hypothesis that genes that show sex-specific expression in mouse liver 
are more likely to be associated with sex-specific DHS sites, compared with sex-
independent genes. Supporting this hypothesis, I observed that sex-specific genes are 8.1-
fold more likely than sex-independent genes to have a sex-specific DHS site in the coding 
region, and 3.1-fold more likely within 100 kb; furthermore, the distance to the nearest 
sex-specific DHS site rises more steeply for sex-specific genes than for sex-independent 
genes (Fig. 4-5A, left). Conversely, sex-specific DHS sites are more likely than sex-
independent DHS sites to be located near a sex-specific gene (Fig. 4-5B, left). Finally, the 
proportion of male-specific genes whose nearest DHS site is also male-specific (20%) is 
~10-fold greater than those whose nearest DHS site is either female-specific or sex-
independent (2% in both cases), and similarly for female-specific genes and female-
specific DHS sites (Fig. 4-5C). Thus, there is a strong association between sex-specific 
DHS sites and sex-specific gene expression. However, this association is seen for only a 
subset of sex-specific genes, insofar as only 20% of sex-specific genes have a high 
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stringency sex-specific DHS site in the coding region, and only 43% have a sex-specific 
DHS site within 100 kb. This compares to 90% of liver-expressed sex-independent genes 
with a sex-independent DHS site in the coding region, and 99% with at least one sex-
independent DHS site within 100 kb (Fig. 4-5A, right). Moreover, only 23% of sex-
specific DHS sites are within 100 kb of a sex-specific gene, while 76% of sex-
independent DHS sites are within 100 kb of a sex-independent gene (Fig. 4-5B, right). 
Sex-specific DHS sites may therefore act as distant regulators. Alternatively, this finding 
may reflect more complex regulatory mechanisms of sex-specific genes, involving 
interactions between multiple regulatory sites and multiple genes (MacIsaac et al. 2010), 
regulatory changes that have no effect on chromatin structure, or post-transcriptional 
regulation. The subsets of sex-specific genes that do and do not have a sex-specific DHS 
site within 100 kb include equal proportions of male-specific and female-specific genes; 
however, the female-specific genes that are within 100 kb of a sex-specific DHS site are 
2.7-fold enriched (p<10-4) for the subset of female-specific genes that are suppressed in 
female liver upon ablation of pituitary of GH stimulation (class I female-specific genes; 
(Wauthier et al. 2010)). The extensive loss of male-specific DHS sites and the induction 
of a substantial fraction of female-specific DHS sites in livers of continuous GH-treated 
male mice (Table 4-4), where the gene expression profile is feminized (Holloway et al. 
2006), supports the conclusion that these sex-specific DHS sites play a functional role in 
the sex-specific expression of the genes associated with these sites. Indeed, the subset of 
female-specific DHS sites that respond to continuous GH is even more frequently 
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associated with female-specific genes compared to the full set of female-specific DHS 
sites (Fig. 4-5C). 
 
4.D.4 Enhancer-like activity of sex-specific DHS sites 
The finding, above, that sex-specific DHS sites are more likely to be associated with 
genes of the same sex specificity suggests that sex-specific DHS sites serve as enhancers 
of sex-specific gene expression. This possibility is supported by a comparison of our 
DHS map with maps of histone H3 lysine-4 mono- and tri-methylation (H3K4-me1 and 
H3K4-me3, respectively) reported for female mouse liver (Robertson et al 2008): 80% of 
high stringency female-specific DHS sites are within 150 bp of nucleosomes marked by 
H3K4-me1 but not H3K4-me3, whereas only 15% are associated with a H3K4-me3 mark 
(Fig. 4-6A). This pattern − presence of H3K4-me1 in the absence of H3K4-me3 − is 
indicative of an enhancer (Heintzman et al. 2007). A smaller proportion of sex-
independent DHS sites exhibit an enhancer-like H3K4-methylation profile, with 32% of 
these DHS sites containing the H3K4-me3 mark and only 61% showing the H3K4-me1-
only pattern (Fig. 4-6A). The frequency of the H3K4-me1 + H3K4-me3 double mark 
decreased dramatically with increasing distance from the promoter, as was seen for both 
female-specific and sex-independent DHS sites (Fig. 4-6A). Both histone marks exhibited 
a trough at the midpoint of female-specific and sex-independent DHS sites, indicating 
nucleosome depletion (Fig. 4-6B and Fig. 4-6C).  
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To assay for enhancer activity, we selected 6 sex-specific DHS sites, 5 of which were 
responsive to continuous GH treatment (Table S8 in Ling et al. 2010), and Dr Guoyu 
Ling cloned them into a reporter vector containing a modified Alb promoter linked to a 
luciferase reporter (Wooddell et al. 2008). The 6 sex-dependent DHS sites were assayed 
for their intrinsic ability to enhance the Alb promoter following in vivo liver transfection 
by hydrodynamic injection. Five of the six sites exhibited enhancer activity when assayed 
7 days after liver transfection (Fig. 4-7). This time point was selected to allow for decay 
of the transiently high activity of the Alb promoter using this transfection method 
(Wooddell et al. 2008). The most active DHS fragment, from intron 2 of the highly 
female-specific Cux2 gene (Laz et al. 2007), was >200-fold more active than the Alb 
promoter alone, but showed similar activity in male and female mouse liver. Two male-
specific DHS sites showed 8 to 17-fold higher activity than the Alb promoter, with 3-fold 
higher activity seen in male compared to female liver for a Cyp2d9 DHS site (Fig. 4-7). A 
female-specific DHS site adjacent to Acot4 showed female-enriched enhancer activity, 
albeit at a modest level. One of the six DHS sites (Cyp2c39) was inactive.  
 
4.D.5 Broad genomic regions of DNase hypersensitivity  
While 87% of the above-identified DHS sites are <1 kb in length, I observed genomic 
regions with considerably longer sex-dependent hypersensitivity, some extending up to 
~100 kb. To identify such regions of extended DNase hypersensitivity, I used SICER 
(Zang et al. 2009), a clustering based algorithm designed to identify diffuse domains of 
ChIP-enriched regions. I found 3,971 DHS regions >10 kb in length, 58 of which showed 
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significant sex-differences (Table 4-5). Continuous GH treatment suppressed 50% of the 
extended male-specific regions and induced 47% of the female-specific regions, as 
compared to <0.2% of the sex-independent regions; the proportion of these >10 kb 
female-specific regions that are induced by GH is even higher than that for the short 
female-specific DHS peaks. Some of the extended DHS regions are comprised of clusters 
of the short DHS peaks identified above (Fig. 4-8A and 4-8B; also see Supplemental Text 
and Fig. S6 in (Ling et al. 2010)), while other extended DHS regions contain few sites 
identified as DHS peaks by PeakSeq, which is optimized for identification of short, well 
defined discrete peaks (Fig. 4-8C and Fig. 4-8D; track marked All DHS sites). Additional 
examples, including GH responses, are shown in Fig. S6 in (Ling et al. 2010). The full 
list of SICER-identified regions is provided in Table S9 in (Ling et al. 2010).  
4.D.6 Transcription factor binding sites enriched in sex-specific DHS sites 
THEME, a hypothesis-based algorithm that tests for enrichment of pre-defined motifs 
(Macisaac et al. 2006), was used to examine sex-specific DHS sites for enrichment of 
transcription factor binding site motifs using sex-independent DHS sites as a background. 
Given the expected heterogeneity of sex-specific DHS sites, I carried out these analyses 
using subsets comprised of male- and female-specific DHS sites that are: (1) within 10 kb 
or within 50 kb of the TSS of a sex-specific gene; (2) within 10 kb or within 50 kb of a 
sex-independent gene; and  (3) distant (>50 kb) from any gene. Each set of DHS sites 
was further divided into sites that respond and sites that do not respond to continuous GH 
treatment in males at p<0.01 and fold-difference >2. Starting with motif families derived 
from the TRANSFAC and JASPAR databases, I identified 16 enriched motifs (Table S10 
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in Ling et al. 2010). The sets of sex-specific sites were then scanned for each of the 16 
motifs, which were then clustered according to fold-enrichment in each of the sets of 
DHS sites (Fig. 4-9).  
 
The discovered motifs include binding sites for two factors known to be required for sex-
specific liver gene expression. Thus, a motif matching the binding site for STAT5b 
(motif 28) is enriched in male-specific GH-responsive sites, as is a motif matching 
HNF4α (motif 70), consistent with the earlier findings that these two transcription factors 
are essential for GH-regulated sex-specific gene expression in male mouse liver 
(Clodfelter et al. 2006; Holloway et al. 2006; Holloway et al. 2007). While the HNF4α-
like motif is most highly enriched in sites within 10 kb of a sex-specific gene, the STAT5 
motif shows highest enrichment in more distal sites, including sites proximal to sex-
independent genes, consistent with other studies on STAT5 binding (Nelson et al. 2004; 
Eleswarapu et al. 2008; Laz et al. 2009 and Chapter 2). The STAT5 motif clusters 
together with motifs that match 9 other transcription factors (or transcription factor 
families), all of which exhibit a common pattern of enrichment in male-specific, GH-
responsive DHS sites (Fig. 4-9; motif cluster A). Eight of these 10 motifs are under-
represented in female-specific GH-responsive sites (cluster A1). These 10 motifs include 
binding sites for: CUX2, a highly female-specific, GH-regulated transcription factor (Laz 
et al. 2007); GFI1, a STAT-inducible transcriptional repressor (Zweidler-Mckay et al. 
1996; Ichiyama et al. 2009); OCT1 (POU2F1), which interacts with STAT5 in binding to 
the cyclin D1 promoter (Magne et al. 2003); PBX1, which interacts with OCT1 
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(Subramaniam et al. 1998; Rave-Harel et al. 2004) and may help penetrate repressive 
chromatin (Sagerstrom 2004); and EVI1 (gene Mecom), a positive regulator of PBX1 
(Shimabe et al. 2009) that interacts with the histone methyltransferase SUV39H1 
(Goyama et al. 2010). Two motifs, binding sites for MYC and MAX, were enriched in 
male-specific DHS sites not responsive to GH. Finally, motifs corresponding to binding 
sites for VDR, TCFAP2A, and TAL1 were most highly enriched at female-specific DHS 
sites. VDR activates the GH-responsive and female-predominant gene CYP3A4 in human 
hepatocytes (Drocourt et al. 2002; Wolbold et al. 2003; Cheung et al. 2006), and a 
female-specific DHS site containing the VDR motif is associated with a female-specific 
mouse homolog, Cyp3a41a (Holloway et al. 2006).  
 
4.E Discussion 
This study presents a set of detailed, high quality, genome-wide hypersensitivity maps 
comprised of more than 70,000 DHS sites, which encompass the transcriptional 
regulatory elements in mouse liver in vivo. DHS maps were generated for both male and 
female mouse liver, from which I was able to identify 1,284 high stringency sex-specific 
DHS sites, a subset of which was responsive to changes in plasma GH status, the major 
determinant of sex differences in liver gene expression. I demonstrate the utility of these 
maps for identifying binding sites for transcription factors previously shown to be 
essential for GH-regulated sex-specific gene expression (STAT5b and HNF4α; 
(Clodfelter et al. 2006; Holloway et al. 2007; Holloway et al. 2008)), as well as binding 
sites for several novel factors, not previously implicated in this process. These DHS sites 
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encompass 1.8% of the mappable mouse genome, which substantially narrows down the 
sequence space in searches for gene regulatory sequences, including binding site motifs 
important for liver gene expression. The fine structure of DHS sites with a high density of 
sequence reads (Fig. 4-2) suggests that it might be possible to visualize transcription 
factor binding directly in the form of digital footprints within DHS sites (Hesselberth et 
al. 2009). Further analysis of hypersensitivity data collected at higher sequencing depth 
will be required to establish the feasibility of this approach in mammalian tissues. DHS 
sites are expected to encompass key regulatory elements, including promoters, enhancers, 
silencers and insulators associated with the expression of thousands of genes in their 
native chromatin structure under physiological conditions. The DHS maps presented here 
for mouse liver tissue, in combination with corresponding sets of genome-wide histone 
modification and transcription factor binding maps (Gao et al. 2008; Robertson et al. 
2008; Seo et al. 2009; Schmidt et al. 2010; Thomas et al. 2010), can be expected to serve 
as a valuable resource for elucidation of transcriptional networks controlling a wide range 
of physiological and pathophysiological processes.  
 
Most sex-dependent DHS sites were short and highly localized (median length ~ 500 nts), 
but in several cases sex-specific hypersensitivity extended over broad regions, up to ~100 
kb in length (Fig. 4-8). The accessibility of many of these sex-dependent DHS sites and 
regions was altered by continuous GH infusion of male mice, which both feminizes the 
overall pattern of liver gene expression (Holloway et al. 2006) and rendered the vast 
majority of the male-specific DHS sites less accessible to DNase while increasing the 
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hypersensitivity of a substantial subset of the female-specific DHS sites and extended 
regions. These findings support the proposal that these GH-responsive DHS sites play a 
functional role in liver sexual dimorphism, and suggest that a common upstream pathway 
responsive to GH, such as the activation of STAT5b (Lichanska and Waters 2008), 
regulates their differential chromatin accessibility in male and female liver.  
 
I also observed a strong association between sex-specific DHS sites and sex-specific gene 
expression, with sex-specific genes significantly more likely than sex-independent genes 
to have a nearby sex-specific DHS site. Moreover, sex-specific DHS sites were 
significantly more likely than sex-independent DHS sites to have a nearby sex-specific 
gene. In some cases, multiple DHS sites, or extended hypersensitivity regions, discussed 
above, were associated with sex-specific genes. These may act in concert to increase the 
magnitude of differences in gene expression between male and female liver. However, in 
other cases, I observed groups of sex-specific DHS sites not located near sex-specific 
genes – one striking example is a cluster of female-specific DHS sites on the X 
chromosome (Fig. S6B Ling et al. 2010), and another is a cluster of male-specific sites on 
chr13, whose nearest sex-specific genes (Cd180 and Sgtb) are weakly female-specific and 
located 800 kb and 500 kb, respectively, from the cluster (Fig. S6A in Ling et al. 2010). 
Indeed, for a majority of sex-specific DHS sites the closest gene was not a sex specific 
gene, and only a subset of sex-specific genes have a sex-specific DHS site within 100 kb 
of the gene. These findings suggest the importance of long-range DNA interactions for 
sex-specific gene expression, as well as more complex interactions between multiple 
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regulatory sites and multiple genes (Magne et al. 2003). While our results are consistent 
with regulation by distal sex-specific DHS sites, it is also possible that some sex-specific 
genes are regulated via sex-independent DHS sites whose cognate transcription factors 
are expressed or regulated in a sex-dependent manner. Other sex-specific genes may be 
regulated post-transcriptionally such as by regulatory RNAs, i.e., by a mechanism that 
does not involve sex differences in chromatin accessibility. Some of the sex-specific 
DHS sites that are apparently distant from sex-specific genes may be associated with sex-
specific RNA genes that are not represented in the microarray dataset. 
 
Histone methylation marks, such as H3K4-me1 and H3K4-me3, are associated with 
active regions of chromatin, including enhancers and promoters, which are anticipated to 
coincide with DHS regions. Indeed, based on H3K4 methylation ChIP-seq maps for 
female mouse liver (Robertson et al. 2008), I found a significantly higher fraction of 
H3K4-me1 marks than H3K4-me3 marks associated with DHS sites, particularly for 
female-specific DHS sites. As H3K4-me1 in the absence of H3K4-me3 is a characteristic 
of enhancers (Heintzman et al. 2007), many liver DHS sites may function as enhancers, 
some of which may exhibit sex-specific activities. This is supported by our in vivo 
reporter gene assays, where 5 out of 6 DHS sites investigated demonstrated intrinsic 
enhancer activity when delivered to mouse liver by hydrodynamic injection. Moreover, 3 
of the 6 enhancer sequences showed sex differences in activity that match the sex 
specificity of the DHS site and their associated genes. The sex differences in in vivo 
enhancer activity seen here, were, however, considerably smaller than the sex differences 
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in expression of the genes themselves, suggesting that multiple DHS sites may be 
required to confer a high degree of sex-specificity to gene expression. Indeed, multiple 
sex-dependent DHS sites are associated with the three genes whose enhancers showed 
sex differences in activity (Acot4, Cyp7b1, Cyp2d9). In the case of the Cux2 intron 2 
DHS site tested, no sex-difference in enhancer activity was observed, indicating that the 
cloned fragment does not recapitulate the strong sex difference in DNA accessibility seen 
in intact liver chromatin (female/male DHS ratio = 7.3). Nevertheless, given the very 
strong enhancer activity of this genomic region (Fig. 4-7), coupled with 7-fold lower 
accessibility in male liver, this DHS site could make a substantial contribution to the 
strong (~100-fold) female specificity that characterizes Cux2 gene expression (Laz et al. 
2007). These findings suggest that some sex-dependent DHS sites exhibit intrinsic sex 
differences in enhancer activity, e.g., due to the binding of transcription factors that are 
expressed or activated in a sex- and plasma GH pattern-dependent manner (e.g., 
STAT5b), while other sex-dependent DHS sites (e.g., the Cux2 intron 2 enhancer) impart 
strong sex differences to gene transcription by virtue of the large sex differences in their 
accessibility in intact liver chromatin per se, even though they might not directly bind 
sex-specific transcription factors. Further studies will be required to identify the factors 
and establish the underlying mechanisms that initiate and maintain these sex differences 
in chromatin structure.  
 
Motif analysis identified 13 transcription factor binding motifs that are enriched in one or 
more subsets of male-specific DHS sites compared to sex-independent DHS sites (Fig. 4-
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9). Three other motifs were enriched in female-specific DHS sites, and one of these, the 
motif for TCFAP2A, was depleted in subsets of male-specific DHS sites. The male DHS 
site-enriched motifs include motifs that bind liver-expressed transcription factor families 
from the FOX and nuclear receptor families (e.g., HNF4α), as well as the binding site for 
STAT5b, which exhibits important sex differences in responsiveness to GH stimulation 
in vivo (Waxman and Holloway 2009). Another male DHS-enriched motif, CDP, matches 
the binding site for CUX2 (Gingras et al. 2005), a transcriptional repressor expressed at a 
100-fold higher level in female compared to male liver (Laz et al. 2007), suggesting that 
CUX2 may enforce male specificity by binding to male-specific DHS sites in female 
liver, thereby suppressing the residual activity of enhancers that are partially accessible in 
females. A cluster of 8 male DHS site-enriched motifs (sub-cluster A1; Fig. 4-9), which 
includes motifs for STAT5b and CUX2, was depleted in a subset of female-specific DHS 
sites responsive to GH. Given the high frequency of these 8 male DHS site-enriched 
motifs, it is not surprising that many male DHS sites contain matches for 6 or more of the 
8 motifs (Fig. S7 in Ling et al. 2010). Further work will be needed to determine whether 
or not particular combinations of these 8 motifs have distinct functions, and to identify 
the specific factors that actually bind to their cognate sequences at DHS sites in male and 
female liver.  
 
My finding that male-specific, GH-responsive DHS sites are enriched for both STAT5b-
like and HNF4α-like (nuclear receptor) motifs is consistent with earlier observations that 
these factors are both essential for sex-specific gene expression in mouse liver. STAT5b 
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is one of the major direct effectors of GH signaling in liver, and its deletion down 
regulates ~90% of male-specific genes in male mouse liver (Clodfelter et al. 2006; 
Holloway et al. 2007). Similarly, knockout of the liver-enriched nuclear receptor HNF4α 
abolishes liver sex differences (Holloway et al. 2008). By carrying out the motif analysis 
separately for DHS sites that are near sex-specific genes, near sex-independent genes, and 
distant from genes, I showed that the HNF4α-like motif is most highly enriched at DHS 
sites within 10 kb of sex-specific genes, while the STAT5-like motif is highly enriched at 
distal sites, as well as at sites proximal to sex-independent genes. This latter finding is 
consistent with the occurrence of functional STAT5 binding sites at large distances from 
target genes (Eleswarapu et al. 2008).  
 
In conclusion, the present investigation of sex differences in chromatin accessibility has 
identified condition-specific transcriptional regulatory sites in mouse liver on a genome-
wide scale. These differences are manifested as sex-specific DHS sites, which in some 
cases encompass extended chromatin regions. A subset of these sex-specific genomic 
sites and regions is associated with genes expressed in a sex-dependent manner, strongly 
suggesting they play a functional role in liver sexual dimorphism; however, a majority of 
sex-specific DHS sites were distal to sex-specific genes, making it more difficult to 
establish their significance. Transcription factor binding motifs identified as enriched in 
these sites serve as candidates for further study of the molecular mechanisms that govern 
sex-specific liver gene transcription. Further study will be required to determine how sex 
differences in chromatin accessibility are established and maintained in response to sex-
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differences in plasma GH patterns, which are programmed by early androgen exposure 
and first emerge at puberty. 
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Table 4-1. Numbers of sequence reads in male and female DNase-digested liver samples 
in background and DHS peak regions. 
Shown are the numbers of uniquely mapped sequence reads obtained in the two male and 
two female DNase-digested mouse liver samples.  Values in parenthesis are percentages 
of the totals in row 1.  Biological replicate 1 yielded a higher percentage of reads within 
DHS peak regions in the female compared to the male sample.  This percentage was 
higher for both males and females in biological replicate 2. 
 
 
  
Biological Replicate 1 Biological Replicate 2 
Male 
reads 
(millions)
Female 
reads 
(millions) 
M/F 
ratio 
Male 
reads 
(millions) 
Female 
reads 
(millions) 
M/F 
ratio 
Total 13 13 1 16.2 13.4 1.21 
Background 
region reads 9.5 (73%) 8.9 (68%) 1.07 9.5 (59%) 7.8 (58%) 1.21 
Reads in putative 
DHS peaks 3.6 (28%) 4.2 (32%) 0.85 6.7 (41%) 5.6 (42%) 1.2 
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Table 4-2. DHS sites in male and female mouse liver.   
Male vs. control and female vs. control DHS sites determined by PeakSeq analysis were 
merged to generate a single list of ‘all DHS sites’ in liver.  Male-specific and female-
specific DHS sites were determined by comparing male vs. female, and female vs. male 
DHS sites, respectively.  Two biological replicates each from male and female mice were 
combined for each comparison.  Stringency differences are as indicated and as described 
in Materials and Methods, and full lists of sites are presented in Table S5 in (Ling et al. 
2010). 
 
  
High 
stringency* 
Standard 
stringency** 
Low 
stringency*** 
All DHS sites 48,762 71,264 110,785 
Male-specific DHS sites 850 2,315 2,800 
Female-specific DHS sites 434 1,064 1,382 
*Sites that meet p<0.01, fold-difference >2, and confirmed separately in both sets of 
biological replicates. 
**Sites that meet p<0.01, fold-difference >2, and confirmed in at least 2 of the 3 
combined samples (Male, Female, and GH-treated male) for sex-independent DHS 
sites, or at least one individual set of biological replicates for sex-specific DHS sites. 
*** All sites that meet p<0.01 and fold-difference >2 in the either the combined male 
replicate or the combined female replicate sequencing data sets. 
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Table 4-3. Overlap between ChIP-chip/ChIP-seq transcription factor binding sites and 
DHS sites in liver.   
67-93% of experimentally determined transcription factor binding sites in mouse liver 
overlap standard stringency liver DHS sites.  The extent to which these sites overlap with 
DHS sites was very similar when only the subset of sites that contain the respective 
binding motif for the factor used for ChIP was considered (last column).  When all de 
novo enriched motifs are considered, regardless of whether they matched the factor used 
for ChIP, the number of factor-binding sites increased substantially, and the overlap with 
DHS sites was similar to slightly higher than the percentages shown below for the full set 
of all binding regions (data not shown).  Data for FOXA2 (Robertson et al. 2008), 
ERa/ESR1 (Gao et al. 2008), FXR/NR1H4 (Thomas et al. 2010), SREBP-1 (Seo et al. 
2009), CEBP4A and HNF4α (Schmidt et al. 2010) are based on ChIP-chip or ChIP-seq 
in various mouse strains.  
 
Transcription 
factor 
All binding regions 
Binding regions containing 
specific motif 
# sites 
% overlap with 
DHS sites # sites 
% overlap with DHS 
sites 
FOXA2 10,958 68% 2,163 75% 
ERa/ESR1 6,272 86% 3,081 89% 
FXR/NR1H4 7,794 93% 1,534 89% 
SREBP-1 426 91% 244 93% 
CEBPA 29,188 67% 14,904 65% 
HNF4α 20,355 90% 3,045 90% 
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Table 4-4. Effect of continuous GH treatment on DHS sites in male liver.   
Numbers of high-stringency sex-specific and standard stringency sex-independent DHS 
sites that are induced or suppressed in continuous GH-treated male liver (p<0.01 and >2-
fold-difference between GH-treated males and untreated males).  Values in parentheses 
are percentages of numbers of DHS sites shown in column 1.  The GH-responses for 
lower-stringency sex-specific DHS sites, and GH-responses at lower stringency (p<0.05), 
are summarized in Table S5H in (Ling et al. 2010). 
 
Sex-specificity of DHS site 
Effect  of continuous GH treatment in male 
# DHS sites Induced # DHS sites Suppressed 
Male-specific sites (n = 850) 0 693 (82%) 
Female-specific sites (n = 434) 114 (26%) 1 (0.2%) 
Sex-independent sites (n = 68,683)* 102 (0.1%) 1,848 (3%) 
*This represents the 71,264 standard stringency DHS sites after removal of sites that 
show sex-specific at low stringency. 
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Table 4-5. Broad DHS regions and their response to continuous GH treatment in male 
liver.   
Numbers of sex-specific and sex-independent hypersensitivity regions that are >10 kb in 
length, and numbers of each that are induced or suppressed in continuous GH-treated 
male mouse liver, as determined by SICER analysis.  All DHS regions are significant 
with FDR < 10-3, and are > 2-fold enriched for sequence reads in the relevant comparison 
(Male vs control or Female vs control for sex-independent regions; Male vs control and 
Male vs Female for male-specific regions; Female vs control and Female vs Male for 
female-specific regions; and Male vs Male+GHcont or Male+GHcont vs Male for GH 
response). Values in parentheses are percentages of numbers of regions shown in column 
1.  Complete lists of the SICER-determined DHS regions are in Table S9 in (Ling et al. 
2010). 
 
Sex-specificity 
# >10 kb regions
Effect  of continuous GH treatment in male 
# Regions Induced # Regions Suppressed 
Male-specific 34 0 16 (47%) 
Female-specific 24 12 (50%) 0 
Sex-independent* 3,913 0 7 (0.2 %) 
*DHS regions significant in Male vs control or Female vs control merged into a single list, 
excluding those regions that are sex-specific.  
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Figure 4-1. DHS sites associated with the Alb gene (A), Cyp2d9 (B), a male-specific gene, 
and Cux2 (C), a female-specific gene.   
A, DHS sites appear as sharp, narrow peaks and are marked by distance upstream of the 
Alb gene.  The four sites marked in red are the same as those discovered earlier using 
conventional methods (Liu et al. 1988).  Green arrows at bottom mark regions of high 
species conservation that coincide with DHS sites.  B, Male-specific DHS sites in the 
region of Cyp2d9 are marked as horizontal bars in the merged DHS sites track, with dark 
blue color used for high stringency male DHS sites and lighter shades of blue for 
standard and low stringency male DHS sites, numbered as in Table S5A.  Sex-
independent DHS sites are shown in gray.  Continuous GH treatment of male mice 
suppresses each of the four high stringency male DHS sites down to female levels 
(bottom track).  C, Intron 2 of Cux2, a highly female-specific gene (female/male 
expression ratio ~100; (Laz et al. 2007)), showing female-specific DHS sites (marked as 
pink horizontal bars), four of which are markedly induced in continuous GH-treated male 
liver, as indicated by red asterisks.  A-C, Individual sequence reads (35 nt) are 
represented as a single nt wide bar graphed at the chromosomal location of the DNase cut 
site; this presentation is clearest in panel B, where individual sequence reads can be seen 
at the resolution presented.  Green and red indicate sequence reads from DNase-digested 
female liver, and blue and yellow indicate sequence reads from DNase-digested male 
liver, or continuous GH-treated male liver, as marked.  Green and blue, (+) strand reads; 
red and yellow, (+) strand reads.   
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Figure 4-1. DHS sites associated with the Alb gene (A), Cyp2d9 (B), a male-specific 
gene, and Cux2 (C), a female-specific gene.  
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Figure 4-2. Fine structure of Alb upstream DNase HS site at -13.7 kb. 
Display shows an apparent digital ‘footprint’, i.e., segments within a DHS site that are depleted of fragments, where TFs may 
be bound.  Shown at top are predicted transcription factor binding site within the -13.7 kb DHS site. 
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Figure 4-3. Linearity of Male reads vs Female reads in non sex-specific peak regions on chromosome 1, before and after 
square root transformation.  
Shown are scatter plots, residual plots, and quantile-quantile plots before (A) and after (B) square root transformation of both 
male reads and female reads. Square root transformation improves linearity. 
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Figure 4-3. Linearity of Male reads vs Female reads in non sex-specific peak regions on chromosome 1, before and after 
square root transformation.  
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Figure 4-4. Relationship between level of gene expression and presence of a 5' DHS 
site.   
Shown is the fraction of sex-independent genes (A) or the fraction of sex-specific genes 
(B) that have at least one 5' DHS site within 200 bp of the TSS, graphed as a function of 
log2 liver expression level (microarray signal intensity).  Sex-specific genes are those 
that show >2-fold sex differences at p<0.005 as determined by microarray analysis 
(Wauthier et al. 2010 and Chapter 3), using expression intensities for the sex showing 
higher expression.  The total number of genes at each range of expression intensity is 
shown above each bar.  The proportions of sex-independent and sex-specific genes that 
have a 5’-DHS site at increasing expression levels are significantly different (Wilcoxon 
signed rank test, p = 0.0006). 
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Figure 4-4. Relationship between level of gene expression and presence of a 5' DHS 
site.   
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Figure 4-5. Proximity of sex-specific and sex-independent DHS sites to genes expressed 
in mouse liver.   
(A) Cumulative distances from the gene body of sex-specific and sex-independent genes 
to the nearest sex-specific and sex-independent DHS sites.  (B) Cumulative distances 
from sex-specific and sex-independent DHS sites to the nearest sex-specific or sex-
independent gene.  X-axes are on different scales in the left and right panels of A and B. 
For A and B, gene expression in liver is defined as a microarray signal intensity ≥ 500 in 
either male or female liver, and sex-specific genes are those that met the combined 
criteria of >2-fold sex difference at p<0.005 in a microarray comparison of male and 
female mouse liver (Wauthier et al. 2010 and Chapter 3).  (C) Sex-specificity of the 
genes closest to the indicated categories of sex-specific and sex-independent DHS sites.  
Shown are the percentages of DHS sites whose closest gene shows male-specific, female-
specific, or sex-independent expression, as indicated, using the above criteria for sex 
specificity, but independent of microarray signal intensity. 
  
166 
 
 
 
Figure 4-5. Proximity of sex-specific and sex-independent DHS sites to genes 
expressed in mouse liver.   
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Figure 4-6. Histone modifications at sex-independent and sex-specific DHS sites in 
female mouse liver.  
 (A) Percentages of sex-independent and sex-specific DHS sites within 150 bp of a 
H3K4-me1 and/or H3K4-me3 mark in female mouse liver.  These data are shown for all 
DHS sites, and for the subsets comprised of sites that are proximal (within 200 bp, or 
between 0.2 and 5 kb, of an active sex-specific or sex-independent TSS) to liver-
expressed genes (microarray signal intensity ≥ 500, as in Fig. 4-5), and those that are 
distal to genes (>5 kb from the TSS), regardless of liver expression intensity level.  
Proportions of DHS sites associated with the different patterns of H3K4 methylation 
marks are statistically significant (between all sex-specific and all sex-independent DHS 
sites: p<10-14; between sites ≤ 200 bp, 0.2-5 kb, and > 5 kb from the TSS: p<10-21 for sex-
independent sites, and p<10-5 for sex-specific sites; χ2 test).  (B-C) Distributions of 
H3K4-me1, H3K4-me3, and FoxA2 ChIP-seq reads relative to sex-independent (B) and 
female-specific (C) DHS sites.   
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Figure 4-6. Proximity of sex-specific and sex-independent DHS sites to genes 
expressed in mouse liver.   
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Figure 4-7. Enhancer activity of six sex-specific DHS sites assayed in mouse liver.   
Four high-stringency female DHS sites (Cux2, Acot4, Cyp3a16 and Cyp2c39) and two 
male DHS sites (Cyp7b1 and Cyp2d9), named after the closest gene to each site, were 
assayed for reporter gene activity after in vivo transfection of mouse liver by 
hydrodynamic injection.  All 4 female-specific DHS sites are associated with H3K4-me1 
and not H3K4me3 marks (Table S8 in Ling et al. 2010).  Data shown represent 
normalized luciferase activity for at least 3 individual mice (mean + SE), each of which is 
based on the average reading from 3 separate pieces of liver.  Relative luciferase activity 
of the parental vector AlbPmo in male and female liver (mean value) was set to 1.   
*, significant difference in activity between male and female liver transfection at p<0.05.   
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Figure 4-8. Broad regions of DNase hypersensitivity.   
Tracks in each panel show (in order, from top) RefSeq genes, DHS peaks identified using 
PeakSeq, and DHS regions identified using SICER, with the length of the SICER-
detected region marked in red.  Grey, blue and pink indicate sex-independent, male-
specific, and female-specific SICER regions, respectively, with lighter blue or pink 
indicating < 2-fold sex-specificity.  Panel A depicts a 102 kb sex-independent region 
overlapping with six sex-independent genes. Panels B and C show 56 to 87 kb male-
specific DHS regions in the vicinity of male-specific genes Ttc39c and Aox3, 
respectively; and panel D shows several female-specific DHS regions at the female-
specific genes Cyp2b9 and Cyp2b13. While the broad DHS regions in panels A and B 
contain multiple individual DHS peaks, as identified by PeakSeq, the broad DHS regions 
shown in panels C and D were not identified by PeakSeq, which is optimized for 
identification of short, well defined discrete peaks.  
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Figure 4-8. Broad regions of DNase hypersensitivity.   
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Figure 4-9. Heat map of transcription factor binding motifs enriched in sex-specific 
DHS sites compared to sex-independent DHS sites.   
Motifs are clustered by fold-enrichment in male-specific (M) and female-specific (F) 
DHS sites that respond (GH) or do not respond to GH (noGH) at p<0.01 and fold-
difference >2, and are either 0-10 kb or 10-50 kb from the TSS of either sex-specific 
('Sex') or sex-independent ('Ind') genes, or >50 kb from any gene (distal), as marked.  
Combined data for 0 to 50 kb is presented for the M-noGH and F-GH sets, which both 
contained <15 DHS sites in the 10-50 kb subset.  Red indicates over-representation and 
green indicates under-representation >1.45, with darker color indicating higher 
enrichment.  The full data set is shown in Table S10A. Where multiple factors are listed, 
they are in order of highest to lowest match to the motif matrix. Major clusters of motifs 
(A-D) are identified on the left.  Cluster A (10 motifs) is enriched in male-specific DHS 
sites; 8 of these motifs (sub-cluster A1) are enriched in several male-specific GH-
responsive (M-GH) sets and depleted in the F-GH, sex-independent (0-10 kb) set. Motifs 
in cluster B are most highly enriched in F-GH sets, and are most highly depleted in 
various male DHS sites and in a F-noGH set.  Motif 94 (TAL1) is most highly enriched 
in the same F-GH set as TFAP2A. Motif 70 is enriched in several M-GH sets, but in 
contrast to the motifs in cluster A, it is most highly enriched in the DHS set that is within 
10 kb of sex-specific genes. Two very similar motifs for MYC/MAX are enriched in 
male-specific non-GH responsive sites. 
  
173 
 
 
 
Figure 4-9. Heat map of transcription factor binding motifs enriched in sex-specific 
DHS sites compared to sex-independent DHS sites.   
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Chapter 5  
Genome-wide analysis of chromatin states reveals distinct mechanisms of sex-
dependent gene regulation in male and female mouse liver4 
5.A Abstract 
Chromatin state maps were developed to elucidate sex-differences in chromatin structure 
and their impact on sex-differential chromatin accessibility and sex-biased gene 
expression, a characteristic of ~1,000 genes in mouse liver. Genes in active, inactive, and 
poised chromatin states exhibited differential responsiveness to ligand-activated nuclear 
receptors and distinct enrichments for functional gene categories. Sex-biased genes were 
clustered by chromatin environments and mapped to DNase hypersensitive sites (DHS) 
classified by sex-bias in chromatin accessibility and enhancer modifications. Results 
were integrated with genome-wide binding data for five transcription factors implicated 
in sex-biased liver gene expression, leading to the following findings: (1) Sex-differential 
chromatin states frequently characterize sex-biased DHS but not sex-biased genes, 
indicating distal regulation. (2) H3-K27me3 is utilized as a major sex-biased repressive 
mark in male but not female liver. (3) FOXA factors are associated with sex-dependent 
chromatin opening in male but not female liver. (4) Sex-biased STAT5 binding is most 
highly enriched at sex-biased genes with sex-differences in proximal chromatin marks 
and at sex-biased DHS marked as active enhancers. However, many female-biased genes 
lack proximal sex-biased chromatin marks and are repressed in male liver by the male-
                                                 
4 Some experimental work was carried out by Dr. Ekaterina Laz, Andy Rampersaud, and Penying 
Hao of this laboratory, and some computational analyses were carried out by Tisha Melia and 
Gracia Bonilla, as noted in appropriate places in this chapter.  
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biased repressor BCL6, which preferentially binds regulatory sites in a sex-independent 
chromatin state. These findings reveal a major role for chromatin states in the control of 
sex-biased gene expression, with FOXA1/FOXA2 acting as pioneer factors that open 
chromatin in a sex-dependent manner, and STAT5 and CUX2, but not BCL6 regulating 
sex-biased genes by binding to sites in a sex-biased chromatin state. 
 
5.B Introduction 
The epigenetic environment is controlled by various histone protein modifications, which 
regulate DNA methylation, chromatin accessibility and transcription factor (TF) binding. 
Distinct combinations of chromatin modifications are characteristic of genomic regions 
associated with transcribed genes, transcription start sites and enhancers, and are 
indicative of how active those genomic regions are in a given cell type or regulatory state. 
Expressed genes can thus be distinguished from silenced genes and genes that are poised 
for expression based on their epigenetic environment (Heintzman et al. 2007; Ernst et al. 
2011). Specific chromatin modifications at promoters and gene bodies correlate with, and 
can be used to predict gene expression in multiple cell types (Dong et al. 2012). 
Enhancers also exhibit cell type-specific patterns of chromatin modifications in their 
local environment, which confer cell-type specificity to enhancer activity and cell type-
specific regulation of distal target genes (Heintzman et al. 2009).  
DNase hypersensitivity is a key feature that characterizes cell type-specific regulation 
(Natarajan et al. 2012; Thurman et al. 2012), with >90% of transcription factor binding 
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occurring at DNase hypersensitive sites (DHS) (Thurman et al. 2012). Regulation of DHS 
opening is thought to have a major impact on cell type-specific TF binding, as do cell 
type-specific differences in nucleosome occupancy and positioning, chromatin 
modifications, and chromatin environment (Arvey et al. 2012; He et al. 2012; Kundaje et 
al. 2012; Wang et al. 2012).  Furthermore, many mammalian transcriptional programs are 
complex and involve multiple activators and repressors, whose impact on gene 
expression may be dependent on the localized chromatin environment surrounding their 
binding sites. Cell type-specific gene expression is likely achieved by interplay between 
TF binding and chromatin modifications, with the recruitment of some TFs to loci with 
distinct chromatin modification profiles and nucleosome repositioning mediated by other 
TFs, which can in turn facilitate binding by additional TFs (Heinz et al. 2010; Hoffman et 
al. 2010; Cheng et al. 2012). Comprehensive approaches are therefore required to 
understand complex mammalian transcriptional networks. These include the development 
of genome-wide chromatin state maps and their integration with binding site maps for 
key TFs and other regulatory factors (Heinz et al. 2010; Hoffman et al. 2010).  
Sex differences in gene expression are commonly found in mammalian tissues, and result 
from differences in genotypic sex as well as sex differences in circulating and local 
hormonal regulators (Rinn and Snyder 2005).  Sex differences in gene expression are 
perhaps best characterized in the liver, where ~1,000 genes are expressed in a sex-biased 
manner in mice, rats and humans (Wauthier and Waxman 2008; Wauthier et al. 2010; 
Zhang et al. 2011). These sex-biased genes regulate diverse processes, most notably the 
metabolism of steroids, lipids and drugs (Schwartz 2007; Scandlyn et al. 2008; Waxman 
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and Holloway 2009), and contribute to sex differences in cardiovascular disease risk, 
fatty liver disease, and the development of hepatocellular carcinoma (Yokoyama et al. 
2005; Ruggieri et al. 2010; Baik et al. 2011; Zhang et al. 2011). Studies in rats and mice 
show that sex differences in liver gene expression are primarily regulated by growth 
hormone (GH), whose secretion by the pituitary gland is sexually dimorphic and 
primarily regulated by exposure to androgens and estrogens during the neonatal period 
(Waxman and Holloway 2009). In males, GH is released from the pituitary gland in 
pulses at regular intervals, with little or no plasma GH detectable between GH secretory 
events, whereas female GH release is more frequent, resulting in more continuous 
exposure to circulating hormone. Consequently, GH signaling to downstream 
transcriptional mediators is pulsatile in male liver and is persistent in female liver (Choi 
and Waxman 1999; Choi and Waxman 2000). 
STAT5 is a major effector of the transcriptional actions of GH in the liver. STAT5 is 
activated by GH-induced tyrosine phosphorylation catalyzed by a GH receptor-JAK2 
tyrosine kinase complex at the liver cell surface, followed by nuclear translocation of 
activated STAT5 dimers(Lanning and Carter-Su 2006). The temporal pattern of nuclear 
STAT5 DNA-binding activity mirrors the plasma GH profile, with liver STAT5 activity 
being pulsatile in males and persistent in females (Choi and Waxman 1999; Choi and 
Waxman 2000; Zhang et al. 2012). STAT5 is essential for sex-biased liver gene 
expression in the mouse, with the sex-differential expression of 75% of male-biased 
genes and 82% of female-biased genes abolished when Stat5b is inactivated (Clodfelter et 
al. 2006). BCL6, a male-biased, GH-regulated transcriptional repressor, antagonizes GH-
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stimulated STAT5 transcriptional activity by competing for STAT5 binding at a subset of 
STAT5 sites in male liver (Meyer et al. 2009; Zhang et al. 2012). CUX2, a female-
specific, continuous GH-inducible repressor (Laz et al. 2007), down regulates many 
male-biased genes and activates a subset of female-biased genes in female liver (Conforto 
et al. 2012). Other transcription factors, including HNF4α and HNF6, also contribute to 
liver sex differences, as indicated by knockout experiments and reporter gene assays, and 
by motif enrichment at regulatory sites (Lahuna et al. 1997; Delesque-Touchard et al. 
2000; Holloway et al. 2006; Holloway et al. 2008; Ling et al. 2010). Sex differences in 
gene expression have been linked to sex differences in GH-regulated chromatin 
accessibility, as revealed by genome-wide DHS mapping (Ling et al. 2010). Sex-biased 
STAT5 binding correlates with sex-differences in DHS, and with activating chromatin 
marks, and inversely correlates with the repressive mark H3-K27me3 in mouse liver 
(Zhang et al. 2012). GH-regulated STAT5 binding requires chromatin opening and 
activating histone modifications, as seen at several early GH response genes in rat liver 
(Chia and Rotwein 2010). However, little is known about the chromatin states of sex-
biased genes and their regulatory sites, and how they might impact binding and regulation 
by STAT5 and other TFs required for sex-biased liver gene expression. 
Here, I characterize chromatin environments on a global scale in both male and female 
mouse liver based on genome-wide data for four activating chromatin marks, two 
repressive chromatin marks, and global DHS maps. I use these data to identify genes in 
active, inactive and poised chromatin states and establish the propensity of genes in each 
state for induction or repression by ligand-activated nuclear receptors, which mediate 
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metabolic responses to myriad steroids, drugs and environmental chemicals (Kakizaki et 
al. 2008; Hernandez et al. 2009; Chai et al. 2013). Further, I elucidate sex-differential 
chromatin states at sex-biased genes and sex-biased DHS, and I develop a model for GH 
regulation of sex-biased gene expression by integrating these chromatin state data with 
ChIP-seq binding site data for the GH-regulated TFs STAT5, BCL6 (Zhang et al. 2012) 
and CUX2 (Conforto et al. 2012), and for FOXA1 and FOXA2, pioneer factors 
(Friedman and Kaestner 2006; Zaret and Carroll 2011)  that impart male bias to 
hepatocellular carcinoma by facilitating androgen-mediated tumor promotion in males 
and estrogen-dependent resistance to tumorigenesis in females (Li et al. 2012). Our 
findings reveal a major role for chromatin states in the control of sex-biased gene 
expression, with distinct sets of regulatory mechanisms utilized in each sex. I show that 
many female-biased genes are associated with sex-independent chromatin marks and are 
preferentially repressed by the male-biased repressor BCL6, while other, more highly 
female-biased genes show sex-differences in proximal chromatin marks and are 
preferentially activated by female-enriched STAT5 binding. I identify H3-K27me3-based 
repression as an important mechanism for regulating female-biased but not male-biased 
genes, and I identify sex-differences in H3-K4me1 profiles at male-biased but not 
female-biased DHS that suggest sex-dependent nucleosome repositioning facilitated by 
FOXA1 and FOXA2.  
 
5.C Methods  
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5.C.1 Chromatin immunoprecipitation (ChIP), carried out by Dr. Ekaterina Laz  
Chromatin isolation from formaldehyde cross-linked liver nuclei prepared from 
individual 7-8 wk old male and female CD-1 mouse livers (Charles River Laboratories, 
Kingston, NY) using institutionally approved protocols, followed by ChIP, was carried 
out by Dr. Ekaterina Laz of this laboratory as reported previously (Zhang et al. 2012) 
using the following ChIP-validated antibodies: H3K27me3 (Abcam antibody #ab6002, 2 
µg per 10 µg sonicated DNA), H3K9me3 (Abcam antibody #ab8898, 0.8 µg per 10 µg 
sonicated DNA), H3K4me3 (Abcam antibody #ab8580, 0.8 µg per 10 µg sonicated 
DNA), H3K4me1 (Abcam antibody #ab8895, 0.8 µg per 10 µg sonicated DNA), 
H3K27ac (antibody #ab4729), H3K36me3 (antibody #ab9050) and normal rabbit IgG 
(Santa Cruz, sc-2027, 7.5-8 µg per 100 µg sonicated DNA). ChIP DNA samples were 
analyzed by qPCR as described (Zhang et al. 2012), by Andy Rampersaud, to interrogate 
genomic regions selected as positive controls and as negative controls for the specificity 
of each antibody based on initial ChIP-seq results.   
 
5.C.2 High throughput sequencing  
Liver genomic DNA isolated by ChIP was prepared for sequencing using a SPRI-TE 
Nucleic Acid Extractor for size selection (Beckman Coulter Genomics, Danvers MA) 
followed by PCR enrichment with barcoding (Zhang et al. 2012) . Sample preparation 
and 35-40 nt single end read sequencing on an Illumina GAII or Illumina HiSeq2000 
instrument, followed by mapping to the mouse genome build mm9 (NCBI 37) using the 
Illumina sequencing software Eland or Bowtie (Langmead et al. 2009) was carried out at 
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the BioMicro Center at MIT (Cambridge, MA). Raw sequencing reads for individual 
livers are available in the GEO database (GSEXXXX; samples GSMXXXX-
GSMXXXX). 40 nt reads were trimmed down to 35 to maintain a constant sequence 
length between samples. Replicates were evaluated by the percentage of reads in straight 
peaks (>5 identical reads that do not overlap any other reads, and are therefore likely 
artifactual), by the degree of overlap between peaks detected in each replicate, and by 
correlation in read count between replicates. The final dataset consisted of 10.7 million 
(K9me3) to 52.5 million (K4me1) total reads (Table 5-1). 
5.C.3 Analysis of ChIP-seq data for chromatin modifications  
To identify peaks and regions of chromatin mark enrichment, each dataset, after 
combining replicates, was analyzed separately for male and female liver, as follows. 
K4me1, K27ac, and K4me3, which form focal peaks, were analyzed using MACS 
version 1.4.1 (Zhang et al. 2008) with default parameters. K27me3, K9me3, and K36me3 
were analyzed using SICER version 1.1 (Zang et al. 2009) to identify broad regions (i.e., 
broad domains or islands). For K27me3, a window size of 400 bp was used and a gap 
size of 2400 was chosen as most appropriate. The same parameters were used for K9me3. 
For K36me3, which was not as broad, a window size of 200 bp and a gap size of 800 bp 
were used. The X chromosome was excluded from all analysis due to the imbalance in 
the number of reads in male and female liver from the X chromosome (Fig. 5-1C). Sex-
enriched peaks and regions were identified for each chromatin mark, as follows. For each 
MACS peak and SICER region, the number of male sequence reads was compared to the 
number of female sequence reads after normalization by the total number of reads in 
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common peaks – peaks (or regions) that were detected by MACS (or by SICER) in both 
male and female liver – in order to account for any bias between male and female in the 
percentage of reads in peaks/regions. The log2 male/female ratio (M-value) was then 
calculated, along with a p-value based on a Bayesian model (Audic and Claverie 1997) as 
implemented by (Shao et al. 2012). Each chromatin mark peaks and region was classified 
as male-enriched (M>1 and p<0.001), female-enriched (M<-1 and p<0.001), or sex-
independent (-1<M<1 or p>0.001). Table 5-1 lists the numbers of peaks and domains 
identified for each chromatin mark.  
5.C.4 Chromatin states in mouse liver 
The six chromatin mark datasets along with DHS data described previously (Ling et al. 
2010) were analyzed using ChromHMM (Ernst et al. 2011) to learn a hidden Markov 
model and to assign chromatin states across the mouse genome. ChromHMM was run 
using an IgG control and with default parameters. A single joint model was learned for 
male liver and female liver together. A 15-state model was previously found to be 
biologically meaningful and consistently recovered across cell types for the human 
genome (Ernst et al. 2011). I therefore started with 20 states and used the ChromHMM 
CompareModels module to compare decreasing numbers of states to the 20-state model, 
and calculated, for each of the 20 states, the similarity – i.e., correlation between 
emission parameters – to its closest state in smaller models (Fig. 5-2A).  With decreasing 
number of states in the model, individual states in the 20-state model are progressively 
lost. Going from a 20-state model down to a 15-state model, zero or one additional state 
is lost at each step with < 0.9 correlation (Fig. 5-2B). From a 15-state to a 14-state model, 
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no additional states were lost (< 0.9 correlation), whereas from a 14-state to a 13-state 
model, two additional states have correlation < 0.9 and < 0.8, with further increasing 
dissimilarity after 12 states (Fig. 5-2B). Therefore, a 14-state model was chosen for 
mouse liver based on the present data, for which emission and transition parameters are 
shown in Fig. 5-2C.   
5.C.5 Clustering of genes by chromatin mark densities around TSS and TES 
RNA-seq analysis of total mouse liver RNA was carried out using two independent pools 
of male and two independent pools of female mouse liver RNA (n=6 livers/pool). Poly-
A-enriched RNA was prepared for Illumina sequencing using a strand-specific protocol 
(Parkhomchuk et al. 2009) and sequenced at the BioMicro Center at MIT (Cambridge, 
MA). 40-nt sequence tags were mapped to the mm9 genome using Bowtie (Langmead et 
al. 2009) and mapped to MGI genes using SeqMonk 
(http://www.bioinformatics.bbsrc.ac.uk/projects/seqmonk/; Babraham Bioinformatics, 
Cambridge, UK). RNA-seq samples were prepared and mapped to the genome by 
Penying Hao of this laboratory.  
The set of all genes represented in this dataset was clustered by their read densities in the 
2 kb surrounding the TSS and 2 kb surrounding the TES, with clustering carried out 
separately in male and female liver. A dataset of 15,533 genes was obtained after 
exclusion of short genes (<5 kb in length) to prevent TSS-associated signals from 
contaminating the TES-associated region; 7,864 of these genes were defined as liver-
expressed based on log2(RPKM)≥1 in either male or female liver. For each gene, TSS ± 1 
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kb and TES ± 1 kb regions were subdivided into a total of twenty 200 bp windows. Read 
counts were obtained for these 20 windows for 7 features − 6 chromatin marks and 
DNase hypersensitivity − yielding 140 columns of data. Read counts were normalized by 
total sequencing library size for each ChIP-seq dataset, and log-transformed. The 15,533 
genes were then clustered by their read densities by k-means clustering using Cluster 
(Eisen et al. 1998), with k=6. The six clusters of genes were visualized as a heatmap 
using Java Treeview (Saldanha 2004). Each cluster was characterized as active or 
inactive based on the relative density of activating chromatin marks (K4me1, K27ac, 
K4me3, K36me3) and repressive chromatin marks (K27me3, K9me3). The frequencies 
with which each 200-bp bin in the TSS ± 2 kb and TES ± 2 kb regions were assigned one 
of the 14 chromatin states were calculated for genes in each cluster. Three of the six 
clusters were identified as active, based on high read density of K27ac, K4me3, K36me3, 
and DNase hypersensitivity. Two clusters were designated poised, based on the presence 
of K27me3 together with K4me1, with the poised chromatin state 12 at the TSS. The 
final cluster was inactive, with K27me3 and low levels of activating marks.  
In a separate analysis, sex-biased genes were clustered by their chromatin mark densities. 
Sex-biased genes were identified from the RNA-seq dataset after analysis for differential 
expression using edgeR (Robinson et al. 2010), as implemented by Penying Hao and 
Tisha Melia of this laboratory. I selected 423 male-biased and 477 female-biased genes 
based on the following criteria: adjusted p-value < 0.01 for sex-difference, corresponding 
to a minimum sex differences in expression of 1.4-fold; liver-expressed at a level of 
log2(RPKM) ≥ 1; genes located on autosomes; and gene length >2 kb. Each set of genes 
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was clustered by read densities in the 2 kb regions surrounding the TSS and the TES, as 
described above, by k-means clustering using k=3.   The three clusters were defined by 
their chromatin activity – high, medium, and low – as indicated by their relative 
abundance of activating and repressive chromatin marks (Fig. 5-6A). Clustering was 
performed separately in male liver and female liver, and genes were then classified into 6 
classes according to the cluster they fell into in male liver and in female liver (Table 5-3).  
Each of the 6 clusters was then characterized by mapping each gene to chromatin 
modifications identified by MACS (Zhang et al. 2008) or SICER (Zang et al. 2009), 
which were subjected to a direct male to female comparison as described above 
(“Analysis of ChIP-seq data for chromatin modifications”). K4me3 marks were mapped 
to the promoter (TSS + 500 bp), K27ac marks to the promoter (TSS + 500 bp) and 
separately to the gene body (from TSS up to TES), and the other four marks to the gene 
body alone. Genes that contained both a male-enriched mark and a female-enriched mark 
for a particular modification were assigned to the sex-independent mark class. 
5.C.6 Gene enrichment analysis 
Gene sets that respond to activators of the nuclear receptors CAR (Tian et al. 2011; 
Tojima et al. 2012), PXR (Tojima et al. 2012) and PPARα (Sanderson et al. 2010) and to 
activators of AhR (Boverhof et al. 2005) were obtained from the indicated references. For 
CAR, the union of up-regulated and down-regulated genes from (Tian et al. 2011) and 
(Tojima et al. 2012) were considered. Genes up- or down-regulated by each of the 
receptors were tested for enrichment for one of the six clusters, compared to the 
background set of all 15,533 genes, using Fisher’s exact test. For sex-biased genes, genes 
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that whose gene body was within 10 kb of a ChIP-seq-determined binding site for STAT5 
(GSE31578) (Zhang et al. 2012), BCL6 (GSE31578) (Zhang et al. 2012), CUX2 
GSE35985) (Conforto et al. 2012), and FOXA1 and FOXA2 (Li et al. 2012) (E-MTAB-
805 in ArrayExpress) were defined as targets of the corresponding TF. Gene targets of 
these TFs were then tested for enrichment for belonging to each of the classes of sex-
biased genes (Table 5-3) compared to a background set comprised of all liver-expressed 
genes, defined as genes expressed at log2(RPKM)≥1 using Fisher’s exact test. Functional 
term enrichment analysis was performed using DAVID (Huang da et al. 2009b; Huang da 
et al. 2009a). 
FOXA1 and FOXA2 ChIP-seq data were analyzed by Gracia Bonilla of this laboratory to 
identify sex-biased binding sites using a method described elsewhere (Zhang et al. 2012).  
5.C.7 Preference of categories of DHS sites to be mapped to categories of sex-biased 
genes.  
Each DHS was mapped to its nearest gene TSS within 250kb; specifically, the nearest 
sex-biased gene TSS for sex-biased DHS, and nearest liver-expressed gene TSS for sex-
independent DHS. The 250 kb limit was chosen based on the observation made using 5C 
technology (Sanyal et al. 2012) that most long-range interactions occur within 250 kb of 
the TSS, and the frequency of interactions peaks ~120 kb upstream of the TSS. The 
preference for each type of male-biased DHS site based on enhancer modifications 
K4me1 and K27ac, Di, to be mapped to each class of sex-biased gene Gj (listed in Table 
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5-3) was computed as an enrichment, as shown below. Enrichments are shown in Table 
5-6.  
(# male-biased DHS of type Di with nearest TSS in class Gi)/(# total male-biased DHS of 
type Di) 
∑i (DHS sites of type Di with nearest TSS in class Gj)/(# total male-biased DHS sites) 
 
5.C.8 Relationship between TF binding and DHS/chromatin mark sex ratios 
The set of 72,862 merged DHS (Ling et al. 2010) was ranked by male-female ratio after 
normalization by reads in male-female liver common peaks. The DHS were ranked 
separately by male-female ratio in DNase hypersensitivity, and by K4me1, K27ac, and 
K27me3 read density over the entire peak region. Overlaps between DHS and TF binding 
sites for male-enriched STAT5, female-enriched STAT5, male-enriched FOXA1 and 
FOXA2, and female-enriched FOXA2 were also computed. A TF binding site was 
considered to overlap a DHS if the ChIP-seq identified peak region for the TF overlapped 
the DHS peak region by at least one base pair.  
Fig. 5-8A: Gene set enrichment analysis (Subramanian et al. 2005) was used to calculate 
a running enrichment score for each of the five types of TF binding sites for each of the 4 
ranked lists.  
Fig. 5-8B: The set of 72,862 merged DHS were ranked separately by male-female ratio in 
DNase hypersensitivity, and by K4me1, K27ac, and K27me3 read density over the entire 
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peak region, and the ranked DHS then divided into bins of 1000 DHS each. For each TF, 
the fraction of TFBS that overlapped a DHS in each bin was determined.  
Fig. 5-8C: To determine if there is a relationship between sex-ratio in TF binding or TF 
binding intensity and sex-ratio DNase hypersensitivity or chromatin modifications, for 
TFBS that overlap DHS, sex-ratio in TF binding (STAT5, FOXA1, and FOXA2) or TF 
binding intensity (BCL6 and CUX2) were plotted against sex-ratio in DNase 
hypersensitivity,  K4me1, K27ac, and K27me3. Pearson’s correlation was calculated for 
each plot. For BCL6 and CUX2, robust linear regression of TF binding intensity (ChIP-
seq read density) against sex-ratio in DHS/K4me1/K27ac/K27me3. 
Female-enriched FOXA1 binding sites did not follow the patterns exhibited by the other 
sex-biased TF binding sites examined (Figs. 5-8B and 5-8C) and were excluded from 
other analyses.  
5.C.9 Characterization of DHS by enhancer modifications and enrichment of TF binding  
Male-biased, female-biased, and sex-independent DHS (Ling et al. 2010) were 
characterized by the presence or absence of the two enhancer-associated chromatin 
marks, K4me1 and K27ac, which were classified as either male-enriched, female-
enriched, or sex-independent. For each DHS, the DHS peak region was defined as a 1 kb 
window centered at the DHS peak summit. Each DHS was considered to contain a 
K4me1 or K27ac peak if at least 200 bp of the 1 kb DHS peak region overlapped a 
K4me1 or a K27ac peak. The requirement for a 200 bp overlap was chosen based on the 
189 
 
 
 
K4me1 and K27ac read profiles at DHS, which peak at ~300 bp on either side of the 
DHS summit (see Fig. 5-3A).  
Since K27ac marks identify active enhancers, and K4me1 without K27ac marks identify 
enhancers that may not be active (Creyghton et al. 2010), DHS were assigned enhancer 
categories in a hierarchical manner, in the following order (Table 5-7A): 1) sex-biased 
K27ac; 2) sex-biased K4me1; 3) sex-independent K27ac; 4) sex-independent K4me1; 5) 
no K27ac or K4me1 mark. If a DHS overlapped both a male-biased mark and a female-
biased mark for a particular modification, that DHS was considered to overlap a sex-
independent mark. Each of these categories of DHS was compared to the same 
background set of sex-independent DHS whose nearest gene TSS was not sex-biased, and 
that were >500 kb from the nearest sex-biased TSS. The background set consisted of 
58,087 DHS in male liver and 52,187 DHS in female liver. DHS were considered to 
contain a STAT5, BCL6, CUX2, FOXA1, or FOXA2 binding site (identified by ChIP-
seq) if the DHS overlapped the binding site by at least 1 base pair. For each category of 
DHS by enhancer status, the enrichment for a particular TF was calculated as follows: 
__  (# DHS in a category that overlap a TFBS)/(# total DHS in that category)____ 
(# background sex-indep DHS that overlap a TFBS)/(# total background sex-indep DHS) 
, where TFBS is a TF binding site. The Fisher exact test was used to calculate a p-value 
for each enrichment or depletion. Enrichments meeting p<0.001 are shown in Fig. 5-8D, 
and enrichments for subsets of DHS that map to different target gene classes are shown in 
Table 5-7 B-D. To obtain target genes, each DHS was mapped to the nearest gene TSS 
within 250 kb; specifically, the nearest sex-biased gene TSS for sex-biased DHS, and the 
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nearest liver-expressed gene TSS for sex-independent DHS. Enrichments for TF binding 
were calculated for each category of sex-biased DHS, and for sex-independent DHS 
whose nearest gene TSS was sex-biased in its expression.  
5.C.10 Sex-difference in K4me1 distribution at sex-biased DHS 
K4me1 read density aggregate plots were generated for male-biased and female-biased 
DHS that were or were not bound by the different TFs, normalized to the total number of 
DHS in each group.  
In order to determine whether the deep trough in K4me1 profile in male liver is related to 
FOXA1/FOXA2 binding, rather than just a feature of highly DNase hypersensitive sites 
or DHS with high M/F ratio in hypersensitivity regardless of FOXA1/FOXA2, samples 
were chosen from the non-FOXA binding set that matched the distributions in DHS 
intensity or DHS M/F ratio exhibited by the FOXA binding sets. The K4me1 
distributions for the matched non-FOXA binding samples were similar to the total non-
FOXA binding set. 
The K4me1 pattern was quantified as follows. For each type of DHS in each sex, to 
calculate the depth of the K4me1 trough, the K4me1 read density at the DHS summit is 
subtracted from the K4me1 read density at the K4me1 maximum (i.e., the position at 
which K4me1 forms local maxima where there are bimodal peaks).  Where K4me1 forms 
a trough, this value is positive, and if K4me1 forms a single monomodal peak, this value 
is negative. The sex-difference in K4me1 distribution was computed as the difference 
between this value in male and female liver:  
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[(K4me1 max – DHS summit)male – (K4me1 max – DHS summit)female ]. 
These values are shown in Fig. 5-9 G.  
The sex-difference in K4me1 distribution was also calculated for pairs of TFs, male-
biased DHS that bind both TFs were compared to male-biased DHS that bind only one 
TF of the pair. These are shown in Fig. 5-9 H. 
 
5.D Results 
5.D.1 Chromatin states and distributions around genomic features 
Six chromatin marks were mapped genome-wide in male and female mouse liver. All 
four activating marks (histone-H3 K4me1, K4me3, K27ac and K36me3) showed the 
anticipated positive correlations with each other and with gene expression, and both 
repressive marks (histone-H3 K9me3 and K27me3) were negatively correlated with gene 
expression (Fig. 5-1 A-B). Genomic localizations and distributions across gene bodies 
(Figs. 5-1 D-E) are consistent with previously reported associations of each mark: K4me3 
with active promoters (Bernstein et al. 2002; Barski et al. 2007; Mikkelsen et al. 2007), 
K36me3 with actively transcribed regions (Bannister et al. 2005; Barski et al. 2007; 
Mikkelsen et al. 2007), K4me1 and K27ac with enhancers (Creyghton et al. 2010; Rada-
Iglesias et al. 2011), K27me3 with polycomb-mediated gene silencing, and K9me3 with 
constitutive heterochromatin and non-genic regions (Rosenfeld et al. 2009).  K27me3 and 
K9me3 were enriched in female liver on Chr X (Fig. 5-1C), consistent with their role in 
X-chromosome inactivation (Silva et al. 2003). Conversely, K4me1 and K27ac are 
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enriched in male liver on Chr X, consistent with K4 methylation depletion from the 
inactive X chromosome in female cells (Boggs et al. 2002). Chr X was excluded from 
further analysis to eliminate bias genome-wide male-female comparisons.  
ChromHMM (Ernst et al. 2011) was used to learn 14 chromatin states in male and female 
liver based on DHS data (Ling et al. 2010) combined with the above six chromatin marks 
(Fig. 5-2). These include inactive states (marked by K27me3 (state 1) or K9me3 (state 
3)), a bivalent promoter-associated state (K27me3 + K4me1; state 12), a transcribed state 
(K36me3; state 14), promoter states, which contain K4me3 (states 7 and 8), and several 
enhancer states, which contain K27ac or K4me1 but lack K4me3 (states 5, 6, 9, 10, 11). 
Liver-expressed genes show active promoter states at the TSS (Fig. 5-3A, left), with an 
asymmetric pattern reflecting the asymmetric distribution of K4me1, K4me3, K27ac and 
DHS at promoters (Fig. 5-3B, left) (Thurman et al. 2012). Liver-expressed genes have a 
strong bimodal K4me1 peak centered at the TSS, while non-liver-expressed genes show a 
much weaker monomodal K4me1 peak (Fig. 5-3B, right). Similarly, the DHS peak 
summit is flanked by a bimodal distribution of K4me1, as well as K27ac and K4me3 
(Fig. 5-3F). At DHS whose accessibility differs significantly between male and female 
liver (sex-biased DHS) (Ling et al. 2010), active chromatin states occur more frequently 
in one sex than the other (Fig. 5-3C). Male-biased DHS have a bimodal K4me1 peak in 
male liver, but have a smooth, monomodal peak at the DHS summit in female liver. This 
is reflected in the pattern of state 11, a K4me1-only state (Fig. 5-3C, 5-3D, left). In 
contrast, both male and female liver show a bimodal K4me1 distribution at female-biased 
and sex-independent DHS (Fig. 5-3C, 5-3D, right; Fig. 5-3F), and K27ac forms a 
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bimodal distribution at all three types of DHS.  Further, K27me3 levels and K27me3 
states are elevated at female-biased DHS in male compared to female liver (c.f. male 
prominence of K27me3-containing states 1 and 12), whereas male-biased DHS do not 
show a marked sex bias in K27me3 (Fig. 5-3C, 5-3D). This indicates a role for K27me3 
in sex-biased gene silencing in male liver but not in female liver. These sex differences in 
chromatin environment are much less pronounced at sex-biased TSS than at sex-biased 
DHS (Fig. 5-3D vs. Fig. 5-3E, and Fig. 5-3G), suggesting that many sex-biased genes are 
controlled by distal regulatory sites. 
5.D.2 Clustering of genes by chromatin modifications around TSS and TES  
To classify genes based on their chromatin environment, a set of 15,533 genes was 
clustered by chromatin mark ChIP-seq read densities surrounding the TSS and TES (Fig. 
5-4A). K9me3 is largely absent from the 6 gene clusters obtained, as it is primarily found 
in intergenic regions (Fig. 5-1D). Gene clusters 1-3 were characterized by high levels of 
DHS and the presence of all four activating marks, and by low levels of repressive marks; 
correspondingly, the genes in these active chromatin state clusters are highly expressed 
(≥80% are expressed at log2RPKM ≥ 1; Fig. 5-4B). Moreover, the genes in clusters 1-3 
are primarily in chromatin state 7 at the TSS (Fig. 5-4C). Genes in cluster 1 are 
distinguished by the high density of K4me1, K27ac, and DHS reads around both the TES 
and the TSS. Cluster 1 genes also have the highest coverage by broad domains of DNase 
hypersensitivity, with 70% of the genes being at least half covered by an extended DHS 
island (Ling et al. 2010), compared to 16-23% for the other two active clusters (Fig. 5-
4D). Cluster 2 genes show a more symmetrical distribution of marks around the TSS than 
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the other two active clusters. Genes in clusters 4-6 have high K27me3 read densities, and 
correspondingly, show low expression (Fig. 5-4B). Genes in clusters 4 and 5 are 
characterized by K4me1 in combination with K27me3 (chromatin state 12 at the TSS; 
Fig. 5-4C), i.e., the signature of a ‘poised’ gene (Bernstein et al. 2006), while cluster 6 
genes have K27me3 without K4me1 or other activating marks (state 1; Fig. 5-4C). The 
poised gene clusters showed higher mean expression levels than cluster 6 genes (Fig. 5-
4B).  
To test the hypothesis that basal chromatin state informs responsiveness to transcriptional 
regulators, genes in all six chromatin clusters were compared to the sets of genes that 
respond to the nuclear receptors/ligand-activated TFs CAR, PXR, PPARα and PPARβ/δ. 
Genes regulated by these nuclear receptors were enriched for one or more active 
chromatin clusters (Fig. 5-5). Further, genes down regulated by PXR and PPARβ/δ were 
enriched for poised chromatin clusters, suggesting that receptor activation induces 
removal of K4me1 while maintaining K27me3 at target genes. In contrast, genes up 
regulated by another ligand-activated TF, AhR, were enriched for genes in a poised 
chromatin state, indicating loss of K27me3 upon ligand activation. Consistent with the 
above preference for activation of genes already in an active chromatin state, the up-
regulated gene targets of all four nuclear receptors were significantly depleted from the 
inactive chromatin state (cluster 6). Thus, basal chromatin state is a determinant of 
responsiveness to these ligand-activated TFs.  
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Functional term enrichment analysis (Table 5-2) indicated enrichment for liver-specific 
terms such as drug, lipid, and steroid metabolism in cluster 1, the most active cluster 
(Table 5-2A), whereas the other two active clusters were enriched for a broad range of 
non-liver-specific terms, e.g. mitochondrion, RNA processing, protein transport and cell 
cycle (Table 5-2 B and C). The two poised clusters were enriched for terms such as cell 
adhesion, cell junction, mesenchymal cell differentiation, and extracellular matrix (Table 
5-2 D and E), while the inactive cluster 6 was enriched for terms describing genes not 
expected to be expressed in liver (e.g., neurotransmission, muscle, vision, memory) 
(Table 5-2 F). 
5.D.3 Classes of sex-biased genes 
Genes that show sex-biased expression (423 male-biased genes and 477 female-biased 
genes) were clustered by their chromatin mark and DHS densities around the TSS and 
TES in male liver, and separately, in female liver (Fig. 5-6A). Three gene clusters that 
differ in chromatin state and, correspondingly, in the level of gene expression, were thus 
obtained for each sex (Fig. 5-6B): active (high levels of activating marks around both the 
TSS and TES), intermediate (high levels of activating marks around the TSS only), and 
inactive chromatin state (low levels of activating marks, high level of K27me3). The 
active and intermediate sex-biased gene clusters were primarily comprised of genes in the 
active clusters among all genes (cluster 1 and clusters 2 and 3 of Fig. 5-4, respectively), 
while the inactive sex-biased gene clusters correspond to the poised and inactive clusters 
among all genes (clusters 4-6 of Fig. 5-4) (Fig. 5-6C). The sex-biased genes were then 
grouped into 12 classes (female-biased gene classes F1-F6, male-biased gene classes M1-
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M6) based on their chromatin activity classification in each sex (Table 5-3). Next, the 
genes in each class were characterized with regard to the sex-specificity of their 
chromatin environments. To do this, I first compared normalized densities of each of the 
six marks on a genome-wide basis in male vs. female liver and thereby identified 
genomic regions that showed significant male enrichment or female enrichment for each 
chromatin mark. The distribution of sex-biased and sex-independent chromatin marks 
was then determined for the genes in each class (Fig. 5-6D). 
A majority of sex-biased genes belonged to the same chromatin-based cluster in both 
male and female liver (classes F1, F2, and M1, M2 in Table 5-3). These genes were 
primarily associated with sex-independent chromatin marks (Fig. 5-6D), with a high 
fraction of F1 and M1 genes containing activating marks and a high fraction of F2 and 
M2 genes containing K27me3 or lacking activating marks, consistent with the chromatin 
activity status designations shown in Table 5-3.  Other sex-biased genes (classes F3, F4 
and M3, M4) belong to a more active chromatin cluster in the sex where the gene is more 
highly expressed, and correspondingly, classes F3, M3 and M4 (but not F4) displayed 
sex-enriched chromatin marks at comparatively high frequencies (Fig. 5-6D). Class F3 
and M3 genes also showed the largest sex-differences in expression (Fig. 5-6E). 
Importantly, class F3 genes are characterized by female-biased activating marks and 
male-biased repressive marks (c.f. high frequency of male-enriched K27me3), whereas 
class M3 and M4 genes frequently show male-biased activating marks but not female-
biased repressive marks (Fig. 5-6D). Thus, classes F3, M3, and M4 represent genes that 
have sex-biased chromatin marks in their immediate vicinity. However, these classes 
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represent only 5.3% of all sex-biased genes, consistent with the conclusion that many 
sex-biased are not in a sex-biased chromatin environment (c.f. Fig. 5-3C). Indeed, taking 
into account distal chromatin marks, which may represent distal regulatory sites, less than 
half of sex-biased genes have sex-biased chromatin marks within 10 kb, and only 66-69% 
within 100 kb (Fig. 5-3F).  Genes that belong to the inactive chromatin cluster in the sex 
in which they were more highly expressed (classes F2, F5, M2 and M5) were more likely 
than others to have a sex-independent K27me3 domain (Fig. 5-6D).  
5.D.4 Enrichment of TF targets among sex-biased gene classes  
Next, I investigated the hypothesis that sex-biased genes in different chromatin states 
utilize different regulatory factors and mechanisms. The sex-biased genes in each class 
were mapped to nearby (within 10 kb) binding sites identified by ChIP-seq for three GH-
regulated TFs that play a role in sex-dependent gene expression: STAT5 (male-enriched, 
female-enriched, and sex-independent STAT5 binding sites; (Zhang et al. 2012)), BCL6, 
a male-biased repressor (Zhang et al. 2012), and CUX2, a highly female-specific 
repressor (Conforto et al. 2012) (Fig. 5-7 A-B), as well as FOXA1 and FOXA2, which 
contribute to the sex-biased incidence of hepatocellular carcinoma (Li et al. 2012). 
Compared to all liver-expressed genes, several of the sex-biased gene classes were 
enriched for being targets of sex-biased STAT5 binding, with the highest enrichments 
seen for genes in classes F3 and M4, which are associated with sex-biased chromatin 
marks (c.f. Fig. 5-6D). In contrast, BCL6 targets were enriched among female-biased 
genes that do not show sex-differences in chromatin marks (F1, F4, and F5), suggesting 
BCL6 repression of female-biased genes in male liver (Zhang et al. 2012) does not 
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introduce a sex-bias in chromatin modifications. BCL6 target genes were also enriched 
among a subset of male-biased genes, reflecting the STAT5 competition mechanism 
described earlier (Zhang et al. 2012).  
CUX2 targets were highly enriched among male-biased genes in class M4, and to a lesser 
extent class M1, consistent with CUX2’s proposed role as a repressor (Conforto et al. 
2012); enrichment was also seen among class F3 genes, consistent with CUX2 directly 
activating a subset of female-biased genes (Conforto et al. 2012). Female-biased CUX2 
targets are more likely than other female-biased genes to have a male-enriched K27me3 
mark, especially class F3 target genes (Fig. 5-7C), which show the greatest enrichment of 
CUX2 binding (Fig. 5-7A) and the highest frequency of male-biased K27me3 marks (Fig. 
5-6D). Since class F3 genes are also highly enriched for being targets of STAT5 and 
FOXA2 (Fig. 5-7A), this could indicate cooperativity between the three factors to 
regulate the most highly female-biased genes.  Overall, at female-biased genes, male-
enriched K27me3 domains at the gene body co-associate with CUX2 binding within 10 
kb more than with any other TF examined, and CUX2 binding is more likely to target 
female-biased genes with male-enriched K27me3 domains than any other sex-biased 
mark (Table 5-4A, 5-4B). Thus, the female-specific expression of CUX2 after puberty 
(Conforto and Waxman 2012) is associated with the loss of K27me3 repressive domains 
on CUX2 target genes, which may in part explain the male bias of those K27me3 
domains in adult liver. The enrichment of female-biased FOXA2 binding at female-
biased gene targets with male-enriched K27me3 domains is almost as high as that of 
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CUX2 (Table 5-4A, 5-4B), suggesting CUX2 and FOXA2 cooperate to de-repress these 
genes in female liver.  
5.D.5 Relationship between sex-bias in DNase hypersensitivity, chromatin modifications, 
and TF binding at regulatory sites  
Female-biased DHS (Ling et al. 2010) are highly enriched (18-fold) for the presence of 
female-biased K27ac or K4me1 marks compared to sex-independent DHS, and 
correspondingly for male-biased DHS and male-enriched K27ac or K4me1 marks (16-
fold enrichment) (Table 5-5). Thus, many sex-biased DHS have the marks of sex-
dependent enhancers. Moreover, sex-biased gene classes F3 and M3, which comprise the 
most highly sex-biased genes, are enriched for association (within 250 kb) with sex-
biased DHS that have sex-biased K27ac (Table 5-6) , the mark of an active enhancer 
(Creyghton et al. 2010; Rada-Iglesias et al. 2011). For class F3 genes, the enrichment for 
female-biased DHS with female-biased K27ac marks is independent of K4me1 status, 
however, for M3 genes enrichment is only seen for male-biased DHS that are male-
biased in both K27ac and K4me1.  
Next, I investigated the relationship between DHS and the sex-bias of their associated 
K27ac, K4me1, and K27me3 marks, and the occurrence of sex-biased binding sites for 
the five liver TFs discussed above. Gene set enrichment analysis of DHS where each 
factor is bound showed positive correlations between the sex-biased binding of STAT5, 
FOXA1, and FOXA2 and the sex-ratio in DNase hypersensitivity, and the sex-ratio of 
both enhancer modifications, and an inverse correlation with the sex-ratio in K27me3 
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(Fig. 5-8A). These findings were confirmed by analysis of the frequency of the above TF 
binding sites in bins of DHS ranked by sex ratios (Fig. 5-8B) and by the correlation 
between sex-ratios in TF binding and sex-ratios in DHS and in activating chromatin 
marks (Fig. 5-8C). BCL6 is most frequently bound at sex-independent DHS (Fig.  5-8B), 
consistent with its preferred target genes (Fig. 5-7A) having sex-independent chromatin 
marks (Fig. 5-6D). CUX2 binding is enriched at male-biased DHS, consistent with 
(Conforto et al. 2012), but is not associated with or correlated with sex-differences in 
chromatin marks at the sites where it is bound (Fig. 5-8 B,C).  
To examine more closely the relationship between chromatin modifications and 
regulation by liver TFs, I integrated TF binding data with the enhancer status of DHS 
sites and the chromatin class of their respective target genes within 250 kb. For each TF, I 
identified significant enrichments (p<0.001) of its binding sites at DHS categorized by 
their patterns of enhancer modifications (Fig. 5-8D). Sex-biased DHS that have sex-
biased enhancer modifications are most highly enriched for being GH-responsive, 
highlighting the link between the sexually dimorphic GH profile and sex-differences in 
enhancer modifications at regulatory sites. Consistent with the results above, female-
biased STAT5 binding and FOXA2 binding are most highly enriched at female-biased 
DHS that have female-biased K27ac, and similarly, male-biased STAT5, FOXA1, and 
FOXA2 binding are most highly enriched at male-biased DHS with male-biased K27ac. 
This preference for sites with sex-biased K27ac is also seen at sex-independent DHS, but 
with lower enrichments (Fig. 5-8D). Next, enrichments of TF binding sites for subsets of 
DHS that target individual sex-biased gene classes were determined Table 5-7 B-D).  For 
201 
 
 
 
sex-biased DHS, target genes were defined as the nearest sex-biased gene TSS up to 250 
kb from the DHS, allowing for the possibility of distal regulation. For sex-independent 
DHS, target genes were defined as the nearest liver-expressed gene TSS up to 250 kb 
from the DHS, and only sex-independent DHS that mapped to sex-biased genes were 
included in this analysis. Female-biased STAT5 binding was most strongly enriched (22-
fold) at DHS that map to class F3 genes, with significantly lower enrichments associated 
with other female-biased gene classes, consistent with Fig. 5-7A. In contrast, the 
strongest enrichment for male-biased STAT5 binding was at DHS that map to class M1 
genes (47-fold), even though class M4 genes, which have nearby sex-biased chromatin 
marks (Fig. 5-6D), show the highest enrichment for male-biased STAT5 binding within 
10 kb (Fig. 5-7B). Thus, distal regulation by male-enriched STAT5 binding is associated 
with male-biased genes that lack nearby sex-differences at the chromatin level.  
BCL6 and CUX2 binding are enriched at both male-biased and sex-independent DHS, 
with preferences for sites with a sex-independent K27ac mark (Fig. 5-8D). These findings 
are consistent with the lack of correlation of BCL6 and CUX2 binding with sex-
differences in chromatin marks described above. Among DHS with sex-independent 
K27ac, and in agreement with Fig. 5-7 A-B, BCL6 binding is enriched in association 
with female-biased genes that lack nearby sex-biased chromatin marks (classes F1, F2, 
F4, and F6), while CUX2 binding is most highly enriched in association with male-biased 
class M4 (7.8-fold) (Table 5-7 C-D). Bcl6 itself is a target of male-biased STAT5 
binding, and is an example of a sex-biased TF that binds to sex-independent regulatory 
sites, which enables it to regulate secondary target genes that do not exhibit sex-
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differences in chromatin marks. CUX2 is also enriched at DHS with female-biased 
K27ac (Fig. 5-8D), and this enrichment is highest in association with female class F2 
(which includes Cux2 itself) and class F3 genes (Table 5-7 B, D).  
5.D.6 Sex-difference in K4me1 distribution surrounding sex-biased DHS summits 
FOXA1 acts as a liver-enriched pioneer factor (Friedman and Kaestner 2006; Zaret and 
Carroll 2011) that opens chromatin at cell type-specific enhancers (Lupien et al. 2008) by 
binding compacted chromatin via a core histone binding motif, resulting in the generation 
of DHS (Cirillo et al. 2002). Given the association of sex-biased FOXA1 and FOXA2 
binding with DHS showing a sex-bias in DNase hypersensitivity, K27ac, and K4me1 
marks (Fig. 5-8), I hypothesized that FOXA1 and FOXA2 act as pioneer factors that 
mediate sex-dependent nucleosome repositioning and sex-differential chromatin opening 
at sex-biased DHS. Supporting this hypothesis, the sex-dependent distribution of K4me1 
marks surrounding the DHS summit at male-biased DHS, with a bimodal peak in male 
liver and a monomodal peak in female liver (Fig. 5-3 C-D, left), is most pronounced at 
DHS that bind FOXA1 or FOXA2 in a male-enriched manner (c.f., greater dip in K4me1 
reads at the summit of male-biased DHS bound by FOXA1 or FOXA2 compared to male-
biased DHS not bound by these factors; Fig. 5-9A). Moreover, in contrast to the 
monomodal K4me1 peak seen in female liver at DHS with male-enriched FOXA1 or 
FOXA2 binding, a trough in K4me1 reads is discernible in female liver at DHS with sex-
independent FOXA1 or FOXA2 binding. Together, these findings indicate sex-dependent 
nucleosome repositioning by FOXA1/FOXA2 at male-biased DHS. Supporting this 
conclusion, male-biased DHS that bind STAT5 in a male-enriched manner exhibit a 
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deeper K4me1 trough in male liver when the binding occurs in combination with FOXA1 
or FOXA2 binding (Fig. 5-9B).  CUX2 binding in female liver is enriched at male-biased 
DHS and at sites with male-enriched STAT5 binding (Conforto et al. 2012), suggesting 
CUX2 may keep male-biased DHS closed in female liver while they are opened by 
FOXA1 and FOXA2 in male liver. Female-biased DHS have bimodal K4me1 peaks in 
both male and female liver and show a less pronounced sex-difference in K4me1 profile 
at sites of female-enriched FOXA2 binding (Fig. 5-9C), even though female-biased 
FOXA2 binding is enriched at female-biased regulatory sites and in association with 
female-biased genes (Fig. 5-7A, Fig. 5-8, Table 5-7B). This suggests that FOXA2 is 
involved in female-biased gene regulation but does not mediate sex-dependent 
nucleosome repositioning at female-biased DHS as it does at male-biased DHS. 
 
5.E Discussion  
Genome-wide chromatin state maps were developed for male and female mouse liver 
based on DHS profiles and six chromatin marks, and these maps were used to elucidate 
chromatin environments at DHS and across gene bodies, in particular, those associated 
with sex differences in gene expression, a characteristic of ~1,000 genes in mouse liver.  
By integrating these chromatin maps with TF binding data, I show that the mechanisms 
of sex-biased gene regulation differ between male and female liver, with male-biased 
DHS, but not female-biased DHS, being characterized by a sexually dimorphic K4me1 
profile that is enhanced by male-enriched binding of the pioneer factors FOXA1 and 
FOXA2 (Fig. 5-10). These FOXA factors, in turn, are proposed to facilitate male-
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enriched binding of STAT5, which activates male-biased genes by mechanisms that 
include distal regulation of male-biased genes that lack nearby sex-differences in 
chromatin marks. Many female-biased genes associated with sex-independent chromatin 
marks are preferentially repressed in male liver by the male-biased repressor BCL6, 
while other, more highly female-biased genes show sex-differences in proximal 
chromatin marks and are preferentially activated by female-enriched STAT5 binding. 
Many of the strongly female-biased genes are regulated by K27me3-based repression in 
male liver, which may be countered by the stimulatory actions of CUX2 in female liver; 
however, strongly male-biased genes are not repressed by a corresponding K27me3-
based mechanism in female liver (Fig. 5-10). These insights underscore the utility of 
functional genomic and epigenetic studies for elucidating transcriptional regulation in 
complex mammalian systems. 
Impact of chromatin state on functional gene enrichments and nuclear receptor 
responsiveness – Clustering of genes by chromatin mark intensities and DNase 
hypersensitivity in the immediate vicinity of the gene identified genes in three distinct 
chromatin environments: active (liver-expressed genes with activating chromatin 
modifications; clusters 1-3), poised (genes encompassing a broad range of gene 
expression levels, and in a K27me3 + K4me1 chromatin state at the TSS; clusters 4, 5), 
and inactive (non-liver-expressed genes with low activating marks and high K27me3 
levels; cluster 6). Genes in cluster 1 (open chromatin, with K4me1 and K27ac marks, 
throughout the gene body) are commonly involved in liver-specific tasks, such as drug, 
steroid, and lipid metabolism. Genes in clusters 2 and 3 (open chromatin only at the 
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promoter, and more dense K36me3 marks in the gene body) carry out many non-liver-
specific functions, while the poised cluster 4 and 5 genes encompass biological processes 
activated in response to specific stimuli. Genes responsive to several ligand-activated 
nuclear receptors that regulate many liver metabolic functions (CAR, PXR, PPARα, 
PPARβ/δ) (Kakizaki et al. 2008; Hernandez et al. 2009; Chai et al. 2013), and genes 
responsive to AhR, were depleted of inactive cluster genes, indicating these TFs do not 
target genes in an inactive chromatin state. Genes in a poised state are enriched among 
the genes down regulated by PXR and PPARβ/δ, and in the genes up regulated by AhR, 
indicating the poised chromatin state resolves into either an inactive or an active state, 
depending on the TF and depending on the target gene. In contrast, many of the genes up 
regulated by PXR and PPARβ/δ, as well as the genes up or down regulated by CAR and 
PPARα, are already in an active chromatin state in un-stimulated liver.  
Regulation of sex-biased genes – Sex-differences in chromatin environment were 
commonly seen at male-biased and female-biased DHS, but not at sex-biased genes, a 
majority of which lacked sex-differences in local chromatin marks. Consistently, genes 
differentially expressed between cell types show cell type-specific chromatin states at 
regulatory sites but common chromatin states at the promoter (Heintzman et al. 2009; 
Song et al. 2011; Natarajan et al. 2012).  However, some of the sex-biased genes showing 
large differences in expression between sexes do show notable sex differences in their 
local chromatin states (e.g., Cyp2b9, Hsd3b5; Fig. 5-11 A-B). Although these and other 
genes with sex-differences in local chromatin environment have the strongest enrichment 
for local sex-biased STAT5 binding, several other highly sex-biased genes are deficient 
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in local sex-differences in chromatin marks (e.g., Sult2a6, Cabyr; Fig. 5-11 C-D), 
consistent with the distal regulation proposed earlier based on sex-biased DHS maps 
(Ling et al. 2010). Distal regulation is most likely for class M1, the largest class of male-
biased genes, which lack sex differences in local chromatin marks but show the highest 
enrichment (47-fold) for male-biased STAT5 binding at male-biased DHS showing male-
biased K27ac when binding events up to 250 kb from the TSS are considered (Table 5-7 
C-D). Overall, male-biased STAT5 binding is more extensive than female-biased STAT5 
binding (seen at 23% of 2,714 male-biased DHS vs. 13% of 1,333 female-biased DHS), 
which may enable STAT5 to distally regulate a larger number of sex-biased genes in 
male compared to female liver. Finally, sex-biased STAT5 binding is most highly 
enriched in association with sex-biased chromatin marks, in particular K27ac, the mark of 
an active enhancer, both at sex-biased DHS and at sex-independent DHS (Fig. 5-8D), 
highlighting the importance of sex-differences in chromatin marks as compared to sex-
differences in DNase hypersensitivity. A failure to recapitulate a sex-dependent 
chromatin environment may explain the inability of some sex-biased DHS to confer a 
sex-difference in expression when assayed in an in vivo liver transfection/luciferase 
reporter assay (Ling et al. 2010). 
Our analysis of sex-differentiated chromatin states, together with binding data for TFs 
known to be involved in sex-biased liver gene regulation, support the model depicted in 
Fig. 5-10. Plasma GH profiles, which are sexually dimorphic, impart sex-differential 
patterns of STAT5 activation (Gebert et al. 1999a; Gebert et al. 1999b) and sex-
differential expression of Bcl6 (Meyer et al. 2009) and Cux2 (Laz et al. 2007), and 
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regulate DHS opening and closing in a sex-biased manner (Ling et al. 2010). This sex- 
and plasma GH pattern-dependent remodeling of regulatory sites involves the enhancer-
associated modifications K4me1 and K27ac, as evidenced by the highest enrichment for 
GH-responsiveness among DHS that show sex-bias in those two activating marks (Fig. 5-
8D). The pioneer factor FOXA1, which initiates chromatin opening that activates 
enhancers during liver development (Zaret 1999), and the related FOXA2, show sex-
dependent binding that correlates closely with sex-bias in DNase hypersensitivity and in 
K4me1 and K27ac marks (Fig. 5-8), and are proposed to induce the observed sex-
differential opening at male-biased DHS in mouse liver. Supporting this proposal, male-
biased DHS show a FOXA-dependent, sexually dimorphic K4me1 distribution around 
the DHS summits (bimodal distribution of K4me1 surrounding the DHS summit in male 
but not female liver, with a much weaker trough at male-biased DHS not bound by either 
FOXA factor; Fig. 5-9A). This pattern is reminiscent of unstimulated LNCaP cells, where 
androgen receptor binding sites lacking FOXA1 binding have a broad K4me2 peak, 
compared to a bimodal peak surrounding the summit of androgen receptor binding sites 
associated with FOXA1 binding (He et al. 2012). Furthermore, in breast cancer and 
prostate cancer cells, cell type-specific binding by FOXA1 is enriched at sites with cell 
type-specific K4me1 and K4me2 marks, which are required for FOXA1 binding at 
enhancers (Lupien et al. 2008). Thus, FOXA1 is recruited to sites marked by cell type-
specific K4 methylation, where it “translates” the epigenetic signature into chromatin 
opening. Correspondingly, our data suggest that FOXA1 and FOXA2 are recruited to 
sites with male-enriched K4me1 marks, followed by repositioning of nucleosomes to 
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flank the site, resulting in increased DNase hypersensitivity in male liver at the peak 
center. In contrast, bimodal K4me1 peaks are seen at female-biased DHS in both male 
and female liver and independent of FOXA binding (Fig. 5-9B), suggesting that other 
mechanisms, such as the persistence of STAT5 binding activity in female liver (Zhang et 
al. 2012) may be responsible for the higher level of chromatin accessibility of these sites 
in female liver.  
Both bimodal and monomodal patterns of K4me1 marks are seen at FOXA2 and HNF4α 
binding sites in liver, but the bimodal loci are associated with more highly expressed 
genes and more likely to confer liver-specificity (Hoffman et al. 2010). Further, 
comparing K4me1 patterns at TF binding sites in liver and islet cells, peaks that are 
bimodal in liver and monomodal in islets are associated with liver-specific genes, and 
similarly for bimodal peaks in islets and islet-specific genes (Hoffman et al. 2010). The 
bimodal K4me1 peak is associated with nucleosome depletion at the peak center, as 
confirmed by micrococcal nuclease digestion followed by qPCR-based mapping of 
nucleosomes at sites that were bimodal in one tissue and monomodal in the other. In 
liver, bimodal K4me1 loci occupied by FOXA2 are most likely to be co-occupied by 
HNF4α (Hoffman et al. 2010), and STAT5 binding sites in female liver show significant 
co-occupation by HNF4α, FOXA1 and FOXA2 (Kang et al. 2013). HNF4α is required 
for sex-biased gene expression and may act co-operatively with STAT5 (Holloway et al. 
2006; Holloway et al. 2008). Thus, FOXA1 and FOXA2, recruited to male-biased DHS 
marked by male-biased K4me1, may act in cooperation with HNF4α and/or STAT5, to 
regulate sex-biased genes in male liver. However, about half of all FOXA2 binding sites 
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in mouse liver occur at nucleosome-bound sites, including some sites that exhibit 
bimodal K4me1 distribution, and consequently, the bimodal distribution of K4me1 
cannot be taken as a definitive indication of nucleosome repositioning at every such site 
(Li et al. 2011). Further studies are needed to identify sites of sex-dependent, GH-
regulated nucleosome remodeling, and to further elucidate the roles of FOXA1 and 
FOXA2 in these remodeling events. 
BCL6 and CUX2: chromatin environments of binding sites and at target genes - BCL6, 
which is expressed in a male-biased manner subject to regulation by GH and STAT5, 
directly competes with STAT5 for binding to STAT5-related sequence motifs and is 
associated with repression of many female-biased genes in mouse liver (Meyer et al. 
2009; Zhang et al. 2012). BCL6 preferentially binds sex-independent DHS with sex-
independent chromatin marks (Fig. 5-8B), and the female-biased targets of BCL6 are 
enriched for genes that lack local sex-biased chromatin marks (Fig. 5-7A, Table 5-7 C-
D). This supports our earlier proposal that sex-biased genes deficient in nearby sex-
biased DHS could be regulated by TFs whose expression or activity is sex-dependent 
(e.g., BCL6), without a need for sex-bias in the chromatin environment at the TF binding 
site (Ling et al. 2010).  
The highly female-specific expression of CUX2 (Laz et al. 2007) restricts its binding to 
female liver chromatin, where it is enriched at male-biased DHS and at sites with male-
enriched STAT5 binding, and is associated with repression of ~30% of male-biased 
genes (Conforto et al. 2012). In contrast to female-biased targets of BCL6, male-biased 
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genes enriched for being a proximal target of CUX2 are characterized by sex-differences 
in local chromatin marks, and show the highest male-enrichment of STAT5 and FOXA1 
binding (class M4 genes; Fig. 5-7B). Conceivably, the repressive activity associated with 
CUX2 binding at those male-biased genes could inhibit DHS opening in female liver and 
contribute to the male bias in chromatin accessibility and STAT5 binding seen at those 
CUX2 binding sites. CUX2 can also activate female-biased genes in female mouse liver 
(Conforto et al. 2012), and accordingly, CUX2 binding was enriched at both female-
biased and sex-independent DHS that map to several classes of female-biased genes 
(Table 5-7 B and D). Furthermore, female-biased targets of CUX2 are frequently marked 
by enrichment for K27me3 at the gene body in male liver (Fig. 5-7C). Thus, the 
activating role of CUX2 may also involve chromatin remodeling at target genes – in this 
case, de-repression of female-biased genes by removal of K27me3 repressive marks 
across the gene body. Further work is required to investigate these proposed actions of 
CUX2 in female liver. 
Conclusions - Comparison of the epigenetic environment and chromatin states that 
characterize male and female liver, and integration with gene expression and TF binding 
data revealed distinct mechanisms of sex-biased gene regulation in male and female 
mouse liver. Sex-dependent K27me3-mediated repression is shown to be an important 
mechanism of repression of female-biased but not of male-biased genes, and a sexually 
dimorphic K4me1 profile, which could indicate sex-dependent nucleosome repositioning 
by pioneer factors, is seen at male-biased but not female-biased regulatory sites. 
Transcription factors that mediate sex-biased gene expression were also found to exhibit 
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distinct relationships with epigenetic marks: STAT5-mediated activation was associated 
with sex-biased chromatin modifications, while BCL6-mediated repression primarily 
occurs in association with sex-independent chromatin modifications both at BCL6 
binding sites and at its target genes.  The female-specific TF CUX2 acts as both a 
transcriptional repressor of male-biased genes, potentially by preventing STAT5 binding, 
and as an activator of female-biased genes, potentially by facilitating removal of 
K27me3. 
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Table 5-1. Numbers of reads obtained and peaks/islands identified for each histone modification.  
K9me3, K27me3, and K36me3 marks were identified using SICER, and K4me1, K27ac, and K4me3 marks were identified 
using MACS. Sex-biased marks were identified by normalizing read counts by the M/F ratio in reads in common peaks, which 
accounts for differences between samples in % of reads in peaks. Sex-biased marks were identified as those that had 2-fold 
higher reads in one sex than the other (|M|>1) and had p<0.001. Numbers of sex-independent peaks/islands were obtained by 
merging sex-independent peaks/islands in male liver and female liver.  
Chromatin 
mark  
 
Total reads 
(millions)  
Peaks (MACS) or islands (SICER)  
Male 
liver 
Female 
liver  
Total  Male-biased 
(M>1 and 
p<0.001)  
Female-
biased (M<-1 
and p<0.001)  
Mean region 
length  
Median 
region length
K9me3  10.7 14.6 20,997 372 394 14 kb 12 kb 
K27me3  42.6 45.7 20,563 160 8 29 kb 22 kb 
K4me1  39.3 52.5 89,384 6,098 3,219 2 kb 1.4 kb 
K27ac  35.3 36.1 43,656 713 1,157 3 kb 2 kb 
K4me3  41.2 36 19,225 714 237 2 kb 1.6 kb 
K36me3  34.9 33.1 22,212 142 86 14 kb 9 kb 
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Table 5-2. Functional enrichment annotations for all genes clustered by chromatin 
density. 
The top 50 DAVID annotation clusters meeting enrichment score > 1.5, for each of the 
six gene clusters in male liver. A: Gene cluster 1 (most active). B: Gene cluster 2 
(active). C: Gene cluster 3 (active). D: Gene cluster 4 (poised). E: Gene cluster 5 
(poised). F: Gene cluster 6 (inactive).  
In each table, for each annotation cluster, the number of genes, the name of first term and 
p-value of first term are listed. 
A. Cluster 1 (most active) 
A
nn
ot
at
io
n 
C
lu
st
er
 
En
ric
hm
en
t 
Sc
or
e 
# 
ge
ne
s 
First term in Annotation cluster p-value of first term 
1 4.83 162 GO:0005739~mitochondrion 1.76E-09
2 4.03 54 GO:0043066~negative regulation of apoptosis 2.90E-05
3 3.95 25 GO:0046486~glycerolipid metabolic process 2.87E-07
4 2.96 71 GO:0042981~regulation of apoptosis 8.99E-05
5 2.82 34 GO:0046486~glycerolipid metabolic process 2.87E-07
6 2.80 7 lipid droplet 9.02E-05
7 2.73 17 mmu00982:Drug metabolism 6.96E-04
8 2.70 15 plasma 2.31E-06
9 2.59 89 GO:0070013~intracellular organelle lumen 1.02E-04
10 2.55 20 GO:0030193~regulation of blood coagulation 4.66E-05
11 2.51 18 GO:0042579~microbody 2.10E-04
12 2.43 36 lipid synthesis 2.00E-05
13 2.31 17 GO:0031669~cellular response to nutrient levels 5.24E-04
14 2.24 89 GO:0044265~cellular macromolecule catabolic process 0.0015122
15 2.23 121 GO:0006357~regulation of transcription from RNA  polymerase II promoter 3.70E-04
16 2.21 30 GO:0008202~steroid metabolic process 1.32E-06
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Table 5-2. Functional enrichment annotations for all genes clustered by chromatin 
density. A (continued) 
17 2.16 236 GO:0046914~transition metal ion binding 6.18E-05
18 2.09 11 GO:0019216~regulation of lipid metabolic process 8.84E-04
19 2.08 27 GO:0019842~vitamin binding 0.0033353
20 2.01 54 GO:0042981~regulation of apoptosis 8.99E-05
21 1.97 21 IPR002085:Alcohol dehydrogenase superfamily, zinc-containing 2.06E-04
22 1.94 32 IPR019775:WD40 repeat, conserved site 9.25E-04
23 1.91 22 nad 7.88E-04
24 1.88 11 GO:0019216~regulation of lipid metabolic process 8.84E-04
25 1.87 24 GO:0051082~unfolded protein binding 0.008756
26 1.87 11 GO:0006956~complement activation 0.0025501
27 1.70 10 
IPR015940:Ubiquitin-associated/translation elongation 
factor EF1B,  
N-terminal, eukaryote 
0.0079213
28 1.69 57 GO:0045087~innate immune response 0.0015982
29 1.62 38 GO:0008134~transcription factor binding 0.0016259
30 1.58 87 mmu04610:Complement and coagulation cascades 6.92E-08
31 1.51 70 GO:0046907~intracellular transport 0.0085876
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Table 5-2. Functional enrichment annotations for all genes clustered by chromatin 
density. 
B. Cluster 2 (active) 
A
nn
ot
at
io
n 
Cl
us
te
r 
En
ri
ch
m
en
t 
Sc
or
e 
# 
ge
ne
s First term in Annotation cluster 
p-value of 
first term 
1 21.12 244 GO:0031974~membrane-enclosed lumen 9.01E-28
2 17.24 187 
GO:0044265~cellular macromolecule catabolic 
process 
4.71E-22
3 13.34 246 GO:0005739~mitochondrion 2.41E-21
4 9.26 260 GO:0031967~organelle envelope 2.04E-13
5 9.15 124 GO:0006974~response to DNA damage stimulus 1.34E-12
6 8.50 570 GO:0000166~nucleotide binding 2.28E-22
7 7.77 527 zinc-finger 9.10E-15
8 7.57 108 GO:0044429~mitochondrial part 2.06E-12
9 7.27 154 GO:0006396~RNA processing 6.57E-15
10 7.01 282 GO:0046907~intracellular transport 1.12E-11
11 5.76 34 GO:0005777~peroxisome 3.11E-08
12 5.75 70 GO:0034660~ncRNA metabolic process 5.08E-08
13 5.48 69 wd repeat 2.52E-07
14 5.02 91 GO:0004842~ubiquitin-protein ligase activity 7.44E-08
15 4.93 279 GO:0043228~non-membrane-bounded organelle 7.88E-09
16 4.56 132 GO:0007049~cell cycle 3.84E-09
17 4.54 76 GO:0001701~in utero embryonic development 1.31E-05
18 4.27 83 GO:0016568~chromatin modification 1.54E-08
19 4.18 119 rna-binding 7.40E-13
20 4.17 27 IPR019787:Zinc finger, PHD-finger 8.38E-06
21 3.93 73 GO:0005635~nuclear envelope 1.69E-06
22 3.87 89 GO:0006915~apoptosis 4.03E-05
23 3.84 71 GO:0000775~chromosome, centromeric region 5.73E-06
24 3.56 65 
GO:0010608~posttranscriptional regulation of gene 
expression 
3.66E-05
25 3.49 24 GO:0016567~protein ubiquitination 8.30E-05
26 3.27 96 GO:0042981~regulation of apoptosis 4.46E-05
27 3.20 68 GO:0065003~macromolecular complex assembly 1.30E-04
28 3.03 460 GO:0006350~transcription 4.01E-10
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Table 5-2. Functional enrichment annotations for all genes clustered by chromatin 
density. B (continued) 
29 2.88 21 
GO:0042770~DNA damage response, signal 
transduction 
1.20E-04
30 2.85 74 GO:0003712~transcription cofactor activity 4.79E-04
31 2.71 92 GO:0015630~microtubule cytoskeleton 3.80E-07
32 2.67 53 protein biosynthesis 5.19E-05
33 2.66 74 mmu05200:Pathways in cancer 2.89E-05
34 2.57 92 
GO:0006511~ubiquitin-dependent protein catabolic 
process 
5.69E-13
35 2.52 53 IPR017907:Zinc finger, RING-type, conserved site 3.57E-04
36 2.49 87 GO:0010629~negative regulation of gene expression 1.43E-04
37 2.42 25 
GO:0042770~DNA damage response, signal 
transduction 
1.20E-04
38 2.41 29 GO:0032774~RNA biosynthetic process 7.21E-04
39 2.29 35 GO:0051186~cofactor metabolic process 0.0020838
40 2.29 17 IPR000961:AGC-kinase, C-terminal 0.0021265
41 2.29 44 fatty acid metabolism 0.0013988
42 2.22 8 GO:0019902~phosphatase binding 0.0048689
43 2.21 16 m_mTORPathway:mTOR Signaling Pathway 2.23E-04
44 2.21 90 mmu05016:Huntington's disease 7.01E-05
45 2.20 58 IPR000357:HEAT 1.29E-05
46 2.20 15 
GO:0001953~negative regulation of cell-matrix 
adhesion 
9.88E-05
47 2.15 67 GO:0051726~regulation of cell cycle 8.62E-07
48 2.11 23 mRNA transport 0.0011557
49 1.96 18 IPR001810:Cyclin-like F-box 0.0086779
50 1.95 51 tpr repeat 1.12E-05
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Table 5-2. Functional enrichment annotations for all genes clustered by chromatin 
density. 
C. Cluster 3 (active) 
A
nn
ot
at
io
n 
C
lu
st
er
 
En
ric
hm
en
t 
Sc
or
e 
# 
ge
ne
s First term in Annotation cluster p-value of first term
1 11.85 271 GO:0005739~mitochondrion 3.73E-21
2 11.50 237 GO:0031974~membrane-enclosed lumen 5.08E-18
3 10.04 596 GO:0008270~zinc ion binding 1.78E-16
4 9.55 277 SM00349:KRAB 2.56E-15
5 8.79 751 nucleus 4.65E-26
6 7.76 385 GO:0017076~purine nucleotide binding 5.26E-11
7 6.90 316 GO:0043232~intracellular non-membrane-bounded organelle 6.31E-11
8 6.53 128 GO:0006259~DNA metabolic process 2.32E-10
9 6.51 208 GO:0031967~organelle envelope 1.95E-09
10 6.34 288 GO:0015031~protein transport 8.62E-11
11 5.49 61 mmu04142:Lysosome 4.68E-07
12 5.44 57 GO:0034660~ncRNA metabolic process 9.13E-08
13 5.32 85 GO:0016887~ATPase activity 2.71E-09
14 5.11 74 SM00320:WD40 3.23E-08
15 4.79 118 GO:0006396~RNA processing 2.01E-09
16 4.59 199 GO:0009057~macromolecule catabolic process 5.39E-06
17 3.55 107 GO:0015630~microtubule cytoskeleton 3.97E-09
18 3.33 143 GO:0007049~cell cycle 2.34E-08
19 2.92 93 SM00164:TBC 1.07E-04
20 2.83 110 GO:0016192~vesicle-mediated transport 1.61E-06
21 2.80 63 GO:0050662~coenzyme binding 1.28E-04
22 2.77 18 GO:0000502~proteasome complex 7.29E-04
23 2.67 60 IPR017907:Zinc finger, RING-type, conserved site 6.22E-04
24 2.60 17 GO:0008094~DNA-dependent ATPase activity 2.43E-05
25 2.47 58 GO:0000226~microtubule cytoskeleton organization 7.80E-05
26 2.37 63 mmu04120:Ubiquitin mediated proteolysis 1.24E-05
27 2.35 35 GO:0016779~nucleotidyltransferase activity 9.75E-06
28 2.32 87 GO:0031410~cytoplasmic vesicle 3.41E-04
29 2.21 69 GO:0044454~nuclear chromosome part 3.53E-05
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Table 5-2. Functional enrichment annotations for all genes clustered by chromatin 
density. C (continued) 
30 2.17 65 GO:0006399~tRNA metabolic process 6.30E-07
31 2.14 23 GO:0005777~peroxisome 0.0038551
32 2.13 51 GO:0005635~nuclear envelope 0.0014349
33 2.10 33 GO:0016591~DNA-directed RNA polymerase II, holoenzyme 1.42E-04
34 2.07 127 GO:0044432~endoplasmic reticulum part 0.0039044
35 2.06 20 mmu03440:Homologous recombination 6.37E-04
36 2.01 60 GO:0017148~negative regulation of translation 8.16E-04
37 1.96 39 GO:0031072~heat shock protein binding 0.0018478
38 1.95 21 GO:0016251~general RNA polymerase II transcription factor activity 0.0025262
39 1.85 15 GO:0016763~transferase activity, transferring pentosyl groups 0.0051492
40 1.85 13 SM00591:RWD 0.0029118
41 1.82 20 GO:0006904~vesicle docking during exocytosis 0.0019847
42 1.80 9 SM00292:BRCT 0.0066369
43 1.79 8 repeat:UIM 2 0.0132453
44 1.79 31 GO:0032318~regulation of Ras GTPase activity 2.51E-04
45 1.78 23 GO:0005788~endoplasmic reticulum lumen 0.007814
46 1.77 10 SM00451:ZnF_U1 0.0059322
47 1.71 34 IPR003960:ATPase, AAA-type, conserved site 0.0039138
48 1.69 14 GO:0000184~nuclear-transcribed mRNA catabolic process, nonsense-mediated decay 0.011816
49 1.66 19 GO:0051053~negative regulation of DNA metabolic process 0.0018967
50 1.63 7 IPR007052:CS domain 0.0151854
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Table 5-2. Functional enrichment annotations for all genes clustered by chromatin 
density. 
D. Cluster 4 (poised) 
A
nn
ot
at
io
n 
C
lu
st
er
 
En
ric
hm
en
t 
Sc
or
e 
# 
ge
ne
s First term in Annotation cluster 
p-value 
of first 
term
1 7.57 342 glycoprotein 2.26E-15
2 7.38 257 glycoprotein 2.26E-15
3 4.63 41 GO:0007155~cell adhesion 1.65E-05
4 4.63 50 extracellular matrix 2.45E-06
5 4.53 36 GO:0008092~cytoskeletal protein binding 3.61E-06
6 2.12 70 GO:0019001~guanyl nucleotide binding 5.32E-04
7 2.08 43 cell junction 4.19E-04
8 2.02 5 IPR002286:P2 purinoceptor 0.004303
9 1.96 22 GO:0030864~cortical actin cytoskeleton 0.001033
10 1.89 18 IPR001452:Src homology-3 domain 0.006353
11 1.70 40 IPR003598:Immunoglobulin subtype 2 2.55E-04
12 1.69 26 IPR000742:EGF-like, type 3 0.003714
13 1.69 27 GO:0006875~cellular metal ion homeostasis 0.002041
14 1.63 10 GO:0030016~myofibril 0.006196
15 1.62 27 GO:0060589~nucleoside-triphosphatase regulator activity 0.003001
16 1.51 7 IPR002049:EGF-like, laminin 0.003308
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Table 5-2. Functional enrichment annotations for all genes clustered by chromatin 
density. 
E. Cluster 5 (poised) 
A
nn
ot
at
io
n 
C
lu
st
er
 
En
ric
hm
en
t S
co
re
 
# 
ge
ne
s 
First term in Annotation cluster p-value of first term
1 5.69 83 GO:0030030~cell projection organization 1.79E-10
2 5.61 77 GO:0007155~cell adhesion 2.50E-07
3 5.08 84 GO:0031012~extracellular matrix 1.03E-07
4 4.92 368 GO:0043169~cation binding 1.14E-11
5 4.89 17 GO:0048762~mesenchymal cell differentiation 1.27E-07
6 4.84 673 membrane 1.70E-13
7 4.81 74 GO:0031225~anchored to membrane 1.87E-07
8 4.50 53 GO:0006928~cell motion 1.12E-06
9 4.16 49 IPR011993:Pleckstrin homology-type 2.23E-07
10 4.09 72 GO:0042995~cell projection 1.39E-05
11 3.92 58 GO:0008092~cytoskeletal protein binding 1.63E-06
12 3.89 160 GO:0005856~cytoskeleton 7.54E-07
13 3.82 59 GO:0030695~GTPase regulator activity 1.43E-06
14 3.78 21 domain:C2 2 2.38E-05
15 3.34 62 GO:0048568~embryonic organ development 2.48E-06
16 3.30 65 GO:0048568~embryonic organ development 2.48E-06
17 3.27 40 GO:0005874~microtubule 9.95E-05
18 2.95 52 egf-like domain 1.70E-07
19 2.69 25 IPR001478:PDZ/DHR/GLGF 2.01E-04
20 2.62 21 GO:0010876~lipid localization 6.51E-04
21 2.61 29 GO:0019900~kinase binding 6.08E-04
22 2.53 38 GO:0005929~cilium 8.29E-05
23 2.51 71 GO:0030054~cell junction 7.81E-06
24 2.50 50 GO:0035295~tube development 2.38E-04
25 2.38 70 GO:0000279~M phase 9.97E-05
26 2.29 55 GO:0051347~positive regulation of transferase activity 1.94E-04
27 2.21 30 IPR001452:Src homology-3 domain 0.001392
28 2.18 5 IPR006626:Parallel beta-helix repeat 0.001258
29 2.14 27 GO:0005912~adherens junction 0.00136
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Table 5-2. Functional enrichment annotations for all genes clustered by chromatin 
density. E (continued) 
30 2.13 13 IPR000859:CUB 8.31E-04
31 2.13 40 IPR018247:EF-HAND 1 2.91E-04
32 2.13 60 GO:0006816~calcium ion transport 3.07E-04
33 2.03 25 GO:0007157~heterophilic cell adhesion 5.79E-04
34 2.02 36 GO:0007017~microtubule-based process 9.49E-04
35 2.02 279 GO:0006796~phosphate metabolic process 3.23E-04
36 2.01 28 IPR003961:Fibronectin, type III 0.0014958
37 1.95 14 GO:0060271~cilium morphogenesis 0.0083704
38 1.89 60 GO:0005624~membrane fraction 0.0037505
39 1.89 63 IPR003599:Immunoglobulin subtype 9.36E-04
40 1.86 37 GO:0035295~tube development 2.38E-04
41 1.83 22 IPR000884:Thrombospondin, type 1 repeat 5.94E-04
42 1.83 13 GO:0048566~embryonic gut development 2.27E-04
43 1.82 17 IPR001660:Sterile alpha motif SAM 0.0024108
44 1.82 49 GO:0006897~endocytosis 0.0035407
45 1.74 19 IPR001715:Calponin-like actin-binding 1.87E-04
46 1.74 12 lipid transport 0.003025
47 1.69 30 GO:0046903~secretion 0.0073388
48 1.69 29 IPR012680:Laminin G, subdomain 2 0.0010998
49 1.67 11 GO:0005044~scavenger receptor activity 0.004358
50 1.66 21 GO:0051270~regulation of cell motion 0.001332
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Table 5-2. Functional enrichment annotations for all genes clustered by chromatin 
density. 
F. Cluster 6 (inactive) 
A
nn
ot
at
io
n 
C
lu
st
er
 
En
ric
hm
en
t 
Sc
or
e 
# 
ge
ne
s First term in Annotation cluster p-value of first term
1 63.63 1026 glycoprotein 7.63E-104
2 51.01 1327 glycoprotein 7.63E-104
3 18.28 185 IPR003599:Immunoglobulin subtype 3.92E-28
4 17.20 171 GO:0031012~extracellular matrix 3.24E-20
5 14.79 274 GO:0022838~substrate specific channel activity 2.43E-34
6 14.07 142 GO:0007155~cell adhesion 8.49E-19
7 10.78 305 GO:0005887~integral to plasma membrane 1.29E-11
8 10.75 87 GO:0007267~cell-cell signaling 2.52E-14
9 9.71 73 IPR003961:Fibronectin, type III 1.25E-14
10 9.39 99 IPR013151:Immunoglobulin 5.52E-19
11 8.64 87 GO:0030246~carbohydrate binding 6.17E-13
12 8.28 95 IPR013032:EGF-like region, conserved site 1.07E-13
13 8.23 85 GO:0015672~monovalent inorganic cation transport 1.26E-14
14 7.96 196 GO:0022834~ligand-gated channel activity 4.08E-16
15 6.67 40 IPR001400:Somatotropin hormone 3.18E-10
16 6.62 59 IPR001828:Extracellular ligand-binding receptor 2.62E-11
17 6.59 87 GO:0030246~carbohydrate binding 6.17E-13
18 6.30 108 palmitate 1.79E-08
19 5.74 34 IPR008160:Collagen triple helix repeat 9.54E-09
20 5.55 56 GO:0044057~regulation of system process 3.53E-09
21 4.94 41 GO:0008528~peptide receptor activity, G-protein coupled 9.29E-08
22 4.75 41 GO:0005262~calcium channel activity 2.43E-08
23 4.64 59 GO:0004866~endopeptidase inhibitor activity 7.68E-08
24 4.46 45 mmu05414:Dilated cardiomyopathy 1.50E-06
25 4.40 53 GO:0003001~generation of a signal involved in cell-cell signaling 1.34E-06
26 3.89 78 IPR016044:Filament 3.62E-07
27 3.65 20 IPR002350:Proteinase inhibitor I1, Kazal 3.00E-05
28 3.46 30 domain:DAPIN 1.16E-06
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Table 5-2. Functional enrichment annotations for all genes clustered by chromatin 
density. F (continued) 
29 3.42 47 GO:0050804~regulation of synaptic transmission 1.52E-06
30 3.31 9 IPR001734:Sodium/solute symporter 7.66E-05
31 3.27 55 IPR000233:Cadherin cytoplasmic region 4.12E-06
32 3.26 26 short sequence motif:Selectivity filter 1.58E-08
33 3.23 73 GO:0006928~cell motion 2.15E-05
34 3.21 45 neurotransmitter transport 1.07E-05
35 3.19 14 domain:DAPIN 1.16E-06
36 3.13 11 GO:0005248~voltage-gated sodium channel activity 7.32E-05
37 3.09 24 GO:0007611~learning or memory 3.57E-04
38 2.96 125 GO:0006928~cell motion 2.15E-05
39 2.80 27 IPR002035:von Willebrand factor, type A 1.07E-04
40 2.75 22 GO:0005540~hyaluronic acid binding 2.38E-04
41 2.63 33 GO:0007218~neuropeptide signaling pathway 1.33E-05
42 2.63 39 vision 4.89E-04
43 2.60 18 PIRSF005452:contactin 1.54E-04
44 2.59 33 GO:0006936~muscle contraction 2.44E-05
45 2.45 31 IPR001791:Laminin G 4.85E-05
46 2.38 8 IPR001283:Allergen V5/Tpx-1 related 6.47E-04
47 2.38 11 GO:0022839~ion gated channel activity 2.17E-04
48 2.34 55 GO:0008066~glutamate receptor activity 2.71E-06
49 2.34 48 GO:0005201~extracellular matrix structural constituent 1.62E-05
50 2.32 23 GO:0050954~sensory perception of mechanical stimulus 0.0014579
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Table 5-3. Classification of sex-biased genes by chromatin cluster.  
Each sex-biased gene was classified according to the cluster it belonged to in male liver 
and the cluster it belonged to in female liver (Fig. 5-6A). There are nine possible 
combinations for each set of sex-biased genes, which were collapsed into the six classes 
shown below (F1-F6 and M1-M6).  
Female-biased genes Male-biased genes 
Female 
liver Male liver 
# 
genes Class Male liver 
Female 
liver 
# 
genes Class 
Active Active 100 F1 Active Active 92 M1 Intermediate Intermediate 184 Intermediate Intermediate 175 
Inactive Inactive 126 F2 Inactive Inactive 100 M2 
Active Inactive 4 F3 Active Inactive 5 M3 Intermediate Inactive 17 Intermediate Inactive 3 
Active Intermediate 18 F4 Active Intermediate 19 M4 
Inactive Active 0 F5 Inactive Active 4 M5 Inactive Intermediate 14 Inactive Intermediate 8 
Intermediate Active 14 F6 Intermediate Active 17 M6 
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Table 5-4. Co-association of genes mapped to a TF binding site within 10 kb and genes 
containing a sex-biased chromatin mark in the promoter or gene body.  
A. Enrichment of sex-biased chromatin marks at female-biased genes (top) and male-
biased genes (bottom) that are targets of TF binding. Enrichment = [(# genes with TFBS 
and chromatin mark)/(# genes with TFBS)] / [(# total genes with chromatin mark)/(total 
genes)]. Enrichments are shown if they meet Fisher Exact Test p-value <0.05 and contain 
at least 5 genes. Among female-biased genes, the highest fold enrichment is for CUX2 
targets, having male-enriched K27me3. B. Jaccard matrices for TF targets and chromatin 
marks for female-biased genes. Each value corresponds to the intersection divided by the 
union of each pair of genes, i.e. (# Female-biased genes that are a target of a particular TF 
within 10kb AND contain a particular chromatin modification at the promoter or gene 
body)/(# Female-biased genes that are a target of a particular TF within 10kb OR contain 
a particular chromatin modification at the promoter or gene body). 
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Table 5-4. Co-association of genes mapped to a TF binding site within 10 kb and 
genes containing a sex-biased chromatin mark in the promoter or gene body.  
A 
Female-biased genes CUX2 STAT5-female BCL6 
FOXA2-
female 
K9me3-male 
K27me3-male 4.69 2.75 1.39 4.30 
K4me1-female 2.15 2.05 1.40 2.22 
K27ac-female (gene body) 2.67 2.37 1.32 3.00 
K27ac-female (promoter) 3.25 2.32 3.12 
K4me3-female 3.47 2.55 2.81 
K36me3-female 4.34 3.38 3.96 
 
Male-biased genes CUX2 STAT5-male 
FOXA1-
male 
FOXA2-
male 
K9me3-female 
K27me3-female 
K4me1-male 1.67 1.77 1.67 1.74 
K27ac-male (gene body) 1.63 1.89 2.07 4.02 
K27ac-male (promoter) 2.25 3.57 
K4me3-male 1.66 2.09 2.86 
K36me3-male 2.20 
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Table 5-4. Co-association of genes mapped to a TF binding site within 10 kb and 
genes containing a sex-biased chromatin mark in the promoter or gene body.  
B 
Female-biased genes all F1 F2 F3 F4 F5 F6 
C
U
X2
 w
ith
…
 
K9me3-male 0.033 0.029 0.083 0.000 0.000 0.000 0.000
K27me3-male 0.278 0.167 0.353 0.583 0.250 0.000 0.000
K4me1-female 0.188 0.153 0.185 0.500 0.000 0.200 0.000
K27ac-female (gene body) 0.220 0.145 0.238 0.533 0.200 0.333 0.000
K27ac-female (promoter) 0.129 0.083 0.063 0.417 0.000 0.000 0.000
K4me3-female 0.119 0.028 0.083 0.417 0.250 0.000 0.000
K36me3-female 0.191 0.083 0.188 0.600 0.333 0.000 0.000
ST
A
T5
-fe
m
al
e 
w
ith
…
 
K9me3-male 0.028 0.016 0.091 0.000 0.000 0.000 0.000
K27me3-male 0.186 0.111 0.259 0.500 0.167 0.000 0.000
K4me1-female 0.274 0.207 0.387 0.533 0.000 0.800 0.000
K27ac-female (gene body) 0.284 0.253 0.276 0.471 0.143 0.400 0.250
K27ac-female (promoter) 0.104 0.031 0.167 0.462 0.000 0.000 0.000
K4me3-female 0.098 0.048 0.091 0.357 0.167 0.000 0.000
K36me3-female 0.173 0.081 0.364 0.385 0.200 0.000 0.000
B
C
L6
 w
ith
…
 
K9me3-male 0.017 0.017 0.040 0.000 0.000 0.000 0.000
K27me3-male 0.098 0.049 0.200 0.429 0.100 0.000 0.000
K4me1-female 0.224 0.206 0.250 0.294 0.200 0.429 0.167
K27ac-female (gene body) 0.176 0.137 0.258 0.333 0.200 0.143 0.182
K27ac-female (promoter) 0.053 0.024 0.111 0.286 0.000 0.000 0.000
K4me3-female 0.059 0.033 0.040 0.385 0.100 0.000 0.000
K36me3-female 0.063 0.033 0.103 0.308 0.111 0.000 0.000
FO
XA
2-
fe
m
al
e 
w
ith
…
 
K9me3-male 0.035 0.032 0.059 0.000 0.000 0.000 0.000
K27me3-male 0.239 0.147 0.400 0.231 0.333 0.000 0.000
K4me1-female 0.184 0.127 0.321 0.286 0.000 0.000 0.333
K27ac-female (gene body) 0.240 0.236 0.292 0.250 0.250 0.000 0.000
K27ac-female (promoter) 0.119 0.059 0.158 0.273 0.000 0.000 0.000
K4me3-female 0.092 0.063 0.059 0.167 0.333 0.000 0.000
K36me3-female 0.167 0.059 0.333 0.182 0.500 0.000 0.000
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Table 5-5. Sex-biased DHS categorized by enhancer status.  
Presence of male-biased, female-biased, or sex-independent K4me1 or K27ac sites and their enrichment compared to 
background, comprised of all sex-independent DHS. DHS regions were defined as peak summit + 500 bp in both directions, 
and at least 200 bp overlap with a K4me1 or a K27ac site.  
Enhancer status 
Female-biased DHS Male-biased DHS 
# 
sites
% of 
sites
Enrichment* 
# 
sites 
% of 
sites
Enrichment* 
p-value
fold 
enrich p-value 
fold 
enrich
Female-enriched K4me1 and/or K27ac 460 35% 0.0E+00 18.1 5 0% 1.3E-12 0.12 
Male-enriched K4me1 and/or K27ac 6 0% 1.1E-04 0.26 804 30% 0.0E+00 16.3 
Sex-independent K4me1 and K27ac 453 34% 1.2E-38 0.65 1285 47% 4.1E-03 0.94 
Sex-independent K4me1 only 304 23% 4.6E-04 1.21 221 8% 6.8E-11 0.67 
Sex-independent K27ac only 7 1% 9.2E-20 0.11 140 5% 2.6E-05 0.72 
Neither K4me1 nor K27ac 99 7% 5.2E-40 0.36 259 10% 2.0E-103 0.36 
*Enrichment compared to a background set of sex-independent DHS that are distant from sex-biased genes. 
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Table 5-6. Association between categories of DHS sites and classes of genes.  
For each set of DHS sites (male-biased (A), female-biased (B), the nearest sex-biased 
gene TSS within 250kb was obtained. Shown here are the number of DHS sites of each 
category that are nearest a sex-biased gene of each class, with the enrichment for that 
association compared to the background set of all sex-biased genes and all female-biased, 
male-biased, or sex-independent DHS sites. Enrichments and depletions that meet p<0.05 
are shown. Subsets of male-biased DHS sites are enriched at female-biased genes and 
may be silencers.  
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Table 5-6. Association between categories of DHS sites and classes of genes.  
A. Female-biased DHS sites 
Enhancer status Gene class for nearest sex-
biased gene # sites
fold 
enrichment p-value K4me1 K27ac 
female female female F3 8 4.09 1.2E-03 
female female female F5 5 10.99 2.8E-04 
female female female F2 12 2.24 1.0E-02 
female sex-indep female F1 13 2.06 7.9E-03 
sex-indep female female F1 45 1.65 1.5E-03 
sex-indep female female F3 20 4.47 8.1E-07 
sex-indep female female F2 26 1.73 1.2E-02 
None female female F3 5 5.26 2.9E-03 
None female female F2 11 4.47 1.7E-05 
sex-indep sex-indep female F3 8 0.36 4.0E-03 
sex-indep sex-indep female F2 27 0.51 6.2E-04 
sex-indep none female F3 3 0.21 1.8E-03 
None none female F1 5 0.33 8.7E-04 
 
B. Male-biased DHS sites 
Enhancer status Gene class for nearest 
sex-biased gene # sites 
fold 
enrichment p-value K4me1 K27ac 
Male male male M3 16 7.01 4.7E-08 
Male male female F2 13 2.85 1.6E-03 
sex-indep sex-indep male M1 267 1.22 1.2E-02 
sex-indep sex-indep male M6 19 2.64 1.9E-02 
sex-indep sex-indep male M2 75 1.49 2.5E-02 
sex-indep sex-indep female F1 73 1.45 3.7E-02 
sex-indep none female F2 11 2.30 1.8E-02 
None sex-indep male M1 56 2.27 2.2E-09 
None sex-indep male M4 22 6.52 5.8E-11 
Male none male M1 16 0.40 9.4E-06 
Male none female F1 3 0.29 1.6E-02 
sex-indep sex-indep male M4 28 0.56 1.0E-02 
sex-indep sex-indep male M3 13 0.50 4.2E-02 
sex-indep none male M1 10 0.23 1.4E-10 
sex-indep none male M4 1 0.14 1.3E-02 
sex-indep none male M3 0 0.00 4.5E-02 
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Table 5-7. Enrichments for TF binding at categories of DHS and subsets mapped to 
different gene classes. 
A: categorization of DHS by enhancer modifications. B-D: Enrichment for STAT5, 
BCL6, CUX2, and FOXA1/2 binding at categories of (B) Female-biased DHS, (C) Male-
biased DHS, and (D) Sex-independent DHS. B-D show enrichments for TF binding at 
categories of DHS, shown in Fig. 5-8D, and also for subsets of each category of DHS that 
map to different classes of sex-biased genes.  In tables B-D, columns that had no 
enrichments or depletions (p<0.001, and at least 5 sites for enrichment) are not shown. To 
obtain target genes, each DHS was mapped to the nearest gene TSS within 250 kb; 
specifically, the nearest sex-biased gene TSS for sex-biased DHS, and the nearest liver-
expressed gene TSS for sex-independent DHS. Enrichments for TF binding were 
calculated for each category of sex-biased DHS, and for sex-independent DHS whose 
nearest gene TSS was sex-biased in its expression. B-D also show the numbers of DHS in 
each enriched or depleted group and their associated p-value. 
A. 
Category 
K27ac mark at 
DHS 
K4me1 mark at 
DHS 
K27ac_female Female-biased Any 
K4me1_female Sex-independent or absent Female-biased 
K27ac_male Male-biased Any 
K4me1_male Sex-independent or absent Male-biased 
K27ac_sex-indep Sex-independent Sex-independent or absent 
K4me1_sex-indep Absent Sex-independent 
neither Absent Absent 
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Table 5-7. Enrichments for TF binding at categories of DHS and subsets mapped to different gene classes. 
enhancer 
modifications at DHS 
B. Enrichment at Female-biased DHS 
GH-induced GH-suppressed STAT5-female CUX2 FOXA2-female 
fold 
enrich 
# 
DHS p-value
fold 
enrich # DHS p-value
fold 
enrich # DHS p-value 
fold 
enrich
# 
DHS p-value
fold 
enrich
# 
DHS p-value
K27ac_female 11.0 78 1.E-56 0.0 1 4.E-17 16.2 67 2.E-58       29.2 33 2.E-36
K4me1_female 8.9 51 1.E-32 0.1 2 2.E-12 6.5 22 8.E-12     24.0 22 5.E-23
K27ac_sex-indep 7.1 91 9.E-48 0.0 3 1.E-28 6.9 52 9.E-27     8.8 18 1.E-11
K4me1_sex-indep 8.4 71 6.E-43 0.0 2 4.E-19 6.7 33 3.E-17     11.9 16 2.E-12
neither 4.4 12 2.E-05 0.3 4 7.E-04             11.5 5 9.E-05
K27ac_female                 
---Female_F1 12.4 22 2.E-18 0.0 0 4.E-05 16.4 17 3.E-16     35.5 10 4.E-13
---Female_F2 15.2 21 7.E-20 0.0 0 5.E-04 16.1 13 1.E-12 6.6 5 1.E-03 49.9 11 5.E-16
---Female_F3 13.2 12 4.E-11       22.5 12 9.E-14             
K4me1_female                 
---Female_F1 11.4 12 3.E-10                   29.9 5 8.E-07
K27ac_sex-indep                 
---Female_F1 8.8 19 4.E-13 0.0 0 4.E-06 9.5 12 6.E-09     14.5 5 3.E-05
---Female_F2 8.0 6 8.E-05                         
K4me1_sex-indep                 
---Female_F1 9.8 13 4.E-10 0.0 0 8.E-04                   
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Table 5-7. Enrichments for TF binding at categories of DHS and subsets mapped to different gene classes. 
enhancer 
modifications at 
DHS 
C. Enrichment at Male-biased DHS 
GH-induced GH-suppressed STAT5-male BCL6 CUX2 FOXA1-male FOXA2-male 
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K27ac_male 0.0 0 5e-05 6.4 366 4e-262 34.9 143 6e-168 1.8 45 3e-04 3.9 21 2e-07 9.5 109 1e-70 44.3 96 5e-119 
K4me1_male 0.0 0 3e-05 6.4 371 5e-263 31.3 131 3e-147     3.7 20 1e-06 7.3 86 1e-46 35.8 79 6e-91 
K27ac_sex-indep 0.1 2 7e-14 6.1 1246 0e+00 18.1 266 4e-218 2.3 211 3e-28 5.7 110 4e-45 3.8 157 2e-43 11.2 87 6e-56 
K4me1_sex-indep     5.9 189 9e-122 18.7 43 5e-40     5.3 16 1e-07 4.5 29 3e-11 13.2 16 3e-13 
neither       5.2 191 2e-102 17.3 46 6e-41             3.5 26 6e-08 17.7 25 7e-23 
K27ac_male                         
---Male_M1     6.7 74 2e-58 46.7 37 8e-52 2.8 14 4e-04     10.8 24 2e-18 33.4 14 2e-17 
---Male_M2     5.7 17 1e-11                     
---Male_M3       6.7 19 2e-15 38.9 8 2e-11             13.8 8 5e-08 55.1 6 1e-09 
K4me1_male                         
---Male_M1       6.7 52 1e-41 27.0 15 1e-17             5.8 9 2e-05 23.8 7 2e-08 
K27ac_sex-indep                         
---Female_F1     6.3 68 3e-49 15.5 12 2e-11 4.2 20 4e-08 6.9 7 7e-05         
---Female_F2     6.0 23 4e-16 18.0 5 8e-06                 
---Male_M1     6.2 287 5e-196 16.8 56 1e-48     5.7 25 6e-12 2.7 25 1e-05 9.7 17 8e-12 
---Male_M2     6.1 69 2e-47 19.7 16 2e-16     5.6 6 7e-04         
---Male_M4       3.8 27 6e-11                               
neither                         
---Male_M1       5.9 38 1.E-25 13.0 6 7.E-06                         
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Table 5-7. Enrichments for TF binding at categories of DHS and subsets mapped to 
different gene classes. 
enhancer 
modifications at 
DHS 
C. Enrichment at Sex-independent DHS (continued on next page) 
GH-induced GH-suppressed STAT5-female STAT5-male BCL6 
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K27ac_female 6.7 28 6e-15 
K4me1_female 3.0 13 5e-04 0.2 4 3e-07 7.8 20 2e-12 
K27ac_male 3.2 90 5e-26 14.3 29 4e-24 
K4me1_male 2.0 66 3e-08 7.9 19 1e-11 
K27ac_sex-indep 1.8 1715 1e-113 2.8 176 6e-27 2.0 898 7e-73
K4me1_sex-indep 0.7 120 1e-06 3.0 59 1e-12 
neither 0.2 7 2e-11 0.4 84 1e-33 0.2 6 1e-05 0.2 25 2e-23
K27ac_female 
---Female_F1 7.9 15 1e-09 
---Female_F2 8.1 5 4e-04 
---Female_F3 
K4me1_female 
---Female_F1 0.1 1 1e-04 7.4 9 4e-06 
---Female_F2 16.0 7 2e-07 
K27ac_male 
---Male_M1 3.5 50 3e-17 18.5 19 1e-18 
K4me1_male 
---Male_M1 2.1 29 1e-04 9.8 10 1e-07 
---Male_M2 2.6 13 7e-04 13.9 5 3e-05 
K27ac_sex-indep 
---Female_F1 2.0 120 5e-12 1.8 64 9e-06 2.3 351 1e-44
---Female_F2 1.8 51 1e-04
---Female_F4 2.4 27 4e-05
---Female_F6 3.1 24 8e-07
---Male_M1 2.4 835 3e-132 4.6 104 2e-33 1.8 290 3e-20
---Male_M2 2.1 155 2e-19 3.0 15 2e-04 2.0 69 1e-07
---Male_M3 3.7 42 3e-16 6.7 5 1e-03 
---Male_M4 2.7 76 3e-17 8.1 15 1e-09 
---Male_M5 
---Male_M6 1.9 81 2e-09 
K4me1_sex-indep 
---Female_F1 0.5 33 2e-05 4.0 28 2e-09 
---Female_F2 4.6 12 2e-05 
---Female_F3 7.6 6 1e-04 14.7 7 4e-07 5.7 11 1e-06
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Table 5-7. Enrichments for TF binding at categories of DHS and subsets mapped to 
different gene classes. 
enhancer 
modifications at  
DHS 
C. Enrichment at Sex-independent DHS (continued from previous page)  
CUX2 FOXA1-female FOXA2-female FOXA1-male FOXA2-male 
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K27ac_female 4.4 17 7e-07 5.2 7 5e-04 12.4 14 2e-11 
K4me1_female 11.5 8 7e-07 
K27ac_male 3.0 17 7e-05 11.2 12 1.7E-09
K4me1_male 3.1 21 6e-06 7.1 9 7.4E-06
K27ac_sex-indep 2.3 224 2e-25 1.3 238 3e-04 
K4me1_sex-indep 2.4 41 5e-07 5.8 28 1e-12 
neither 0.4 16 7e-07 
K27ac_female 
---Female_F1 17.5 9 4e-09 
---Female_F2 
---Female_F3 10.0 5 1e-04
K4me1_female 
---Female_F1 15.1 5 2e-05 
---Female_F2 
K27ac_male 
---Male_M1 11.0 6 2.1E-05
K4me1_male 
---Male_M1 
---Male_M2 
K27ac_sex-indep 
---Female_F1 2.0 65 8e-07
---Female_F2 
---Female_F4 
---Female_F6 
---Male_M1 2.4 81 3e-11 1.5 102 5e-05 
---Male_M2 3.2 24 1e-06
---Male_M3 
---Male_M4 7.8 22 2e-13
---Male_M5 7.5 6 2e-04
---Male_M6 
K4me1_sex-indep           
---Female_F1 2.9 17 2e-04   8.8 15 6e-10     
---Female_F2 4.5 10 9e-05   11.1 7 5e-06     
---Female_F3                               
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Figure 5-1. Chromatin mark read densities in gene bodies and across chromosomes.  
A: Mean and 95% confidence intervals for ChIP-seq read densities within gene bodies of 
top 1000, middle 1000, and bottom 1000 genes by expression in male liver (left) and 
female liver (right). Average gene expression for each category of genes (log2(RPKM), 
right y-axis) is shown in yellow. B: Correlation between reads in promoters or coding 
regions, as indicated between each of the six chromatin modifications and gene 
expression as measured by RNA-seq or by microarray (Wauthier et al. 2010 and Chapter 
3). C: Male/Female ratio in total ChIP-seq reads for each chromatin modification on each 
chromosome. D: Genomic localization of reads for each of the six chromatin 
modifications, generated using CEAS (Shin et al. 2009). K9me3 is mostly intergenic: 
67% of K9me3 reads are intergenic, compared to 50% for K27me3 and ≤ 25% for each 
of the other marks. E: Read profiles across gene bodies and at TSSs for each mark at 
three sets of genes: top 1000 by expression in liver, middle 1000 by expression in liver, 
and bottom 1000 by expression in liver. Figures were generated using CEAS (Shin et al. 
2009). Read profiles across gene bodies were generated by averaging gene lengths into 
meta-genes with three 1000-bp segments as described in CEAS (Shin et al. 2009). 
 
 
  
237 
 
 
 
Figure 5-1. Chromatin mark read densities in gene bodies and across chromosomes.  
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Figure 5-1. Chromatin mark read densities in gene bodies and across chromosomes.  
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Figure 5-1. Chromatin mark read densities in gene bodies and across chromosomes.  
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Figure 5-1. Chromatin mark read densities in gene bodies and across chromosomes.  
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Figure 5-1. Chromatin mark read densities in gene bodies and across chromosomes.  
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Figure 5-1. Chromatin mark read densities in gene bodies and across chromosomes.  
E, contd. 
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Figure 5-1. Chromatin mark read densities in gene bodies and across chromosomes.  
E, contd. 
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Figure 5-2. Chromatin states in mouse liver. 
A: correlations between each state in a 20-state model to the most similar state in smaller 
models, ranging from 5 to 19. Green = highest correlation, Red = lowest correlation. B: 
Calculated from numbers in A. For each smaller model, number of states from the 20-
state model that are not represented, i.e., that have a correlation of 0.9 or less. C: 
Emission and transition probabilities for the chromatin states in the 14-state model. 
Darker shade of blue corresponds to greater emission frequency of a chromatin 
modification in that state or greater transition probability from one state to another. State 
2, which has low emission parameters for all marks, appears to be an inactive state based 
on its high transition probability with State 3, which is a K9me3-containing inactive state. 
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Figure 5-2. Chromatin states in mouse liver. 
A 
state in 20-
state model 
# states in model 
5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 
1 0.9990 0.9990 0.9991 0.9991 0.9991 0.9995 0.9992 0.9992 0.9993 0.9994 0.9994 0.9999 0.9999 0.9999 1.0000 1.0000 
2 0.9995 0.9996 0.9995 0.9995 0.9994 0.9994 0.9995 0.9995 0.9994 0.9994 0.9994 0.9993 0.9993 0.9993 0.9988 1.0000 
3 0.9055 0.9055 0.9288 0.9259 0.9288 0.9640 0.9291 0.9468 0.9446 0.9373 0.9388 0.9339 0.9522 0.9539 0.9963 1.0000 
4 0.6831 0.7993 0.8478 0.7961 0.7961 0.8380 0.8443 0.8456 0.8423 0.8442 0.8436 0.9160 0.9179 0.9183 0.9998 1.0000 
5 0.8743 0.9494 0.9503 0.9508 0.9507 0.9888 0.9974 0.9972 0.9976 0.9972 0.9973 1.0000 1.0000 1.0000 1.0000 1.0000 
6 0.7827 0.7970 0.8240 0.8863 0.8863 0.8645 0.9955 0.9986 0.9996 0.9992 0.9996 0.9999 1.0000 1.0000 1.0000 1.0000 
7 0.5866 0.8093 0.8143 0.8168 0.8168 0.8308 0.8339 0.7976 0.7700 0.8402 0.8298 0.8344 0.8232 0.8251 1.0000 1.0000 
8 0.7443 0.7659 0.7596 0.7546 0.7547 0.7665 0.7683 0.9855 0.8980 0.9821 0.9952 0.9944 0.9963 0.9960 1.0000 1.0000 
9 0.8390 0.9628 0.9587 0.9563 0.9563 0.9511 0.9497 0.9219 0.9565 0.9210 0.9999 0.9999 1.0000 0.9999 1.0000 1.0000 
10 0.8790 0.8589 0.8497 0.8604 0.8604 0.9989 0.9989 0.9992 0.9989 0.9994 0.9993 0.9991 1.0000 1.0000 1.0000 1.0000 
11 0.6361 0.6588 0.6721 0.6017 0.6023 0.8396 0.9560 0.9751 0.9773 0.9103 0.9352 0.9378 0.9879 0.9879 0.9968 1.0000 
12 0.0031 0.1314 0.1347 0.1882 0.1889 0.4520 0.8645 0.8313 0.8228 1.0000 1.0000 0.9999 0.9999 0.9956 0.9999 1.0000 
13 0.4384 0.4726 0.4837 0.6529 0.6535 0.7472 0.8446 0.8085 0.8067 0.8915 0.8645 0.8627 0.9999 0.9999 1.0000 1.0000 
14 0.5316 0.8485 0.8562 0.8619 0.8618 0.8596 0.8599 0.9393 0.9989 0.9402 0.9983 0.9982 0.9992 0.9992 1.0000 1.0000 
15 0.9721 0.9792 0.9807 0.9937 0.9937 0.9967 0.9977 0.9988 0.9991 0.9982 0.9985 0.9996 0.9999 0.9999 1.0000 1.0000 
16 0.8014 0.8223 0.8311 0.8585 0.8579 0.8613 0.8741 0.8798 0.8673 0.8660 0.8669 0.8615 0.8627 0.8629 0.8619 1.0000 
17 0.7998 0.8294 0.8554 0.8737 0.8730 0.8525 0.8818 0.8722 0.9988 0.9714 0.9761 0.9803 0.9994 0.9880 0.9998 1.0000 
18 0.9871 0.9872 0.9886 0.9888 0.9996 0.9996 0.9996 0.9995 0.9995 1.0000 1.0000 1.0000 1.0000 0.9993 1.0000 1.0000 
19 0.9816 0.9815 0.9801 0.9802 0.9998 0.9993 0.9998 0.9999 0.9994 0.9999 1.0000 1.0000 0.9999 0.9931 0.9999 1.0000 
20 0.6391 0.6434 0.6547 0.6538 0.9986 0.9993 0.9986 0.9983 0.9994 0.9999 0.9998 0.9999 0.9999 0.9982 1.0000 1.0000 
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Figure 5-2. Chromatin states in mouse liver. 
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Figure 5-2. Chromatin states in mouse liver. 
C 
Repressive states 
State1 (K27me3) 
State3 (K9me3) 
State2 (?) 
Active states 
States 7 and 8: promoter (K4me3) 
State14: transcribed (K36me3) 
State13: transcribed (?) 
States 5-6, 9-11: enhancers with different combinations of K27ac, K4me1, 
DHS. 
Other 
State12: K27me3 with activating marks 
State4: no marks 
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Figure 5-3. Chromatin environments surrounding TSSs and DHS summits.  
A: Chromatin states surrounding TSSs of liver-expressed genes (left) and non-liver-
expressed genes (right). The y-axis represents the frequency with which each 200-bp bin 
in the 4 kb region surrounding the TSS is assigned each of the 14 chromatin states shown 
in Fig. 5-2C. B: Average ChIP-seq read densities for each of the six chromatin marks and 
DNase hypersensitivity in 4kb surrounding TSS of liver-expressed genes (left) and non-
liver-expressed genes (right). C-D: Chromatin states (C) and chromatin mark read 
densities (D) surrounding DHS peak summits in male liver (left) and female liver (right), 
for male-biased DHS (left panel) and female-biased DHS (right panel). E: Chromatin 
mark read densities surrounding TSSs in male liver (left) and female liver (right) for  
male-biased genes (left panel) and female-biased genes (right panel). F: Chromatin states 
(top panel) and chromatin mark read densities (bottom panel) surrounding sex-
independent DHS summits in male liver (left) and female liver (right). G: Chromatin 
states surrounding sex-independent, male-biased, and female-biased genes in male liver 
(left) and female liver (right). 
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Figure 5-3. Chromatin environments surrounding TSSs and DHS summits.  
A-B 
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Figure 5-3. Chromatin environments surrounding TSSs and DHS summits.  
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Figure 5-3. Chromatin environments surrounding TSSs and DHS summits.  
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Figure 5-3. Chromatin environments surrounding TSSs and DHS summits.  
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Figure 5-4. Genes clustered by chromatin densities around TSS and TES. 
A: Top: Heatmap for 15,533 liver-expressed and non-liver-expressed genes clustered by 
chromatin read densities in 200-bp non-overlapping windows within 2 kb regions 
surrounding the TSS and TES. Bottom: Aggregate plots of chromatin density at each 
cluster around the TSS (left) and TES (right). B: Top: Gene expression boxplots for each 
cluster. Bottom: fraction of genes in each cluster expressed with log2(RPKM) ≥ 1. C: 
Chromatin state environments, as in Fig. 5-3A and 5-3C, surrounding the TSS (left) and 
TES (right) of the six gene clusters. D: Top: Percentage of the gene body covered by a 
DHS domain (SICER island), for each of the 6 clusters. Bottom: Percentage of genes in 
each cluster for which at least 50% of the gene body is covered by a SICER island. DHS 
islands are from (Ling et al. 2010, Chapter 4). 
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Figure 5-4. Genes clustered by chromatin densities around TSS and TES. 
A 
K9me3 K27me3 K4me1 K27ac K4me3 K36me3 DHS 
TS
S
  
TE
S
  
TS
S
  
TE
S
  
TS
S
  
TE
S
  
TS
S
  
TE
S
  
TS
S
  
TE
S
  
TS
S
  
TE
S
  
TS
S
  
TE
S
  
         
 
  
255 
 
 
 
Figure 5-4. Genes clustered by chromatin densities around TSS and TES. 
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Figure 5-4. Genes clustered by chromatin densities around TSS and TES. 
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Figure 5-4. Genes clustered by chromatin densities around TSS and TES. 
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Figure 5-5. CAR, AhR, PXR, and PPAR-responsive genes mapped to the six gene 
clusters.  
For each category of up-regulated (A) or down-regulated (B) gene, the percentage that 
belong to each of the six clusters are shown. Enrichments for each geneset belonging to a 
cluster compared to the background set of all 15,533 genes are indicated with a black 
asterisk and depletions are indicated with a gray asterisk. One asterisk indicates p<0.05; 
two asterisks indicate p<0.01. “PPARa” = PPARα, “PPARbd” = PPARβ/δ. 
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Figure 5-5. CAR, AhR, PXR, and PPAR-responsive genes mapped to the six gene 
clusters.  
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Figure 5-6. Characteristics of sex-biased genes classified by chromatin cluster.  
A. Heatmaps of chromatin mark read densities for female-biased (top) and male-biased 
(bottom) genes clustered separate in female (left) and male (right) liver by read densities 
in TSS+/-1kb and TES+/-1kb. B. Gene expressions for genes in each cluster in livers of 
each sex. C. Correspondence between sex-biased gene clusters and all-gene clusters 
(shown in Fig. 5-4) for male-biased genes in male liver and female-biased genes in 
female liver. D. Chromatin marks identified using MACS/SICER associated with each 
class of female-biased (top) and male-biased (bottom) gene, along with sex-specificity of 
each chromatin mark. “none” indicates there was no MACS or SICER-identified mark 
associated with the promoter (K4me3) or gene body (all other modifications). Asterisks 
indicate chromatin marks for which the distribution of (male, female, sex-indep, none) 
for that category of genes is significantly different from that for the set of all male-biased 
or all female-biased genes (p<0.05; Chi-square test). Although a small number of sex-
biased genes (classes F5, F6 and M5, M6) apparently belong to a higher chromatin 
activity cluster  in the sex where they are less highly expressed (e.g. F6 genes belong to 
the intermediate cluster among the three chromatin-based clusters of female-biased genes 
in female liver, but to the active chromatin cluster according to the independent clustering 
carried out for male liver), a large majority of chromatin mark peaks and domains 
associated with these gene classes were either sex-independent or were absent, indicating 
that these genes do not exhibit significant sex-differences in chromatin that are opposite 
to the sex-difference in expression. E. Gene expression log2 sex ratios for classes of 
female-biased genes (left) and male-biased genes (right). Dashed horizontal line indicates 
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median log2 sex ratio for all female-biased genes or all male-biased genes. F. Fraction of 
sex-biased genes that lack a sex-biased chromatin mark up to 100kb from the gene body. 
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Figure 5-6. Characteristics of sex-biased genes classified by chromatin cluster.  
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Figure 5-6. Characteristics of sex-biased genes classified by chromatin cluster.  
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Figure 5-6. Characteristics of sex-biased genes classified by chromatin cluster.  
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Figure 5-6. Characteristics of sex-biased genes classified by chromatin cluster.  
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Figure 5-6. Characteristics of sex-biased genes classified by chromatin cluster.  
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Figure 5-6. Characteristics of sex-biased genes classified by chromatin cluster.  
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Figure 5-7. Enrichments among the 12 classes of sex-biased genes for being TF 
targets.  
A: Female-biased genes; no enrichments were seen for female-enriched FOXA1 binding. 
B: Male-biased genes. Fold-enrichment for being a target of each TF (i.e., within 10 kb of 
a TF binding site), compared to the background of all liver-expressed genes. A-B: 
Asterisks mark gene classes with sex-biased local chromatin marks. Data is shown for 
enrichments that meet p<0.05 and that contain at least 5 genes. C: CUX2 binding and 
male-enriched K27me3 at female-biased genes. 
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Figure 5-7. Enrichments among the 12 classes of sex-biased genes for being TF 
targets.  
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Figure 5-8. Relationship between TF binding and sex-bias in DHS and chromatin 
marks at regulatory sites.  
A: GSEA analysis for DHS ranked by M/F ratio in (from left to right) DNase 
hypersensitivity, K4me1, K27ac, and K27me3. In each panel, the x-axis represents DHS 
ranked in male/female ratio in each mark, from male-bias on the left to female-bias on the 
right. The y-axis represents the running enrichment score for each TF. Male-enriched 
STAT5, FOXA1, and FOXA2 binding are enriched towards the male-biased end of the 
ranked lists for DHS, K4me1, and K27ac, and enriched towards the female-biased end of 
the ranked list for K27me3. The opposite pattern is seen for female-enriched STAT5 and 
FOXA2 binding. 
B: Fractions of ChIP-seq determined TFBS that occur at DHS in bins of 1000 DHSs 
each, ranked by M/F ratio in DNase hypersensitivity (blue), K4me1 (purple), K27ac 
(green), and K27me3 (red).  On the x-axis in each panel are ranked DHS bins with high 
M/F ratio (male-bias) towards the left and low M/F ratio (female-bias) towards the right. 
The y-axis indicates the fraction of binding sites of (from left-right, top then bottom) 
male-enriched STAT5, female-enriched STAT5, male-enriched FOXA2, female-enriched 
FOXA2, male-enriched FOXA1, female-enriched FOXA1, BCL6 in male, and CUX2 in 
female. 
C: Scatter plots of sex-ratios in DNase hypersensitivity, K4me1, K27ac, and K27me3 
(left to right) on the y-axis and sex-ratios in STAT5, FOXA1, and FOXA2 binding (first 
three rows) and BCL6 and CUX2 binding intensity (rows 4 and 5) on the x-axis. Pearson 
correlations with p-values are shown in top left of each panel. For FOXA1, FOXA2 and 
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STAT5, male-enriched binding sites are shown in blue, female-enriched binding sites in 
red, and sex-independent in black. For FOXA1, there are very few female-enriched 
binding sites, which results in curved plots, especially in relation to DNase 
hypersensitivity (leftmost panel) where there is a relationship for male-enriched sites but 
not for female-enriched sites. For BCL6 and CUX2, green line shows linear regression 
line. For BCL6 no relationships are seen, but for CUX2, there is some correlation 
between CUX2 binding intensity and male-bias in DNase hypersensitivity. 
D: Enrichment of ChIP-seq binding sites at male-biased, female-biased, and sex-
independent DHS categorized by their patterns of enhancer-associated modifications 
K27ac and K4me1. DHS are assigned enhancer categories in a hierarchical manner as 
described in Methods. Sex-independent DHS shown here are limited to those whose 
nearest gene TSS within 250 kb was sex-biased in expression. Enrichments and 
depletions that met p<0.001 are shown, and enriched groups were additionally required to 
contain at least 5 DHS sites. Green = enrichment, purple = depletion. Numbers of DHS 
and enrichment p-values associated with these enrichment scores are shown in the upper 
sections of Table 5-7 B-D. Mapping of these DHS to the nearest gene TSS within 250 kb 
(to include more distal regulatory sites compared to the 10 kb distance used to map TF 
targets in Fig. 5-7) yielded enrichments for enhancer categories further broken down by 
the gene class of their target genes (Table 5-7 B-D).   
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Figure 5-8. Relationship between TF binding and sex-bias in DHS and chromatin 
marks at regulatory sites.  
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Figure 5-9. K4me1 read profiles at sex-biased DHS sites.  
K4me1 read density in male liver (blue) and female liver (red). Read counts are 
normalized to the total number of DHS in each panel. A: Male-biased DHS with and 
without FOXA1 or FOXA2 binding. B: Male-biased DHS with male-enriched STAT5 
binding, with and without FOXA1 binding or FOXA2 binding. C: Female-biased DHS 
and FOXA2 binding. As shown in Fig. 5-3F, the K4me1 profile at sex-independent DHS 
exhibits a similar, bimodal distribution in male and female liver. D: Male-biased DHS 
with and without STAT5 binding. E: Male-biased DHS with male-enriched STAT5 
binding, with and without CUX2 binding in female liver. F: Female-biased DHS with 
and without and STAT5 binding. G: K4me1 trough depths and sex-differences in K4me1 
pattern quantified as described in Methods. For male-biased DHS sites, this value is 
highest where there is male-enriched FOXA1 binding or male-enriched FOXA2 binding 
(bold, green) and lowest where there is no FOXA1 or FOXA2 binding (bold, red), and 
similarly for female-biased DHS sites, though to a much lower degree. STAT5 binding 
does not confer as much difference as FOXA1 and FOXA2 do. H: For male-biased DHS 
sites, sex-difference in K4me1 pattern for pairs of co-occurring TF binding sites. For 
each TF in each row, shown is the sex-difference in K4me1 profile with and without the 
TF in each column binding at the same site. Sex-difference in K4me1 pattern at male-
enriched STAT5 binding sites is greatly reduced when binding does not occur in 
combination with male-enriched FOXA1/FOXA2 binding, or CUX2 binding in female. 
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Figure 5-9. K4me1 read profiles at sex-biased DHS sites.  
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Figure 5-9. K4me1 read profiles at sex-biased DHS sites.  
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Figure 5-9. K4me1 read profiles at sex-biased DHS sites.  
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Figure 5-10. Model for sex-biased gene regulation.  
Male liver on the left; female-liver on the right. Shown are classes of sex-biased genes 
with sex-biased local chromatin marks (M4, F3), and the largest classes of sex-biased 
genes that lack local sex-biased chromatin marks (M1, F1). Male-biased chromatin 
marks, genes, and TF binding sites are indicated in blue text; female-biased in red text; 
and sex-independent chromatin marks in green text. Orange curves represent K4me1 
distribution around DHS summits. A. in male liver, male-biased DHS are marked by a 
bimodal distribution in K4me1, male-enriched K4me1/K27ac, and bound in a male-
enriched manner by STAT5 and/or FOXA1/FOXA2. These sites activate male-biased 
genes with local sex-differences in chromatin (M3, M4) as well genes that lack local sex-
differences in chromatin (M1). In female liver, male-biased DHS exhibit a monomodal 
K4me1 distribution and lack STAT5 and FOXA1/FOXA2 binding. CUX2 binding is 
enriched at sites with sex-independent enhancer modifications, and preferentially targets 
for repression male-biased genes with local sex-differences in chromatin (M4 class 
genes). CUX2 binding in female is enriched at sites that are bound by STAT5 in a male-
enriched manner (Conforto et al. 2012), but it is unclear whether these sites, which 
exhibit sex-independent enhancer modifications, are as important as sites with male-
enriched enhancer modifications in activating genes in male liver. B. Female-biased DHS 
exhibit a bimodal K4me1 distribution in both male and female liver, have female-
enriched enhancer modifications, and are bound by STAT5, CUX2, and FOXA2 in 
female liver, where these TFs preferentially target female-biased genes with sex-
differences in local chromatin marks (F3 class genes). It is not known whether STAT5, 
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CUX2, and FOXA2 cooperate in female liver. CUX2 may de-repress female-biased 
genes by facilitating removal of K27me3. C. BCL6 binds sex-independent DHS that have 
sex-independent enhancer modifications. BCL6 shows higher expression in male liver, 
where it preferentially represses female-biased genes that lack local sex-differences in 
chromatin.  
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Figure 5-10. Model for sex-biased gene regulation.  
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Figure 5-11. Visualizations of chromatin mark signal at some sex-biased genes. 
The following sex-biased genes are shown. For chromatin marks, “M” indicates the gene 
has a male-enriched mark in the promoter (K4me3) or coding region (other marks), “F” 
indicates a female-enriched mark, “I” indicates a sex-independent mark, and “N” 
indicates no mark in the promoter (K4me3) or coding region (other marks). 
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Figure 5-11. Visualizations of chromatin mark signal at some sex-biased genes. 
A.Cyp2b9 and Cyp2b13 (F3 genes) 
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Figure 5-11. Visualizations of chromatin mark signal at some sex-biased genes. 
B. Hsd3b5 (Male M3) 
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Figure 5-11. Visualizations of chromatin mark signal at some sex-biased genes. 
C. Sult2a6 (Female F2) 
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Figure 5-11. Visualizations of chromatin mark signal at some sex-biased genes. 
D. Cabyr (Male M1) 
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Chapter 6  
Conclusions and Future Directions 
6.A Conclusions 
Motif scanning with phylogenetic conservation was used to predict STAT5 binding sites 
across broad genomic regions surrounding GH-responsive genes (Chapter 2). This 
method was successful in predicting some functional STAT5 binding sites, including 
sites that were distant (up to 75 kb) from target genes. The ability of STAT5 to bind to 
distal regulatory sites may explain my finding that sex-biased GH-responsive genes, 
identified by analyzing global gene expression data from livers of mice following 
pituitary gland removal and GH treatment (Chapter 3), are not enriched for containing a 
STAT5 motif in the promoter region. Promoter analysis instead identified another 
candidate regulatory factor, MEF2. The analysis of mouse liver gene expression revealed 
intrinsic sex differences between male and female mice in their responsiveness to 
hypophysectomy, which could be a consequence of epigenetic differences between male 
and female liver.  
The overall success of STAT5 binding site prediction by motif scanning and phylogenetic 
conservation was limited, and may reflect factors such as chromatin accessibility and 
epigenetic environment that influence the in vivo binding ability of a predicted TF 
binding site. Indeed, my analysis of genome-wide open chromatin regions by DNase-seq 
in mouse liver (Chapter 4) revealed that 67-93% of experimentally determined 
transcription factor binding sites are located within DNase hypersensitive sites and thus, 
open chromatin regions provide valuable information about the localization of functional 
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TF binding sites. Motif analysis of subsets of sex-biased DHS provided further evidence 
that STAT5 acts as a distal regulator. Motifs for other TFs known to be involved in sex-
biased liver gene regulation were also discovered, showing that DNase-seq is useful in 
identifying candidate regulatory factors without TF binding data. The novel TFs 
implicated, such as PBX1 and TAL1, provide avenues for further investigation.   
Treatment of male mice with continuous GH − mimicking the female GH profile – 
feminized chromatin accessibility in male liver, by suppressing male-biased DHS and 
inducing female-biased DHS. Thus, chromatin accessibility in liver is sex-dependent and 
GH-regulated. I next investigated histone modifications at sex-biased regulatory sites and 
at sex-biased genes (Chapter 5). Different TFs have different relationships with 
chromatin at their binding sites and target genes: STAT5 predominantly binds at 
regulatory sites that are sex-biased in chromatin accessibility and in chromatin marks, 
and targets genes with sex-differences in the local chromatin environment, while BCL6 
binding sites and target genes are predominantly sex-independent in DNase 
hypersensitivity and chromatin marks. Thus, binding of the male-biased TF BCL6 can 
achieve sex-dependent regulation via sex-independent regulatory sites, which may in 
part, along with distal regulation and other mechanisms, explain the observation made in 
Chapter 4 that a majority of sex-biased genes are distant from sex-biased DHS. 
Differences were also observed between mechanisms of regulation employed in male vs. 
female liver, with K27me3-mediated repression being a mechanism of suppression of 
female-biased genes in male liver but not the reverse. De-repression of female-biased 
289 
 
 
 
genes marked by K27me3 in male may be mediated by CUX2, which is considered a 
repressor. Therefore, the mechanisms of action of CUX2 warrant further investigation.  
I also observed that male-biased DHS, but not female-biased DHS, are characterized by a 
sex-differential K4me1 distribution – a bimodal peak surrounding the summit in male 
liver, and a monomodal peak in female liver. This pattern may indicate sex-dependent 
nucleosome positioning, and was heightened at male-biased DHS that are bound by the 
pioneer factors FOXA1 or FOXA2 in a male-enriched manner, and even more so at sites 
that are bound by both STAT5 and FOXA1/FOXA2 in a male-enriched manner. FOXA1 
and FOXA2 are known as pioneer factors (Zaret and Carroll 2011) and sex-dependent 
nucleosome positioning by these factors at male-biased DHS in male liver may explain 
the observation by Zhang et al (2012) that male-enriched STAT5 binding sites and 
female-enriched STAT5 binding sites exhibit similar levels of chromatin accessibility in 
male liver, but male-enriched STAT5 binding sites are much more closed in female liver. 
This difference may be achieved by sex-dependent nucleosome repositioning at male-
biased but not female-biased DHS.  
 
6.B Future directions 
Order of events 
The genomics and epigenomics studies in liver detailed in this dissertation, as well as 
other published work, have generated many hypotheses that need to be tested and verified 
experimentally. These studies have shown that hormone-mediated regulation involves 
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complex interplay between transcription factors and chromatin structure, but many 
questions remain to be answered. For instance, it is still unclear how GH mediates the 
sex-differences that are visible in chromatin structure. Continuous GH feminizes 
chromatin accessibility and histone modifications such as H3K4me1 and H3K27me3 play 
important roles in sex-dependent gene regulation, but it is not known whether these 
histone modifications are GH-responsive, or whether they are relatively static in male and 
female liver, and serve as markers for GH-dependent TF binding or nucleosome 
repositioning to take place. Further work will be needed to answer these questions. Time 
course studies measuring DNase hypersensitivity, as well as chromatin modifications and 
the binding of STAT5, FOXA1 and FOXA2, in response to continuous GH treatment of 
males will shed light on the requisite sequence of events. Comparisons between these 
events during and between GH pulses could also be carried out to determine whether, like 
STAT5 binding, the changes are dynamic in response to GH pulses, which would help 
further elucidate the differences between male and female liver. Further elucidation of 
GH action can be made by identifying distinguishing chromatin features at the promoter, 
gene body, and associated regulatory sites of Class I (genes that are suppressed by 
hypophysectomy) and Class II (genes that are induced by hypophysectomy) sex-biased 
genes described in Chapter 3. 
Nucleosome positioning 
Although K4me1 distribution has been shown in select cases to reflect nucleosome 
positioning, including at sites that are distinguished by a bimodal distribution in one cell 
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type and a monomodal distribution in another cell type (Hoffman et al. 2010), K4me1 
pattern is not always a reliable indicator of nucleosome positioning, as was demonstrated 
by genome-wide profiling of MNase accessibility in mouse liver (Li et al. 2011). This 
data may be used to interrogate male-biased DHS in order to test whether sites bound by 
FOXA1 do in fact contain a positioned nucleosome at the DHS summit in female liver or 
are depleted at the summit for nucleosomes in male liver. 
In addition to the sex-dependent K4me1 pattern found at male-biased DHS, there may 
exist other interesting patterns of chromatin modifications surrounding sites of interest, 
which can be explored using CAGT (Kundaje et al. 2012), which clusters sites by 
patterns in seq data. The association between the sex-dependent K4me1 pattern and 
FOXA binding could also be further confirmed by working backwards: clustering male-
biased DHS by K4me1 patterns, then determining whether the cluster(s) with the deepest 
K4me1 trough are most likely to bind FOXA1/FOXA2, or bind FOXA1/FOXA2 with the 
greatest intensity. CAGT may reveal asymmetric patterns that are not apparent in 
aggregate plots at non-TSS DHS sites, and that are characteristic of certain TFBSs, which 
might provide insights into how particular TFs interact with DNA. 
While sex-dependent nucleosome repositioning is proposed in Chapter 5 to be a 
mechanism by which male-biased DHS are kept open in male and relatively closed in 
female, it is unclear how STAT5 is prevented from binding at female-biased DHS in 
male liver, given that female-biased DHS appear to be more open in male than are male-
biased DHS in female. K27me3 is elevated at female-biased DHS in male, but not 
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markedly so, and I was unable to detect localized peaks of K27me3 that might be 
expected if they mark inactive enhancers, unlike the broad domains observed at repressed 
genes. It is possible that female-biased DHS lie in regions of broad K27 trimethylation in 
male liver, which can be investigated. In female liver, it may be that the more persistent 
presence of active STAT5 in female liver is sufficient to confer more regulatory action on 
its target genes in female liver than in male liver, or more persistent STAT5 binding 
might stabilize binding of other interacting factors. 
Concurrent binding and co-operative regulation by multiple TFs 
Several lines of evidence have indicated cooperative behavior by multiple TFs in sex-
biased gene regulation: the enrichment reported in Chapter 4 of binding sites for several 
TFs, including STAT5, CDP (CUX2-like motif), and FOX-like motif at distal, male-
biased, GH-responsive DHS and similarly, subsets of sex-biased genes are enriched for 
being targets of the same TFs (Chapter 5); and the observation that the sex-dependent 
K4me1 profile at male-biased DHS is most pronounced at sites where FOXA1/FOXA2 
and STAT5 are both bound in a male-enriched manner (Chapter 5). The possibility of co-
operative binding can be investigated by determining whether co-occurrence of binding 
sites for particular TFs, or co-targeting of the same gene, happens more frequently than 
would be expected by chance. 
TF binding prediction 
Three different methods of computational prediction of TF binding sites have been used 
in this dissertation: phylogenetic conservation coupled with PWM scanning in broad 
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genomic regions surrounding select genes (Chapter 2), testing for enrichment among co-
regulated genes for pre-computed genesets that have conserved sequence motifs at the 
promoter (Chapter 3), and motif analysis at subsets of sex-biased DHS that share 
characteristics such as GH-responsiveness and distance to sex-biased genes (Chapter 4). 
Both the second and third methods identified novel candidate TFs that have yet to be 
verified as playing a role in sex-biased gene regulation. The third method was an 
improvement on the first two, in that regions of open chromatin, which are most likely to 
be bound by TFs, were first identified. A further refinement on TFBS prediction would 
be to identify digital DNase footprints, which have been found to have greater predictive 
value than using full DHS sites in delineating regions where TFs might be bound (Boyle 
et al. 2011). Using digital footprinting, some of the predicted novel TFs, such as MEF2 
and PBX1, can be computationally interrogated by testing for footprints at their proposed 
binding sites, and additional new predictions can be made. Predicted TF binding sites can 
also be computationally validated by looking for depletion in K4me1 and K27ac at motif 
instances. 
Mapping distal regulatory sites to genes 
In identifying TFs that target sex-biased genes, the approach used in Chapter 5 was 
limited in that each distal DHS was mapped to only a single target gene, whereas recent 
studies have shown that multiple regulatory sites regulate multiple genes (Thurman et al 
2012). This limitation may be mitigated by the fact that high throughput chromatin 
conformation capture (5C) experiments across 79 human cell types (Thurman et al 
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2012) have shown that promoter DHS are more promiscuous than distal DHS, with 48% 
of distal DHS being mapped to a single promoter DHS. However, mapping each DHS to 
its nearest sex-biased gene TSS, as was done in Chapter 5, is also likely to be limited, 
given that only a fraction of physical distal DHS-promoter interactions genome-wide 
occur between a DHS and its nearest TSS or nearest expressed gene TSS (Sanyal et al. 
2012).  
In future studies, distal regulatory sites may be mapped more accurately to target genes 
by experimental approaches such as 5C. Alternatively, information already available may 
be made use of to more accurately predict distal DHS-promoter pairs, such as the method 
employed by Ernst et al (2011), whereby enhancers were mapped to putative targets by 
correlating ‘activity profiles’ – gene expression and signal intensities for enhancer-
associated modifications – of enhancers and genes. Ernst at al and other groups verified 
predicted distal interactions by using eQTL data, and the same could be done for mouse 
liver using publicly available eQTL data. Such methods may be of limited use with only 
two tissue types, male and female liver, being compared.  Motif analysis at promoter 
DHSs and distal DHSs may also provide insights, by identifying TFs or members of TF 
complexes that bind at both a gene TSS and at a distal enhancer that could be associated 
with it, thus narrowing down the potential distal regulatory sites surrounding a gene.  
RNA 
The studies described in this dissertation do not account for alternate promoter usage or 
antisense transcripts, which can confound observed relationships between a gene’s 
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expression level and the chromatin environment at that locus. We now have RNA-seq 
data available from male and female mouse liver, from which alternative transcripts can 
be identified. 
Sex-dependent gene regulation may also involve post-transcriptional mechanisms that are 
not operative at the chromatin level, such as regulation by microRNAs. miRNA gene 
targets may be predicted computationally, for instance using miRBase (Griffiths-Jones et 
al. 2006). Furthermore, given the direct role of long noncoding RNAs (lincRNAs) in 
PRC2-mediated gene silencing (Tsai et al. 2010), sex-biased long lincRNAs could play a 
similar role in K27me3-mediated silencing of female-biased genes. lincRNAs, including 
transcripts expressed in a sex-dependent manner, may now be identified from the RNA-
seq data, or predicted computationally using the signature signal of a K4me3 mark 
adjacent to a K36me3 domain, described by (Guttman et al. 2009) as an epigenetic 
identifier of lincRNAs. 
Sex-biased genes poised for activity 
Given my finding that genes marked by bivalent chromatin modifications – K27me3 in 
combination with K4me3 – are down-regulated by some ligand-activated receptors and 
up-regulated by others (Chapter 5), it would be interesting to explore the possibility that 
genes are similarly marked in a sex-dependent manner, resulting in sex-dependent 
regulation upon stimulation. Genes that encode drug metabolizing enzymes, or genes that 
confer resistance or susceptibility to liver disease, that exhibit such a property might 
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provide further insight into the mechanisms leading to physiological sex differences in 
liver. 
 
In conclusion, the studies presented in this dissertation advance our understanding of the 
mechanisms of GH-mediated sex-dependent liver gene regulation, by accumulating 
evidence to support hypotheses proposed by previous research, and by proposing novel 
mechanisms for interactions between TFs and chromatin to achieve sex-biased gene 
expression. Experimental work and additional computational analysis discussed in this 
chapter will help confirm and consolidate results presented in this dissertation, as well as 
build on them to address as yet unanswered questions. 
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